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Re´sume´
L’objectif de cette the`se e´tait de de´velopper des designs adaptatifs applicables dans
les essais de phase I / II des the´rapies mole´culaires cible´es (TMC) en cance´rologie. Les
essais de phase I sont la pierre angulaire du de´veloppement de me´dicaments et leur correct
design peut aider a` ame´liorer la proce´dure globale. Une e´tape majeure pour ame´liorer les
essais de phase I consiste a` inte´grer toutes les informations recueillies au cours de l’essai.
Tout d’abord, nous nous sommes inte´resse´s au de´veloppement d’un design, pour identifier
la dose optimale (DO) qui peut prendre en compte plusieurs cycles de traitement et pas
uniquement le premier, typique de ces essais. Le but principal e´tait de prendre en compte
les toxicite´s tardives et cumulatives. En outre, l’utilisation constante de biomarqueurs qui
mesurent l’activite´ du me´dicament ne´cessite des approches alternatives, qui conside`rent
le biomarqueur comme une variable continue, mesure´e a` plusieurs moments au cours
de l’essai. Il est bien connu que la dichotomisation de ces crite`res principaux ne peut
que conduire a` une perte substantielle d’information. De plus, conside´rer qu’une seule
mesure de biomarqueur n’est pas suffisant pour de´finir l’activite´ du me´dicament, puisque
l’e´volution du biomarqueur change au cours du temps, indiquant une premie`re re´ponse au
traitement et e´ventuellement la progression de la maladie. Une autre question importante
qui inte´ressait cette the`se e´tait celle des donne´es censure´es. Lorsque la se´lection de la
DO est de´finie sur une longue pe´riode, c’est-a`-dire 3-6 cycles, rencontrer des donne´es
manquantes est ine´vitable.
Pour la se´lection de la DO, nous avons propose´ un design adaptatif qui combine a`
la fois la toxicite´ et les donne´es d’activite´, mesure´es sur une pe´riode de six cycles de
traitement. Nous avons imple´mente´ une technique de mode´lisation conjointe re´cente, qui
prend en compte le temps avant la premie`re toxicite´ dose-limitante (DLT) et de mesures
re´pe´te´es de biomarqueurs continus, sous un effet ale´atoire partage´. Cette me´thode de
mode´lisation conjointe e´tait base´e sur l’infe´rence de vraisemblance et les parame`tres du
mode`le ont e´te´ obtenus a` partir de la maximisation nume´rique de la vraisemblance. La
dose maximale tole´re´e (DMT) a e´te´ associe´e a` un certain risque cumule´ de DLT sur un
nombre pre´de´fini de cycles de traitement. La DO a e´te´ de´finie comme la dose la moins
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toxique parmi les doses actives, sous la contrainte de ne pas de´passer la DMT.
Pour e´tudier la performance du design et sa capacite´ a` identifier correctement la DO,
nous avons e´value´ un large e´ventail de sce´narios. Plus pre´cise´ment, nous avons envisage´
de re´duire la taille de l’e´chantillon, d’augmenter les variances, d’alte´rer la distribution
des effets ale´atoires, de supposer un risque croissant par cycle de traitement et finalement
nous avons ge´ne´re´ plusieurs sce´narios sous divers degre´s d’erreur de spe´cification des
mode`les. La me´thode e´tait tre`s efficace en ce qui concerne la correcte se´lection de la
DO. Meˆme en cas de censure excessive, avec seulement 7% des patients arrivant a` la fin
de l’essai, la me´thode e´tait robuste et les estimations tre`s peu biaise´es. En outre, notre
design e´tait assez fiable, puisque les participants de l’e´tude n’e´taient ge´ne´ralement pas
expose´s a` des doses hautement toxiques ou sous-the´rapeutiques. Il s’agit du premie`re
design pour les essais de phase I qui comprenait plusieurs cycles de traitement, continus
et re´pe´te´s mesures de biomarqueurs, une de´finition cumulative pour la DMT et qui a
aborde´ la question des re´ponses manquantes.
L’e´tude de la performance du nouveau design s’est focalise´e sur le meˆme exemple
motivant de l’essai du cancer de l’ovaire afin de permettre la comparaison des deux
approches. Des simulations approfondies ont montre´ que le nouveau design e´tait tre`s
efficace sous divers degre´s d’erreur de spe´cification du mode`le. Une proprie´te´ importante
du mode`le de plateau e´tait que lorsque les donne´es e´taient ge´ne´re´es a` partir du mode`le de
log, le pourcentage de recommandation correct de la DO e´tait presque identique a` celui
observe´ lors de l’analyse des donne´es avec le mode`le de log. Ceci e´tait une indication de
l’adaptabilite´ du mode`le a` diffe´rentes trajectoires de biomarqueurs. Enfin, nous avons
aborde´ le cas de l’e´chec de la convergence. Dans le mode`le de log, certaines simulations
n’ont pas pu eˆtre re´alise´es avec la mode´lisation conjointe, alors qu’avec le mode`le de
plateau et pour les meˆmes simulations, aucun proble`me de ce type n’a e´te´ observe´.
Une limite des deux designs adaptatifs a` e´te´ lie´e a` leur manque de comparabilite´ avec
les me´thodes existantes. Plusieurs me´thodes de recherche de dose ont e´te´ propose´es dans
la litte´rature. Il existe des me´thodes qui prennent en compte une pe´riode de DLT plus
longue, sans toutefois prendre en compte plusieurs cycles de traitement ou une de´finition
cumulative pour le DMT. Il existe e´galement des me´thodes qui conside`rent l’activite´
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comme un crite`re d’e´valuation continu, mais avec une seule mesure par patient. Par
conse´quent, la comparaison de notre design avec des approches alternatives n’e´tait pas
re´alisable, car il ne serait pas possible de cre´er des sce´narios correspondants.
La dernie`re partie de cette the`se a porte´ sur l’analyse de 27 e´tudes des TMCs de phase
I, en tant que monothe´rapie. Ces essais ont e´te´ re´alise´s par le NCI et ont e´te´ fournis a`
l’EORTC et au DLT-TARGETT. Auparavant, nous avons discute´ de l’importance de
prendre en compte le temps lors d’un essai de phase I. Cependant, jusqu’a` pre´sent, il
n’y avait rien dans la litte´rature, documentant le risque de toxicite´ se´ve`re, pour plus
d’un cycle de traitement. Par conse´quent, notre inte´reˆt principal e´tait d’estimer le risque
par cycle, ainsi que l’incidence cumulative de la toxicite´ se´ve`re, jusqu’a` six cycles de
traitement. Un objectif secondaire e´tait d’estimer les meˆmes quantite´s, mais se´pare´ment
pour les toxicite´s se´ve`res he´matologiques et non-he´matologiques. Ces types de toxicite´s
ne surviennent pas de la meˆme manie`re et ils n’ont pas le meˆme impact sur le corps
humain, d’ou` l’inte´reˆt d’estimer le risque se´pare´ment.
A` cette fin, nous avons mis en œuvre un mode`le de probit qui prend en compte le
temps avant la premie`re toxicite´ se´ve`re et qui permet d’estimer a` la fois le risque par
cycle et l’incidence cumulative. Nous avons effectue´ l’analyse, d’abord se´pare´ment pour
les groupes de patients traite´s aux doses ci-dessous, ci-dessus, et a` la DMT, et ensuite
sur tous les patients et nous avons fourni un nomogramme. Nous avons e´tudie´ le risque
de toxicite´ pour les toxicite´s he´matologiques et non-he´matologiques, et enfin, nous avons
effectue´ une analyse de sensibilite´. Nous avons montre´ que l’incidence cumulative de la
toxicite´ se´ve`re chez les patients traite´s a` la DMT e´tait de 27% a` la fin du premier cycle
et elle a atteint 53% a` la fin du sixie`me cycle. Pour les patients ayant rec¸u la DMT,
l’incidence cumulative de la toxicite´ non-he´matologique et he´matologique e´tait de 35% et
18%, respectivement.
Ce projet a e´te´ le premier a` fournir des re´sultats sur le risque par cycle et l’incidence
cumulative de la toxicite´ se´ve`re sur plusieurs cycles de traitement. Nous avons e´galement
fourni des guidelines pour la bonne conduite des essais de phase I et des niveaux de
toxicite´ cibles raisonnables, base´s sur les re´sultats du DLT-TARGETT. Une limite de
cette analyse est lie´e a` la de´finition de toxicite´ se´ve`re. Traditionnellement, la DMT est
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de´finie sur la base des DLT survenant au cours du premier cycle de traitement. Les DLTs
sont de´finies pour certaines toxicite´s de grade 3 et 4, et elles sont spe´cifiques a` l’e´tude.
Nous nous sommes inte´resse´s au risque de toxicite´ sur plusieurs cycles, et pour cela nous
aurions besoin de reconstruire la variable de la DLT pour les six cycles. Cependant, nous
n’avons pas eu acce`s aux 27 protocoles d’e´tude. En conse´quence, pour l’analyse, nous
nous sommes concentre´s sur la premie`re toxicite´ se´ve`re, qui ne co¨ıncide pas ne´cessairement
avec une DLT. Par conse´quent, en conside´rant la premie`re toxicite´ se´ve`re, on aurait pu
surestimer le risque de toxicite´.
Avec cette the`se, nous avons voulu apporter la preuve qu’il y a de la place pour
l’ame´lioration et a` cette fin, nous avons de´veloppe´ un design adaptatif et une extension
de ce design qui pourrait eˆtre applique´ a` ces essais. Finalement, apre`s l’analyse du
DLTTARGETT, il est apparu que pour la de´finition de la dose recommande´e pour les
e´tudes de phase II, il est vital de conside´rer 3 a` 6 cycles de traitement, d’envisager une
de´finition cumulative du niveau de toxicite´ cible´ et, si possible, d’inte´grer les mesures
d’activite´. En conclusion, l’inte´gration d’un plus grand nombre d’informations pourrait
conduire a` des essais de the´rapies cible´es de phase I qui sont plus efficaces.
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Chapter 1
Dose finding in anti-cancer drugs
1.1 Thesis objective
Before a new drug is approved as a medical product, it has to pass through a series of
tests and trials in order to establish that it is both safe and active. The drug development
process starts in the laboratories, in vitro, where they mainly test the new agent on cells,
tissues or organs. After the agent has demonstrated some pharmacological activity, then
further development proceeds with testing the agent on animals, also known as pre-
clinical studies. The purpose of these tests is to examine the safety and activity of the
new drug on animals and to suggest a starting dose or a range of doses, that will be later
on administered to humans. After the agent has been successfully tested on animals,
we proceed with the in human clinical trials. These trials are further divided into four
phases, called phase I, phase II, phase III and phase IV clinical trials. In this thesis we
will focus on phase I and phase II trials.
The main objective in anti-cancer early phase trials is to establish a dose of a phar-
macological agent (drug candidate) is safe and active. When a treatment regimen is
considered to be safe that translates into not exceeding a predefined probability of toxic-
ity. Activity is achieved when the agent has a “positive” treatment effect on the disease,
i.e. partial or complete response.
More precisely, the principal goal of a phase I trial is to evaluate and establish the
maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of the new
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drug. Interest lies in the drug’s safety and therefore, the primary endpoint is toxicity.
Toxicity is categorized into 5 grades, with 1 showing minimum toxicity, whereas 5 in-
dicates toxic death. Particularly, we are interested in the dose limiting toxicity (DLT),
which is defined as severe toxicity (typically grade 3 or 4 toxicity) that entails dose reduc-
tion or treatment interruption (Table 1.1). The probability of DLT occurrence is assumed
to monotonically increase with increasing dose, as shown in Figure 1.1 a). The MTD is
the dose associated with some predefined probability of DLT, known as target toxicity
level (TTL). The TTL is determined by clinicians before trial initiation and is typically
between 20% and 33%. The RP2D is the dose administered to phase II trials and quite
often it coincides with the MTD.
Phase I trials consist of small sample sizes, usually between 20 and 100 patients.
In most diseases, phase I trials are conducted with healthy volunteers. However, in
the circumstance of anti-cancer drugs volunteers are patients in the final stages of their
disease. The study begins with the introduction of the first cohort that is a group of one
or maximum three patients. These patients are assigned to a specific dose level, usually
the first one, and they are followed for a pre-specified period of time. This period of time
is divided into treatment cycles, typically 3-4 weeks. At the end of the first treatment
cycle patients are evaluated as to whether they had a DLT or not. DLTs are defined solely
for the first treatment cycle. The information collected from those patients is utilized in
order to assign the next cohort of patients to the same or another dose level. Phase I
trials are sequential designs, because patients enter the study in cohorts and not all at
the same time. The motivation behind this is to impose a safety constraint in case of
excessive toxicity. After all patients have been followed, for one treatment cycle, the MTD
is defined as the dose producing a probability of DLT closest to the TTL. Therefore, dose
finding is conventionally based on the toxicity data collected during the first treatment
cycle.
This design for phase I trials dates from the era of cytotoxic agents and have been
widely used over the years. Nevertheless, the emergence of molecularly targeted agents
(MTAs) has challenged this type of design, due to their different mechanisms of actions.
MTAs are often administered in chronic schedules, until DLT occurrence, disease progres-
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Table 1.1: Table of definitions
Term Definition
Adaptive Design
A trial design that allows modifications to some aspects of the design, based on collected data, after its
initiation and without undermining the validity and integrity of the trial.
Adverse Event (AE)
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical
product and which does not necessarily have to have a causal relationship with this treatment. =
Consent Withdrawal A subject’s decision to cease participation in a trial.
Dose Limiting Toxicity It is defined as the occurrence of a severe toxicity (typically grade 3 or 4 toxicity) that entails dose
(DLT) reduction or interruption.
Drug Activity
A measure of the physiological response that a drug produces. A less active drug produces less
response, and a more active drug produces more response.
Expansion Cohort
Prolongation of phase I studies, with the addition of patients, often with different eligibility
criteria, so as to better characterize the toxicity and activity profiles of experimental agents.
Maximum Effective Dose The dose above which there is no clinically significant increase in pharmacological effect or
(MaxED) activity.
Maximum Tolerated Dose The maximal dose acceptably tolerated by a patient population. It is usually the dose
(MTD) recommended for phase II trials.
Minimum Effective Dose The lowest dose producing a clinically important response different from the placebo response.
(MinED)
Pharmacodynamics (PD) The study of the biochemical and physiological effects of drugs on the body.
Recommended Phase II Dose The dose administered to patients in a phase II clinical trial, as that was chosen from phase I
(RP2D) trial (Maximum Tolerated Dose).
Target Toxicity Level The maximum probability of DLTs that is considered acceptable in the trial. The TTL is used to select
(TTL) the MTD and is typically between 20% and 33% at the end of the first treatment cycle. = =
Treatment Cycle
In medicine, a course of treatment that is repeated on a regular schedule with possibly periods of rest in
between. For example, treatment given for one week followed by three weeks of rest is one treatment cycle.
= ICH (1994)
= = Tourneau et al. (2009)
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Figure 1.1: a) Dose-DLT relation. b) Dose-activity relation.
sion or consent withdrawal, rather than a predetermined number of cycles. Prolonged
administration of these agents may induce late-onset or cumulative toxicities. Therefore,
considering DLTs only from the first cycle of therapy can result in incorrect dose selec-
tion (Soria, 2011). In particular, Postel-Vinay et al. (2011) considered the data of 34
phase I trials of MTAs, from two large hospitals, with a total of 445 patients included.
They showed a 20% incidence of grade 3 and 4 toxicities during the first treatment cycle
with that number halving for each successive cycle. These results are pretty much in
line with Postel-Vinay et al. (2014) and the analysis of the DLT-TARGETT database,
which is composed of 54 completed phase I trials of MTAs as monotherapy. These dis-
coveries clearly lead us to the conclusion that more attention should be paid to delayed
toxicities, indicating that prolongation of the DLT period is crucial. Recently the Eu-
ropean Medicines Agency (EMA) followed the report from the European Organization
for Research and Treatment of Cancer -led DLT-TARGETT group (Postel-Vinay et al.,
2014) and released a draft Guideline on the evaluation of anticancer medicinal products
in man (European Medicines Agency, 2016). EMA stated that “in contrast to cytotoxic
chemotherapy, MTAs are typically administered continuously and the toxicity profiles
tend to differ so that DLTs may occur after multiple cycles of therapy. This is of im-
Overview of dose-finding methods 5
portance for the RP2D in cases where tolerability and toxicity guide dose selection, and
may require alternative strategies with regard to definition of DLT and MTD”. The same
guideline then recommends “Broader DLT definitions with longer DLT observation peri-
ods may therefore be relevant to consider. A distinction between cycle 1 acute toxicity,
prolonged toxicity impacting on tolerability and late severe toxicity may be informative.
Adverse events (AEs) should therefore always be reported by treatment cycle and the
RP2D should be based on an integrated assessment of likely adverse reactions”.
Another challenge faced with MTAs is related to the dose-activity relationship. For
cytotoxic agents the underlying premise is that both toxicity and activity increase mono-
tonically with increasing dose (Figure 1.1 b)). The dose-toxicity relationship can serve
as a surrogate for activity and thus there is merit in pushing the dose as high as safety
allows. Consequently, the MTD is also the RP2D, as it is safe and at the same time the
most active dose. Nevertheless, for MTAs this assumption may not hold (Kummar et al.,
2006); it has been shown that the dose-activity curve of MTAs may reach a plateau after
a certain dose level, countermining the widely accepted principle of the more the better.
For that reason, EMA stated that “The use of pharmacodynamic endpoints (Table 1.1),
where available, may also assist in dose selection”. For example, imagine a dose-activity
relationship that plateaus after a certain dose level, as depicted in Figure 1.2. The red
line represents the MTD. We can see from this figure that all doses located on the plateau
have equal probability of activity. So the question raised here is what dose is the most
appropriate to continue to subsequent phases. Is it possible to recommend a dose that is
less toxic than the MTD, but equally active? Given the toxicities observed in a phase I
trial in oncology, a lower dose with the same activity properties would constitute an
optimal dose (OD).
From the above, it becomes clear that dose finding in the era of MTAs requires
alternative methods that take into account both toxicity and activity, as well as treatment
time (Reitsma et al., 2015). Phase I trials are a vital part of the drug development
procedure, since inappropriate dose selection comes with a set of major drawbacks. To
begin with, patients might be exposed to highly toxic or subtherapeutic doses, that
cause undesirable adverse events or even death. Contrary to other diseases, in oncology
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Figure 1.2: Dose-activity relation for MTAs.
exposure to low doses is considered an important issue. The reason is that we treat
patients and not healthy volunteers and as a corollary under-treating them is equally
dangerous as over-treating them. Another consequence of wrong dose selection after a
phase I trial is the continuation or not to the next phases. In other words, a misspecified
dose can result to either stop a potentially interesting drug or to promote a rather non-
active or even hazardous one to the next levels. All mentioned above apart from an
enormous cost on patients’ life, they additionally have a colossal cost on the economy.
Every year billions of dollars are spent for drug development, a big amount of which
could be avoided if phase I and phase II trials improved. It is estimated that the cost of
developing a new drug that will ultimately arrive in the market is 648 million US dollars
(Prasad and Mailankody, 2017). What is more, millions of dollars are spent on agents
that do not take approval to go into the market even though they succeeded to pass
from phase I and II. Overall, the probability of success moving an anti-cancer drug from
Phase I to the market is 3.4% (Wong et al., 2018).
The thesis is organized as follows. The remainder of this chapter is dedicated to
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a review of several of the existing dose finding methods. We first present the two large
categories of dose finding methods (rule based versus model based designs) and we discuss
some of them in detail. Following, we talk about MTAs and their mechanisms of action.
We introduce certain designs that consider both toxicity and activity for the OD selection.
We close Chapter 1 with certain concerns regarding dose finding methods that need to
be taken into account and addressed when designing a phase I trial. In Chapter 2,
we present our adaptive design for the identification of the OD. We implement a joint
modeling of continuous biomarker measurements and time-to-first DLT, using a shared
random effect. We thoroughly explain the underline models, the study design as well as
the decision process. Simulation scenarios with the corresponding results, follow, and we
also discuss certain limitations of the proposed design, concerning model convergence and
model flexibility under the case of a dose-activity plateau. Chapter 3 is an extension of
our method presented in Chapter 2. In this extension the aim was to improve the dose-
activity relationship, by allowing for more flexibility in the fitted model and improve
arising issues regarding model convergence. In Chapter 4, we discuss the impact of
cumulative toxicity in phase I trials of MTAs. More precisely, we analyzed toxicity data
of 27 phase I trials of MTAs as monotherapy, with the objective to estimate the risk of
toxicity and the cumulative incidence function per treatment cycle. Finally, we provided
recommendations regarding the design and conduct of phase I trials. Conclusion and
discussion of the thesis follow in Chapter 5.
1.2 Drug development
Before proceeding with the dose finding designs we will briefly introduce phase II,
phase III and phase IV clinical trials of the drug development.
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1.2.1 Phase II clinical trials
Once a phase I trial is completed, we continue with phase II clinical trials, also ex-
ploratory studies. Phase II are called “Proof of Concept Studies”, since their main goal is
to assess the activity of the new drug. Consequently, activity constitutes the primary end
point. Phase II enroll 50 to 300 patients and they last for a few years. Eligibility criteria
are stricter than in phase I trials, with participants having a specific type of cancer. It
is very often required that the patients’ condition is not too critical or too mild, so as
to better investigate the activity. In these trials the RP2D is tested with the purpose to
define its activity. It is possible that the drug is compared to a control compound, even
though this is not always the case. Finally, we wish to obtain more information with
regard to the pharmacokinetics and pharmacodynamics properties of the agent.
Outside of oncology, certain parameters of interest within phase II trials are the
minimum and the maximum effective dose (MinED),(MaxED), as shown in Figure 1.3.
The minimum effective dose is defined as the lowest dose producing a clinically important
response that can be declared statistically significantly different from the control response,
whereas the maximum effective dose is the one above which there is no clinically significant
increase in pharmacological effect or efficacy. Both quantities can be of interest in clinical
trials, since they can help to better understand and evaluate the properties of the drug
under investigation. In oncology, since we investigate only one dose level, we do not
consider MinED and MaxED, even though it would be of great interest.
For these studies to be considered successful both safety and activity must be shown.
Then and only then it is safe to proceed with a phase III trial. Phase II trials, including
successful ones, come with a set of certain limitations. First of all, due to the narrow
patient population it is difficult to generalize the results to a broader one. What is more,
due to their duration, their sample size and usually the lack of control group, phase II
cannot provide definite and detailed conclusions.
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1.2.2 Phase III clinical trials
Phase III clinical trials are large confirmatory trials that aim to compare the new
treatment to the standard of care and establish the results obtained from previous trials.
The goal is to further investigate and prove the clinical activity of the regimen, compared
to the standard of care and to evaluate the risk-benefit balance.
Phase III are large studies usually of several hundreds to thousands patients and can
last up to several years. The eligibility criteria for patient inclusion is less restricted than
phase II and as a result generalizability of the findings can be accomplished. In these
trials there is always a control group of patients, to whom another drug is administered.
This latter is known as standard treatment and it has already been shown to work. If a
standard treatment does not exist, then the new agent is compared to placebo.
Once participants are enrolled into the study, they are randomized between the exper-
imental and the standard treatment. Randomization ensures that possible confounders
are eliminated and the two or more groups are comparable. Another important aspect of
phase III is blinding. Patients or both physicians and patients, if possible, should not be
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aware of the treatment administered.
Even though recommendation of doses is part of early phase trials, it is still possible
that dose selection is further refined in phase III. One reason for this is that because of
study duration patients are exposed to the drug for a longer period of time and conse-
quently later on or cumulative toxicities can be recorded and taken into account. An
example is the re-evaluation of the MTD of MTAs, in phase II and in phase III trials (Le
Tourneau et al., 2010b; Iasonos et al., 2012; Jardim et al., 2014).
After a phase III is completed a study report is transmitted to the European Medicines
Agency (EMA) or the Food and Drug Administration (FDA) for United States and is
evaluated. These regulatory agencies are responsible to decide whether the new agent
can go to the market for public use or get rejected (Crowley and Hoering, 2012).
1.2.3 Phase IV clinical trials
After the successful completion of phase I, II and III clinical trials and the approval
by the regulatory agencies, the drug arrives to the market. Evaluation of the drug can
continue even when it is on the market. These studies are known as phase IV or post-
marketing studies.
One major advantage of these studies is that they account for the full patient popula-
tion. As a result, it is feasible to record rare adverse events that were not detected during
the previous trials. What is more, post-marketing surveillance comes with a large scale
duration compared to the past trials. This way, cumulative effects of the concentration of
the drug can also be detected and dealt with. Phase IV designs can use various designs,
such as a randomized trials with control arm, but single-arm, non-randomized or open-
label studies are also accepted. Phase IV trials in oncology aim as well to investigate
individualized or personalized treatment and thus, randomization or blinding is not that
often (Zhang et al., 2016).
Compared to premarketing phase I–III trials, phase IV studies evaluate drug safety
in a real-world setting, which may provide evidence to ensure or further refine the safety
Overview of dose-finding methods 11
and activity of approved drugs.
1.3 Dose finding designs: Rule based designs
Dose finding methods are divided into two categories, the rule based and the model
based. Rule based, also known as “up and down” designs are widely utilized, because of
their simplicity. Their principal aspect is that they only make one assumption; toxicity
increases monotonically with dose. Dose escalation or de-escalation proceeds based on
certain rules, that vary among these methods. In the next section, a few of them will be
shortly presented. On the other hand, model based designs, they do assume a model that
describes the dose-toxicity relationship and they can be more complicated to implement.
A particular model based design will be analytically discussed in Section 1.4.
1.3.1 ‘3+3’ design
The ‘3+3’ design is probably one of the most commonly used designs since till now it
has been applied on 95% of published phase I trials clinical trials (Ji and Wang, 2013).
The basic idea behind this method is that participants enter the study in groups of three,
also known as cohorts. The MTD is defined as the dose with a percentage of toxicity
equal or below 33%. Every cohort is allocated to a specific dose and then is followed for
one treatment cycle. Based on their toxicity outcome, i.e. the number of observed DLTs,
the next cohort of patients is assigned to the same, the next or the previous dose level, if
possible. The principal rule is that if non of the three patients had a DLT then the next
cohort will be assigned to the next dose level. If one of the three had a DLT, then the
next cohort will get the same dose. Finally, if two or more DLTs have occurred, then this
dose is defined as the maximum administered dose (MAD). The MAD is the dose that
is considered to produce a probability of toxicity greater than the MTD, so it will not
be given to any more patients. In this case three more patients will be assigned to the
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Table 1.2: The 3+3 rule based method
No. of patients with DLTs Escalation decision rule
at a given dose level
0 out of 3 Enter 3 patients at the next dose level.
1 out of 3 Enter at least 3 more patients at the same dose level.
≥ 2 out of 3
Dose escalation will be stopped.
This dose will be declared the MAD.
Enter 3 more patients at the next lowest dose level,
if only 3 patients were treated previously at that dose.
previous level, if only three patients had been treated to that level before. Otherwise,
the previous dose level is declared MTD. The trial halts after observing 2 or more DLTs
at a given dose level and 1 or none DLTs for the 6 patients treated at the previous dose
level. So we systematically identify the MTD or we stop enrollment after the first 3 or 6
patients due to excessive toxicity at the first dose level. Table 1.2 is given so as to better
clarify how this method works.
As mentioned above, this technique has been widely applied over the years due to its
simplicity. However, there are certain limitations that need to be taken into account when
implementing this design. First limitation is the poor accuracy of the estimation of the
MTD, since its identification can be achieved after only six patients have been enrolled.
Furthermore, due to the size of the cohorts and because dose escalation begins from the
first dose level, many patients are ultimately treated at low or else sub-therapeutic doses.
Additionally to that, only few of the participants will eventually be assigned to the MTD
or to doses close to the MTD. Given the severity of the patients’ condition, under-treating
them is not ethical, since it can prove to be fatal. Another drawback of the ‘3+3’ is the
lack of flexibility, increasing this way the risk of recommending a phase II dose, that is
below the true MTD (Tourneau et al., 2009).
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1.3.2 Other rule based designs
Several rule based designs can be found in bibliography, such as variations of the ‘3+3’
(‘2+4’, ‘3+3+3’, pharmacologically guided dose escalation) (Tourneau et al., 2009). An-
other variation of the ‘3+3’ that was proposed to shorten the timeline of pediatric phase I
trials, when there is no prior information about the dose range under investigation, is the
rolling six design. With this design, two to six patients are allowed to be concurrently
enrolled in the study. Every cohort starts with three patients entering the study and be-
ing assigned to a dose level. If toxicity information is available for all three of them and
no DLT has occurred then the fourth patient is assigned to the next dose. If data is not
available for one or more of the first three patients or if one DLT has been observed then
the fourth patient is administered to the same dose. Finally, if two or more DLTs have
occurred the fourth participant is assigned to the previous dose. The same procedure is
followed for patients number five and six (Skolnik et al., 2008; Eisenhauer et al., 2015).
According to Skolnik et al. (2008), the two methods, the ‘3+3’ and the rolling six, have
been shown to have similar operating characteristics. Additionally, Doussau et al. (2012)
showed in simulation scenarios that the probability of identifying the correct dose is the
same between the two designs. Accelerated titration design was developed to reduce the
number of patients treated at subtherapeutic dose levels and the trial’s duration, as well
as to collect important information, such as cumulative toxicity (Simon et al., 1997). To
that end, three designs were created, with cohorts of one patient. If a patient experienced
a DLT or two patients experienced grade 2 toxic effects, during the first cycle for designs
1 and 2 and during any cycle for design 3, then the design switched to the ‘3+3’. Acceler-
ated titration design allows for intrapatient dose escalation. The authors compared their
models with the ‘3+3’ method and concluded that their method reduced the number of
patients who were undertreated and accelerated the completion of the trial.
Rule based methods have been adopted to a great extent, mostly because they are
easy to implement, with regard to statistical software. What is more, they seem to be
more easily accepted by institutional review boards. Despite all this, these methods
are insufficient in establishing a dose that corresponds to a certain target toxicity level.
Furthermore, due to the way they function, they do not consider all information gathered
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during a phase I. Consequently, in the past years implementation of model based designs
has increased, even though these techniques exist for many years now.
1.4 Model based designs
1.4.1 Continual reassessment method
Model based designs are an alternative proposal for the dose finding process. The
principal difference with rule based dose escalation techniques is that they utilize statis-
tical models to describe the dose response relationship. Additionally, toxicity outcomes
of all patients, observed during the trial, are used so as to better estimate the model
parameters and allocate patients to appropriate doses. Statistical inference can be either
Bayesian or frequentist. One very popular approach that constitutes the cornerstone of
model based techniques is the continual reassessment method (CRM). The CRM and its
variations are thoroughly discussed in the next sections, since they are of great importance
for this project.
The CRM was introduced by O’Quigley et al. (1990) in 1990. The CRM can be
summarized in 7 steps.
1. Select a TTL, based on clinician’s views and a dose-toxicity function.
2. Enroll one or more patients and treat them at the first dose level or a dose chosen
based on prior knowledge.
3. Follow the patients for a time period (e.g. for one treatment cycle) and record
whether they have a DLT.
4. After the follow up period and before the entry of the next patients update knowl-
edge on the dose-toxicity function.
5. Using either Bayesian methods or the classic likelihood approach estimate the new
probability of toxicity at each dose level.
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6. Finally, choose the dose level that has the probability of toxicity that is closest to
the TTL.
7. Repeat this process before the entry of every new patient and till you reach the
maximum sample size or study stops due to excessive toxicity.
The main objective is to suggest a dose with a given TTL and to concentrate experi-
mentation at that which all current available evidence indicates to be the best estimate
of this level. This technique is based on constantly updating our knowledge with regard
to the dose-toxicity relationship, as observations become available. Patients are always
treated at the dose whose response probability, based on the observations of all patients,
is closest to the desired level.
In this section we present the original design suggested by O’Quigley et al. (1990),
as well as alterations recommended over the years with the goal to improve the CRM.
The approach by O’Quigley et al. (1990) was based on Bayesian statistics, whereas a
maximum likelihood approach was later on suggested.
Consider a range of M planned doses to be tested D = {d(1), . . . , d(M)}. Let Zi be a
binary random variable (0, 1), with 1 indicating DLT for the ith individual, i = (1, . . . , N).
We assume an increasing dose-toxicity function E(Zi) that is depicted by ψ(di, a), where
a ∈ A is a parameter. We assume that ψ(di, a) is monotonic in d and a. Now, let  be
the TTL. Then, there is a d∗ for which ψ(d∗, a0) = , where a0 is the true state of nature.
1.4.1.1 Bayesian approach
Let Ωi = ((z1, d1), ..., (zi−1, di−1)) and suppose f(a,Ωi) to be a positive function or
else the prior, that contains all the information for a. Assuming that A = (0,∞), then
∫ ∞
0
f(a,Ωi) da = 1. (1.1)
Here, f(a,Ωi) is the prior before the entry of the i
th observation. Then, we want to
estimate the posterior distribution f(a,Ω(i+1)). Taking Bayes’ theorem, we need the
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prior 1.1 and the model likelihood for subject i that is
φ(di, zi, a) = ψ
zi(di, a){1− ψ(di, a)}(1−zi).
Then, the posterior distribution is
f(a,Ω(i+1)) =
φ(di, zi, a)f(a,Ωi)∫∞
0
φ(di, zi, v)f(v,Ωi) dv
.
The probability of toxicity at dose level l after the enrollment of i patients is given by
p(l) =
∫
A
ψ(d(l), a)f(a,Ωi) da.
Instead of working with the expected values of the probabilities over A the authors
proposed to work directly with the expected value of a over A . Thus,
pˆ(l) = ψ{d(l), µ} µ =
∫
A
af(a,Ωi) da.
After having estimated all the above quantities, the next patient is assigned to the dose
that produces a probability of toxicity closer to the TTL.
For a better understanding, the method will be illustrated by an example from
O’Quigley et al. (1990).
1. As discussed above, the first step is to define the TTL , here 20%. Suppose
now that we want to test 6 parameterized dose levels D = (−1.47,−1.1,−0.69,
−0.42, 0.0, 0.42). The authors have chosen the hyperbolic tangent function to depict
the dose-toxicity relationship
ψ(di, a) =
{
tanhdi + 1
2
}a
, (1.2)
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and for the prior distribution they proposed the exponential function
f(a,Ω1) = exp
−a.
2. The first patient is allocated to the prior estimation of the MTD. In our function aˆ is
assumed to be equal to 1, since this is the mean value of the exponential distribution
that we have chosen as prior. The third dose level d(3) = −0.69 gives a probability
of DLT pˆ(3) = 20.1%, which is the closest to  = 20%. Thus the first patient will
be treated at dose level 3.
3. After the first patient is enrolled, he will be followed for one treatment cycle, so as
to observe whether DLTs occur. Assuming that no DLT occurs, z1 = 0, the next
step is to estimate the dose to which the second patient will be allocated to. To do
so we need to take into account the first patient’s toxicity outcome to estimate the
posterior distribution of a. For the posterior distribution we take the likelihood for
the first patient and the prior distribution. For the likelihood,
φ(d(3)1, z1, a) = ψ
z1(d(3)1, a)× {1− ψ(z(3)1, a)}(1−z1)
=
(
tanhd(3)1 + 1
2
)a∗0
×
(
1−
(
tanhd(3)1 + 1
2
)a)
=
(
1−
(
tanhd(3)1 + 1
2
)a)
.
So the posterior distribution of a after the first patient is observed takes the form
f(a,Ω2) =
(
1−
(
tanhd(3)1+1
2
)a)
× exp−a∫∞
0
(
1−
(
tanhd(3)1+1
2
)v)
× exp−v dv
.
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We proceed by calculating the mean of the posterior distribution as shown below,
µ2 =
∫ ∞
0
a× f(a,Ω1) da
=
∫∞
0
(
1−
(
tanhd(3)1+1
2
)a)
× exp−a∫∞
0
(
1−
(
tanhd(3)1+1
2
)v)
× exp−v dv
= 1.38.
4. Having summarized the information of the prior knowledge and the one provided
after the first patient, we use that information to estimate the posterior probability
of DLT at every dose level. To do so, we substitute in the function ψ(di, a), a with
µ2 and we calculate the pˆ(l) for every d(l) ∈ D. For instance, for the first dose in
the dose range
pˆ(1) =
(
tanhd(1) + 1
2
)µ2
= 0.0161104 or 1.6%.
5. After obtaining all pˆ(l) we select the one that gives a probability of DLT closer
to the TTL, by absolute value i.e. | − pˆ(l)|. That dose is administered to the
second patient. In this case that would be the fourth dose level d(4) = −0.42 with
a probability of DLT equal to 19.1%.
6. We repeat steps 3-5 before the entry of every new patient.
General remarks
The authors have run extensive simulations with the goal to test the operating char-
acteristics of their design and to investigate how it performs under various scenarios.
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Initially, O’Quigley et al. (1990) tested three different models. They concluded that all
models seemed to perform quite well, in most of the scenarios tested, which was a proof of
the robustness of the method. That means that the models were sufficiently successful in
choosing the right dose level, and not treating many patients in subtherapeutic or highly
toxic doses. However, later on Shen and O’Quigley (1996) pointed out the importance
of working with a one-parameter model. They argued that a single parameter suffices
to model the toxicity at any given level. Once the method has settled at some level the
introduction of a second parameter poses the problem of instability of the parameter
estimates. This issue does not arise when considering continuous doses because, even
though we may have a single target, each subsequent experiment takes place at a distinct
design level, thereby providing adequate information to fit both slope and intercept in a
linear setting.
O’Quigley and Shen (1996) discussed a concern that had been the source of worrying
when the CRM was originally introduced. Their concern was related the choice of prior
(Mick and Ratain, 1993). In the case phase I trials, little or no information exists on
the molecule under investigation. Even when the prior is vague enough, it can be argued
that its selection can have an impact on the estimation of the posterior, under very small
sample sizes. Despite the fact that dependence on the prior diminishes as the sample size
increases, it is true that in phase I trials, and especially in the past, most of the times
the sample size does not exceed 20 or 30 patients. Therefore, attention should be paid
on the prior selection.
1.4.1.2 Likelihood approach
In an attempt to address the above concerns O’Quigley and Shen (1996) presented
an alternative version of the CRM that is based on the maximum likelihood theory. This
design is identical to the Bayesian approach, with the only difference being in the initi-
ation of the escalation scheme. In particular, under the maximum likelihood, parameter
estimation is not feasible before some heterogeneity is encountered in the responses. To
maximize the likelihood, it should be non-monotone, so that the estimates are not on the
boundary of the parameter space, i.e. (0,∞). That translates into having at least one
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DLT and one non-DLT in the data, given the one-parameter model. This is accomplished
by introducing some initial escalation scheme. This scheme can be a ‘3+3’ design or any
other kind of “Up and Down” schemes. After some patients are treated and heterogeneity
is observed, we can then switch to the CRM.
Taking the previous example, once again we select a TTL that is  = 20% and a range
of 6 doses D = (−1.47,−1.1,−0.69,−0.42, 0.0, 0.42). Contrary to the Bayesian design,
the first cohort of patients is always treated at the first dose level, d(1) = −1.47. The
dose-toxicity relationship is depicted by a reparameterization of the hyperbolic tangent
function 1.2 that is
ψ(di, a) = a
a
i , where ai =
{
tanhdi + 1
2
}
.
Then, the log-likelihood takes the form
V (a) =
i−1∑
m=1
zmlogψ(dm, a) +
i−1∑
m=1
(1− zm)log(1− ψ(dm, a)).
After estimating the model parameter, we use that information to reassess the prob-
ability of toxicity at every dose level. We substitute in our function ψ(d, a) the aˆ and we
estimate the pˆ(l) for every d(l) ∈ D. Similarly to the Bayesian approach, after obtaining
all pˆ(l), we identify which dose level gives a probability of toxicity closer to the TTL, and
that dose is recommended for the next patient.
General remarks
O’Quigley and Shen (1996) have run simulations with the purpose to compare the
Bayesian and the maximum likelihood approach as far as dose allocation and final rec-
ommendation is concerned. Based on the simulations, the authors concluded that no
significant differences were observed among the models regarding the recommended dose
level at the end of the trial.
An advantage of this approach is that no prior is requested and calculations are
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somehow simplified. What is more, researchers might feel more comfortable with this
approach because no initial “guess” is required concerning the dose allocation of the first
patient. However, the authors argued that the purpose of this method was not to improve
any of the existing methods, but rather to suggest a new formulation that would seem
more “friendly”.
1.4.1.3 Time-to-event CRM
One of the major challenges, with regard to phase I trials and the CRM, is the
sequential nature of the design. Before the entry of a new cohort, it is required that all
patients, already in the study, are fully observed. The main reason is that decisions on
dose allocation are based on the toxicity outcomes observed from the previous patients.
Consequently, a study could last for years before recruiting all patients. Additionally, the
DLT is defined with respect to some time duration, that is usually one treatment cycle.
Even though this does not pose a problem for diseases that progress rapidly, in oncology
toxicities can occur after the first treatment cycle. Therefore, a DLT assessment period
can last beyond one treatment cycle, since late-onset toxicities is a common phenomenon
and they should be taken into account when estimating the MTD.
Cheung and Chappell (2000) proposed a method that embodies the time-to-event
outcome of each patient into the CRM (TITE-CRM). The purpose of this technique is to
decrease the total duration of a phase I trial and at the same time exploit the benefits of
the sequential design. In other words, a patient can enter the study before the previous
patients have completed a treatment cycle, a property that can significantly decrease the
duration of the study. The basic notion of TITE-CRM is to estimate the dose toxicity
curve based on the current toxicity status of all patients, including those who have not
been followed up to the end of the DLT assessment period. That is accomplished by
assigning weights to every patient in the likelihood.
Assuming again a dose-toxicity function that increases monotonically with dose and
T to be the total duration of follow-up, called “observation window”. Each patient in the
study carries a weight w that is 0 ≤ w ≤ 1. Patients entering the study are assigned to a
weight equal to 0 and the longer their follow-up the higher becomes the weight. A patient
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can have a weight equal to 1 in two cases, either if they had a DLT or if they completed
the follow-up. Finally, we denote by Si the time to toxicity of the i
th individual. Then
for s ≤ T ,
P (Si ≤ s) = P (Si ≤ s|Si ≤ T )P (Si ≤ T )
≡ w(s;T )ψ(di, a).
The likelihood function is based on conditionally independent current toxicity outcome
data. The authors selected a linear weighting scheme that is described by the following
function
w(s;T ) = min(
s
T
, 1).
Independently of the weighting formulae, the core of the CRM method remains the same.
After selecting the weighting scheme, we estimate the model parameters and finally the
probability of DLT at every dose level in order to select the dose for every new entry.
General remarks
Extensive simulations were conducted comparing three different types of CRM with
the TITE-CRM. The maximum follow-up duration for every patient was 6 months and
two different sample sizes were tested n1 = 25 and n2 = 48. The range of dose levels was
equal to 6. The purpose of this process was to compare the accuracy of each method in
selecting the correct final dose and the study duration.
CRM simulations gave results comparable to its TITE counterparts. As far as the
final recommendation was concerned models seemed to produce quite similar results. It
was the in-trial allocation that slightly changed depending on the time failure model that
was chosen. In addition to this, the study duration in all cases of TITE was significantly
shorter than the CRM counterparts. More simulation results can be found in the Cheung
and Chappell (2000) article. It is worth mentioning that when delaying accrual is con-
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sidered unethical, i.e. when patients should enter the study before the previous patients
have completed their follow-up, the TITE-CRM can be a good solution in assigning pa-
tients to dose levels, given all available information. Even though this technique does
not improve the accuracy of CRM, it affects in-trial allocation. What is more, according
to Cheung (2011) it can be useful when late onset toxicity is prominent or we expect
non negligible dropout. However, in the case of excessive dropout bias is induced in the
estimations (Cheung, 2011).
1.4.1.4 Interval-censored survival model
Most dose finding designs estimate the probability of DLT after one treatment cycle.
Consequently, all DLTs occurring after the first cycle are not considered discarding a big
fraction of the information acquired during a phase I trial. Sinclair and Whitehead (2014)
addressed this concern by proposing an interval-censored survival (ICS) model, which
models the probability that the first occurrence of a DLT is in a particular treatment
cycle, conditionally on having no DLTs in the previous cycles.
Let C = {1, . . . , k} denote the treatment cycles and k be the last cycle in the trial.
Then for the probability of DLT p(l)s in cycle s and at dose level l we have
p(l)s =

(pi(l)1) s = 1
(1− pi(l)1)(1− pi(l)2) . . . (1− pi(l)(s−1))pi(l)s s = 2, . . . , k
(1− pi(l)1)(1− pi(l)2) . . . (1− pi(l)(s−1))(1− pi(l)s) s > k
where pi(l)s is the conditional probability of DLT in cycle s and at dose l. Let S be the
probability of not having a DLT. For the dose-toxicity relationship Sinclair and Whitehead
(2014) chose a linear model for the complementary log–log transformation of pi(l)s so that
log(−log(1− pi(l)s)) = log
(
−log
(
S > s
S > s− 1
))
+ a2logd
= as + a2logd
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where as is the model intercept that is cycle specific and a1 is the parameter for the dose
effect. The dose assigned to the next patient is selected on the basis of the dose that has
the modal posterior probability of a DLT closest to the TTL after k cycles of treatment.
This distance is calculated via a gain function
gˆ(l) =
1
(− pˆ(l)k)2 .
An advantage of the ICS model compared to the previously presented TITE-CRM
is related to missing values. The ICS model allows for censoring and dropout, while at
the same time taking advantage of all available information. According to Sinclair and
Whitehead (2014) a limitation of their method is that it assumes a model for the data
that may not be appropriate in some situations, for instance, in the case of a non-linear
dose effect.
1.4.1.5 Summary of CRM designs
The CRM is a model based technique for the evaluation of the MTD in phase I clinical
trials. It is widely accepted and utilized over the past few years. As a method it is accurate
enough concerning the recommendation of the final dose and most importantly it exploits
all the knowledge gathered throughout the trial. After extensive simulations O’Quigley
et al. (1990) and O’Quigley and Chevret (1991) showed that the CRM outperformed
other sequential designs (Neuenschwander et al., 2008; Berry et al., 2010; Cheung, 2011).
More specifically, in the context of phase I cancer trials, rule based designs were inferior
with regard to identifying the MTD and for that reason O’Quigley and Chevret (1991)
recommended that the FDA and other regulatory agencies encourage the use of CRM in
these trials. Shen and O’Quigley (1996) and later Cheung and Chappell (2002) showed
that even under model misspecification asymptotic convergence of the CRM algorithm to
the correct dose is feasible, under certain conditions. However, investigators need to be
careful when selecting the dose-toxicity model and the number of included parameters.
Paoletti and Kramar (2009) argued that under limited sample sizes, typical of phase I,
asymptotic convergence can be affected by model choices. In their article, they examined
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a set of scenarios for 4 working models, under both the Bayesian and the likelihood
framework. Their principal conclusion was that model selection has a significant effect
on the operating characteristics.
In this section, two different types of CRM algorithms were described; the Bayesian
and the maximum likelihood. It is pointed out in several occasions that despite the fact
that both approaches produce quite similar results, the likelihood approach tends to be
more easily accepted, since it is more conservative and does not require prior information.
As far as the TITE-CRM is concerned, shortening the study duration is an essential
quality of this approach, even though investigators are required to be extra careful with
its implementation.
1.4.2 Other model based designs
Escalation with overdose control (EWOC) is an alteration of the Bayesian CRM that
was proposed by Babb et al. (1998) and Rogatko et al. (2005), with the goal to improve
the safety of the CRM. “The only difference between the EWOC and the CRM is that
with the EWOC method, the probability of administering a dose that exceeds the MTD
for each higher dose level is assessed after each patient, with an interdiction of dose
escalation if this probability exceeds some critical prespecified value” (Tourneau et al.,
2009). Despite the fact that this technique can protect participants from being treated to
highly toxic levels, it seems to be more conservative and it requires flexible models with
the addition of more informative priors.
The last model based design presented here is the “modified toxicity probability in-
terval” (mTPI) design, proposed by Ji and Wang in 2013. It is based on the principal
idea of the ‘3+3’ design, however it is categorized as model based since it makes use
of probability models. In the mTPI approach dose escalation or de-escalation proceeds
with respect to toxicity probability intervals, created based on the TTL. Let us assume
that the TTL is 20%. Then three probability intervals are constructed. The first one
(underdosing) is [0%, 15%), the second one (proper dosing) is [15% , 26%) and the third
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one (overdosing) is [26% , 100%]. In order to decide to what dose level each patient will
be assigned to, the toxicity rate of the currently used dose is taken into account. If this
rate is within the underdosing interval, then dose escalation is the way to proceed. If
the rate is in the proper dosing range then continuing at the same dose level is recom-
mended. Finally, de-escalation is suggested in case of overdosing. The mTPI is simple
to implement and it is quite safe, since it has a lower probability of exposing patients to
highly toxic doses, compared to the 3+3.
1.5 Molecularly targeted agents
Routinely administered anti-cancer treatments, such as chemotherapy, are called cyto-
toxic drugs. Cytotoxic agents are medicines used to treat cancer, because of their ability
to kill cancer cells. They tend to work by interfering with some aspect of how the cells
divide and multiply. For instance, some work by affecting the cells’ genetic ”makeup”.
There are many different cytotoxic medicines used in the treatment of cancer. In each
case the one (or ones) chosen depend on the type and stage of cancer.
Nevertheless, in the past years the emergence of novel agents as a new therapeutic
option has caused a major shift in the treatment of cancer. These agents are called
molecularly targeted agents (MTAs) or targeted therapies. Targeted cancer therapies are
drugs or other substances that target a protein or an enzyme that carries a mutation or
other genetic alteration that is specific to cancer cells and not found in normal host tissue.
Particularly, these proteins are involved in processes such as cell signaling, oncogenesis
or tumor suppression, cell cycle regulation, angiogenesis, immunologic pathways, metas-
tasis and apoptosis. Therapies that have been approved for treatment of cancer include
hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis
inducers, angiogenesis inhibitors, immunotherapies, and toxin delivery molecules. Can-
cer vaccines and gene therapy are sometimes considered targeted therapies because they
interfere with the growth of specific cancer cells (National Cancer Institute, 2018).
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1.5.1 Mechanisms of action
In order for MTAs to properly function identification of targets is essential. Targets
are receptors or proteins that play an important part in the cancer cell growth and
survival. There are two main approaches to identify potentially good targets. The first
one is associated to the amount of proteins located in cancer cells. If a specific protein is
found only in cancer cells or in abundant quantities in them compared to healthy cells,
then this protein could be a candidate target. An example of such a target is the human
epidermal growth factor receptor 2 protein (HER-2) (Wikipedia, 2018). This factor is
expressed at high levels on the surface of some cancer cells. Several targeted therapies are
directed against HER-2, including trastuzumab (Pratt et al., 2015), which is approved to
treat certain breast and stomach cancers that overexpress HER-2.
The second approach to identify possible targets is related to the ability of cancer cells
to produce mutant proteins that are responsible for cancer progression. For example,
the cell growth signaling protein BRAF is present in an altered form (known as BRAF
V600E) in many melanomas (Cheng et al., 2018). Vemurafenib targets this mutant form
of the BRAF protein and is approved to treat patients with inoperable or metastatic
melanoma that contains this altered BRAF protein (Luke and Hodi, 2012). Chromosome
abnormalities in cancer cells, also, are responsible for fusion gene creation. A fusion gene
is when a gene incorporates parts of two different genes and their product the fusion
protein might drive cancer development. These proteins can be targets of MTAs. An
example is imatinib mesylate that targets the BCR-ABL fusion protein (Sharma et al.,
2010), which is made from pieces of two genes that get joined together in some leukemia
cells and promotes the growth of leukemic cells.
After identifying a possible target, a new therapy is developed aiming for this target.
This therapy can reduce the activity of the target or prevent the target from binding to
a receptor that it normally activates. That way it interferes with its ability to promote
cancer cell growth or survival. Most targeted therapies are either small molecules or
monoclonal antibodies. Small-molecule compounds are mainly developed for targets that
are located inside the cell, whereas monoclonal antibodies are used for targets outside or
on the surface of the cancer cell, due to their large size.
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An issue with targeted therapies, also present in cytotoxic therapies, is the potential
cancer cell resistance to the treatment. In other words, after a period of time the target
might mutate and hence, the therapy can no longer interact with it. Another type
of resistance is when the tumor finds an alternative pathway to achieve tumor growth
that does not depend on the target. It is for that reason that targeted therapies are
usually administered in combination either with another targeted therapy or with classic
cytotoxic agents. Another issue with regard to MTAs is patient eligibility. For certain
types of cancer, most patients with that cancer will have an appropriate target for a
particular targeted therapy and, thus, will be candidates to be treated with that therapy.
Nonetheless, there are cancers for which not all patients can profit from targeted therapies.
Patients are eligible for a targeted therapy if for instance, their tumor has a specific gene
mutation that codes for the target. If no such a mutation is present then the therapy will
have nothing to target.
For targeted therapies, biomarkers play an important part. Their first role is to iden-
tify eligible patients, indicating who would likely respond to a treatment. An example of
such a biomarker is HER2 for breast cancer. Patients with HER2/neu amplified tumors
are more likely to respond to Trastuzumab, which is a monoclonal antibody. Another as-
pect of biomarkers is to measure patients’ response to a specific treatment. When a good
biomarker has been identified, we use this biomarker to measure the activity of the treat-
ment. In oncology, we classically work on two types of biomarkers with different patterns
of trajectories. (i) Biomarkers that are produced by the tumor, such as cancer antigen
125 (CA 125) in ovarian cancer, prostate specific antigen (PSA) in prostate cancer, and
angiotensin-converting enzyme (ACE) in colorectal cancers, and reflect the tumor pro-
gression; they may decrease in case of response to treatment before re-increasing when
the tumor escapes the treatment and progresses (Figure 1.4 a)). (ii) Other biomarkers
reflect the direct action of the treatment such as the plasma concentration or the level
of antibodies binding to their target. The trajectory would then be an increase in time
followed by a decrease when the tumor gets resistant and subsequently progresses (Fig-
ure 1.4 b)). Most often, in oncology, we measure activity with tumor reduction alone
or tumor reduction in combination with a biomarker. Even though tumor reduction is
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a precise measure of treatment activity, it is evaluated with CT scans, ultrasounds or
MRIs (magnetic resonance imaging), therefore, it is not possible to measure it at regular
intervals (James et al., 1999).
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Figure 1.4: Types of biomarker trajectories.
1.5.2 Designs combining toxicity and activity
As mentioned before, targeted therapies require different techniques for dose finding,
due to their biological activity and their administration route. In an attempt to address
some of the concerns described in 1.1, new designs have been developed over the past
few years, that consider as a primary endpoint both toxicity and activity (O’Quigley
et al., 2001), targeting now the OD or the optimal biological dose (OBD), that may
not necessarily be the MTD. Usually, the OD is defined as the dose that achieves high
activity, as that defined by clinicians, while at the same time satisfying certain toxicity
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requirements. The value of these designs is that they combine phase I and phase II
designs and they make it feasible to recommend a dose, the OD, that might be as active
as the MTD, but at the same time less toxic. In the next sections, we divide dose-
finding designs in three large categories: (1) designs that consider toxicity and activity as
binary endpoints, measured over one treatment cycle, (2) designs that consider toxicity
and activity as binary endpoints, including time in their models, and (3) designs that
consider binary toxicity and continuous activity outcomes.
1.5.2.1 Binary toxicity and activity
The majority of the proposed designs usually considers outcomes of interest to be
binary variables. Toxicity is measured based on the DLTs (1 for DLT and 0 for non-DLT).
Similarly, activity is a variable that is dichotomized, indicating patients who respond and
do not not respond to a treatment. For example, patients with a 30% tumor reduction are
considered as responders, whereas anything below 30% is considered as a non-response.
In one of the landmark papers, Thall and Cook (2004) described an adaptive model
based Bayesian procedure with a dose escalation scheme based on a “trade-off” between
toxicity and activity. In particular, they allowed to escalate to doses that might be more
toxic than the usual TTL as long as they produced a high probability of activity, as
that defined by clinicians. Thall and Cook (2004) formulated their models in terms of
marginal probabilities. For dose-toxicity relationship they assumed a monotonic increase
piT (d,θ) = g
−1{ηT (d,θ)},
with θ being the model parameter vector and
ηT (d,θ) = a0 + a1d,
where a0 and a1 are unknown parameters. For the dose-activity relationship they allowed
for more flexibility and non-monotone relations, by adding a quadratic term for dose.
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The marginal probability is described as
piA(d,θ) = g
−1{ηE(d,θ)},
where
ηE(d,θ) = β0 + β1d+ β2d
2,
where β0, β1 and β2 are unknown parameters. They jointly modeled the two outcomes
using a Gumbel copula model
piλ,ν = (piA)
λ(1− piA)1−λ(piT )ν(1− piT )1−ν
+(−1)λ+ν(piA)(1− piA)(piT )(1− piT )
(
eγ − 1
eγ + 1
)
,
where γ is the association parameter of the two models and (λ, ν) ∈ {0, 1}. Then the
likelihood function for a single individual is given by
L(YA, ZT , d|θ) =
1∏
λ=0
1∏
ν=0
{piλ,ν(d,θ)}I((YA,ZT )=(λ,ν)),
where YA and ZT are the indicators of activity and toxicity, respectively.
For the identification of the OD, Thall and Cook (2004) developed a “trade-off”
algorithm that selects the dose with the best compromise between the probability of
toxicity and of activity. Before the trial initiation they construct a target activity–toxicity
“trade-off” contour, by fitting a curve to target values elicited from clinicians. Doses on
the contour are considered to be “equally” desirable. The target contour is then used to
estimate the desirability of each dose that is associated to some probability of toxicity
and some probability of activity. For a better understanding we illustrate an example. To
construct the contour clinicians elicit three target values {pi∗1, pi∗2, pi∗3} that are considered
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to be equally desirable. These target values are pairs of probabilities of activity and
toxicity. The first target pi∗1 = (pi1,A, 0) is the acceptable activity in the absence of
toxicity. The second target pi∗2 = (1,max(pi1,T )) refers to the maximum toxicity that
clinicians are willing to accept if we have the maximum activity. Finally, the third target
pi∗3 is between the two first extreme targets. For our example (Figure 1.5) pi
∗
1 = (0.15, 0),
pi∗2 = (1, 0.60) and pi
∗
3 = (0.25, 0.30).
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Figure 1.5: Activity-toxicity trade-off contour. The three
elicited target points that determine the contour are given
by pi∗1, pi
∗
2, and pi
∗
3. L(q0) indicates the line from q0 to (1, 0).
To design the contour any function can be used piT = f(piA) that increases continuously
over pi∗1,A ≤ piA ≤ 1. For Figure 1.5 they used
f(x) = δ0 +
δ1
x
+
δ2
x2
.
After designing the contour we use it to calculate the desirability of each dose level. Imag-
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ine that we are interested in a dose with a pair of probabilities equal to q0 = (0.35, 0.60).
First, we draw a line L(q0) from q0 to (1, 0) and find the point q1 where L(q) and the
contour intersect. Then, we calculate the Euclidean distance ρ(q0) from q0 to (1, 0) and
ρ(q1) from q1 to (1, 0). The desirability of the dose is calculated by
des(q0) =
ρ(q1)
ρ(q0)
− 1.
A dose with a probability pair q between the contour and (1, 0) will have a des(q) >
0, whereas outside of the contour region des(q) < 0. The dose that maximizes the
desirability function is the dose administered to the next patient.
As previously discussed, the activity of MTAs increases monotonically with dose and
contrary to cytotoxic therapies, it may reach a plateau after a certain dose level. This is of
importance when modeling activity, since usually there is not merit in further escalating
to doses located after the beginning of the plateau. Riviere et al. (2016) considered
such a dose-activity relationship and introduced a Bayesian design that aimed to identify
the OBD. The OBD is the dose with the lowest toxicity among those with the highest
activity. Imagine that there are M planned doses and D = {d(1), . . . , d(M)}. For the
toxicity outcome they used a logistic model
logit(pi(l)) = a0 + a1d(l),
where pi(l) is the probability of DLT at the l
th dose and a0 and a1 are unknown parameters.
Let zi denote the DLT outcome, (1 DLT and 0 no DLT), of the i
th individual, i = 1, . . . , N ,
treated at dose level l. Then, the likelihood after i patients have been enrolled is
L(DT |a0, a1) =
i∏
m=1
pizmm(l)(1− pim(l))1−zm ,
where DT = {(d1, z1), . . . , (di, zi)}. For the activity outcome, they considered a dose-
activity relationship that reaches a plateau after a certain dose level. Thus, they employed
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a logistic model with a plateau parameter that can capture the increasing-then-plateau
pattern of the dose-activity relationship of MTAs. Let φ(l) denote the probability of
activity at dose level l. Then,
logit(φ(l)) = β0 + β1(d(l)1(l<pl) + d(pl)1(l≥pl)),
where β0 and β1 are unknown parameters, 1 is the indicator function, and pl is an index
of plateau taking values between 1 and M . For all dose levels below pl we make the
assumption that the dose-activity relationship increases monotonically, whereas for all
doses equal or above pl the dose-activity relationship admits a plateau. Let yi denote the
activity outcome, (1 activity and 0 no activity), and DA = {(d1, y1), . . . , (di, yi)}. The
likelihood for the activity outcome is formulated as
L(DA|β0, β1, pl) =
i∏
m=1
φymm(l)(1− φm(l))1−ym . (1.3)
The authors accommodated for the case of delayed activity outcomes by weighting the
likelihood 1.3 with the patient’s follow-up time. Therefore, the likelihood for the activity
outcome is
L(DA|β0, β1, pl) =
i∏
m=1
(wm,iφm(l))
ym,i(1− wm,iφm(l)))1−ym,i .
Riviere et al. (2016) selected the same weighting scheme as Cheung and Chappell (2000)
for the TITE-CRM.
For the dose finding algorithm, Riviere et al. (2016) started with a dose escalation
scheme, in which patients enter the trial in cohorts of three. The first cohort is treated
at the first dose level and if no DLT is observed then a second cohort is allocated to the
second dose level. They continue with this rule based design until they encounter the
first DLT. Then they switch to the model based dose finding phase. This dose escalation
scheme serves to collect some information before applying the Bayesian inference. For the
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model based part consider c to be the cohort size and n(l),i to be the number of patients
treated at dose level l. The dose level l is considered to be admissible if it satisfies a
safety requirement
P (pi(l) > ζ) < LT ,
and an activity requirement
P (φ(l) > ξ) ≥ LA1(n(l),i>max(c,3)),
where ζ and ξ denote the pre-specified toxicity upper bound and activity lower bound,
respectively. LT and LA are the respective probability thresholds for toxicity and efficacy.
If we assume that B contains all the admissible doses, then the (i+ 1)th will be allocated
to the dose level with the highest activity in B
d = min
(
argmax(l)∈B(φˆ(l))
)
.
If several dose levels have the same activity, it means that activity reached a plateau
and among them the dose with the lowest toxicity is selected. Even under they Bayesian
framework, we see that it is preferred to start with a rule-based dose escalation scheme,
so as to acquire some data before applying the Bayesian inference.
Below, we briefly present similar designs that can be found in the literature. Huns-
berger et al. (2005) developed two types of designs for binary outcomes, with the goal
to identify a biologically adequate dose. Toxicity was assumed to be relatively low and
thus dose escalation was established only upon activity measurements, mimicking the
‘3+3’ design, till the moment a DLT occurred. A different approach that can be found
in the current bibliography is the TriCRM (Zhang et al., 2006). This design considered
a trinomial ordinal outcome of no activity and no toxicity, activity without toxicity and
just toxicity, with these three probabilities summing up to one. It was assumed that the
probability of no response at all decreased monotonically with dose, the probability of
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toxicity increased monotonically with dose, whereas for the probability of response there
could be a non-monotone relationship with dose. The dose-escalation process initiated
with a screening based on toxicity measurements and from a safe range of doses the OBD
was selected upon some predefined activity criteria. This approach allowed for early
stopping due to safety constrains. Ivanova and Xiao (2013) compared three designs, with
the purpose to investigate which one performs better under the assumption of plateau
shaped functions for activity data. These three designs were a group design imitating the
‘3+3’ design, the t-statistic (Ivanova and Kim, 2009) and the classic CRM (O’Quigley
et al., 1990). They showed that the t-statistic performed better than the other two, due
to the fact that it allocated many patients to the estimated target dose and selected the
lowest dose on the plateau quite often. Cai et al. (2014) proposed a Bayesian design
that accommodated for non-monotonic dose-activity relationships. In particular, for the
toxicity endpoint they assumed a change-point model accounting for the fact that the
dose-toxicity surface of the combinational agents may plateau at higher dose levels. A
flexible logistic model was implemented to capture the possible non-monotonic pattern of
the dose-activity relationship. Three different models for the activity measurements were
also compared by Zang et al. (2015). In particular they introduced a Bayesian based tech-
nique for a binary beta-binomial model for toxicity and three separate models for activity;
a logistic (parametric), an isotonic (non parametric) and local logistic (semi-parametric).
The isotonic and local logistic seemed to have good operating characteristics, but the main
limitation of all three of them was that they could not address cases of delayed outcomes.
Another design under the Bayesian framework that combined features of the CRM and
the order restricted inference (Robertson et al., 1988) was introduced by Wages and Tait
(2015). Toxicity was represented by a bivariate binary model, whereas for activity they
made use of a class of working models. Specifically, they considered both unimodal and
plateau skeleton models. Safety and futility rules for early stopping of the trial were also
taken into consideration in the study design. A common goal among several designs was
to reflect in their models the plateau shape of the dose-activity relationship.
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1.5.2.2 Time-to-event outcomes
Even though the above designs included both toxicity and activity outcomes, only
few of them included time in their models. Yuan and Yin (2009) developed a Bayesian
adaptive design by jointly modeling time-to-DLT and time-to-activity, using a copula
model. Their primary objective was to identify the OD, tackling the issue of delayed
outcomes, so as to allow subjects to be enrolled in the trial, even when only partial
information had been acquired from the previous cohorts.
Let t be the time from the initial treatment until the occurrence of a DLT. The hazard
function for the time-to-DLT, under the Cox proportional hazards model is
hT (t|d) = h0T (t) exp(ad),
where h0T (t) is the baseline hazard, modelled by a Weibull distribution, and a is the
parameter for the dose variable. Then the survival function is given by
ST (t|d) = exp{−λT t(µT ) exp(ad)},
where λT and µT are the scale and shape parameters of the Weibull distribution, respec-
tively. The survival function for the time-to-activity outcome is
SA(t|d) = exp{−λAt(µA) exp(βd)},
where β is the parameter for the dose variable. Yuan and Yin (2009) jointly modeled
toxicity and activity using a Clayton copula model, such that
S(tT , tA|d) = {ST (tT |d)−1/γ + SA(tA|d)−1/γ − 1}−γ,
where tT and tA denote time to toxicity and activity respectively, and γ > 0 measures
the correlation of the two outcomes.
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For the dose finding algorithm the authors suggested selecting the OD using the areas
under survival curves (AUSC), see Figure 1.6. More precisely, they took the ratio of the
AUSC of toxicity AT and activity AA up to a prespecified follow-up time τ ,
Figure 1.6: Illustration of the AUSCs corresponding to toxicity
and activity.
AT
AA
=
µ−1T {λT exp(ad)}−1/µTΓ{µ−1T , λT exp(ad)τµT}
(1− pi)τ + piµ−1A {λA exp(βd)}−1/µAΓ{µ−1A , λA exp(βd)τµA}
,
where Γ is the Gamma distribution and pi is the fraction of patients that benefit from
the treatment. Then, the OD is the dose that maximizes AT
AA
.
An advantage of the AUSC ratio for the dose finding algorithm is that it takes into
account the toxicity and activity rates, as well as how quickly patients experience toxicity
or achieve activity. However, a limitation of their design is related to the start up phase
of the design. To acquire some information, before applying the Bayesian inference, the
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authors suggested initiating the trial with a rule based design that mimics the ‘3+3’
design. The related issue is that before a new cohort enters the study, the previous one
should have been completely followed. We can imagine that this constraint can be a
hindrance in cases where we expect to have a long follow-up period.
Similarly, Koopmeiners and Modiano (2014) modeled both endpoints as time-to-event
outcomes and based their dose escalation decision rules on the activity-toxicity “trade-off”
(Thall and Cook, 2004). Another design for delayed outcomes (Jin et al., 2014) treated
late-onset responses as missing data. More specifically, Jin et al. (2014) proposed a design
that handles the problem of delayed outcomes, by accounting for each patient’s follow-up
time prior to evaluation of toxicity and activity outcomes, and treating outcomes that
have not yet been observed as missing values. They used data augmentation to impute
each missing outcome using partial follow-up times and complete outcome data. For the
design’s decision rules, they combined observed and imputed data for all patients who
have been treated.
1.5.2.3 Binary toxicity and continuous activity
Nonetheless, binary variables are known to be associated with irreducible variances
and are often less informative than continuous variables. Nowadays, more and more
biomarkers are used as indicators of activity in oncology (CA 125, PSA, circulating tumor
cells, ACE, etc.). An approach of jointly modeling, under the Bayesian framework, binary
toxicity and continuous activity outcome, measured at a unique timepoint, via a latent
Gaussian variable, was originally suggested by Bekele and Shen (2005). An essential
aspect of their article focused on the importance of modeling continuous and not binary
biomarker measurements, indicating that dichotomization of the response variable can
lead to substantial loss of information and as a corollary to inappropriate dose selection.
To describe the dose-toxicity relationship, Bekele and Shen (2005) employed a probit
model. To allow for model flexibility, they assumed that there is a separate parameter for
each dose level. They introduced a latent variable Wi for the i
th patient, which follows a
normal distribution with mean awdi and variance 1, where aw = (aw,(1), . . . , aw,(M))
T is
a M × 1 vector of unknown parameters, M being the total number of doses. The latent
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variable is related to toxicity Zi via the condition
Zi =
 0 if Wi ∈ A01 if Wi ∈ A1,
where A0 = (−∞, 0] and A1 = (0,∞). Then, the marginal probability of toxicity is
Pr(Zi = 1|di(l)) = Φ(aW,(l)),
where aW is an unknown parameter. For the activity endpoint, we have a state-space
model. Let Y denote the continuous biomarker variable and βY = (βY,(1), . . . , βY,(M))
T
define an unknown vector of parameters, where βY,(l) reflects the mean biologic activity
for the lth dose. The state-space model assumes a recursive relationship between βY,(l)
and βY,(l−1). Then the relationship between the two parameters is given by
βY,(l) = βY,(l−1) + u(l), u(l) ∼ N(0, σ2),
This model was motivated so as to consider a flexible dose-activity relationship, which
does not necessarily increase monotonically. The authors joint modeled the two outcomes
via a latent Gaussian variable. The joint distribution of (Yi, Zi) is assumed to have a
bivariate normal distribution with mean (diβY , diaW )
T and variance covariance matrix
Ω, such that
Ω =
σ2Y + ρ ρ
ρ 1
,
that is positive definite and ρ is the covariance parameter between Y and Z, which induces
the dependence between toxicity and activity. Given the observed data the likelihood for
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the ith patient takes the form
f(yi, zi|βY , aW ,Ω, di) =
1∏
m=0
{∫
Am
φY,W (yi, wi; (diβY , diaW )
T ,Ω)dwi
}I(zi=m)
,
where φY,W (y, w, µ,Σ) is a bivariate normal density with mean µ and variance covariance
matrix Σ.
In the beginning of the trial the first cohort of patients is assigned to the first dose
level. The size of the cohort c can vary between 1 and 6 patients. A dose is considered to
be adequately tried, i.e. there is enough information concerning toxicity and activity of
that dose, if at any point n(l) ≥ c. In other words, a dose is considered to be adequately
tried, if more than one cohort has been treated to that dose level. Before the trial, a clin-
ician defines the minimally acceptable biomarker level Y ∗min and the maximum acceptable
toxicity probability piT . Finally, let η1 and η2 be the prespecified probability thresholds.
Then a set of doses is considered to be acceptable if it satisfies two requirements. For
activity
Pr(β(l) > Y
∗
min|data, n(l) ≥ c) > η1
and for toxicity
Pr(Φ(aW,(l)) < piT |data, n(l) ≥ c) > η2.
Therefore, a dose is defined as acceptable if the posterior probability of the mean biomarker
level is greater than Y ∗min is greater than η1 and if the posterior probability of toxicity is
less than piT is greater than η2. If more than one dose is deemed acceptable then the dose
administered to the next cohort of patients is selected based on a rule similar to that
proposed by Thall and Cook (2004). Let py(d(l)) = E(βY,(l)|data) be the expected pos-
terior mean for the biomarker and pz(d(l)) = E(Φ(aW,(l))|data) be the expected posterior
probability of toxicity at dose d(l). Finally, we elicit from clinicians the largest possible
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biomarker value Y ∗max and define (Y
∗
max, 0) to be the optimal point, which corresponds
to the maximum activity and zero toxicity. Then, for each of the acceptable doses we
estimate their Euclidean distance g(l) from the optimal point.
g(l) =
√[
Y ∗max − py(d(l))
Y ∗max
]2
+ pz(d(l))2.
A dose that minimizes the distance from the optimal point is considered to be the OD,
allocated to the next cohort.
A similar design to that of Bekele and Shen (2005) was proposed by Hirakawa (2012).
On the same page, Yeung et al. (2015) introduced an adaptive design for the identification
of the OD, that combines toxicity and activity through a logistic regression and a linear
log-log regression model, respectively. The activity model was restricted only to patients
with no DLTs. Dose escalation was achieved via a gain function or otherwise a “trade-
off” between the two outcomes. Stopping rules were applied either for safety or when
the OD was reached. Finally, Yeung et al. (2017) proposed a similar design with the
one described above, only in this case activity was modeled via a flexible non-parametric
model.
1.5.3 Future concerns
Despite the growing popularity of designs that model both toxicity and activity out-
comes, there are still important aspects of phase I trials that need to be considered. As
mentioned before, the prolonged administration of MTAs can lead to cumulative toxi-
cities. Ignoring this information when designing a trial may result in selecting a dose
that could eventually be highly toxic in the long-term. Unfortunately, given the current
designs that can only be investigated in phase II or III trials, in which follow-up is signif-
icantly longer. It is vital to define the MTD or the RP2D based on DLTs occurring after
multiple cycles and not just the first one. Furthermore, most of the methods consider
time as a continuous variable. However, in most clinical trials the exact time of the event
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is not known. Severe toxicities are recorded at the time of a patient’s visit, which is
usually at the end of the treatment cycle or the beginning of the next one. As a result,
toxicity data are censored by intervals, which most often are the treatment cycles. If we
account for this censored information it is feasible to measure the cumulative probability
of toxicity of each dose at each treatment cycle. An additional point here is with respect
to the activity measurements. When a certain biomarker is used as an indicator of ac-
tivity then for each patient we have repeated measurements during the follow-up. These
measurements are collected in regular time intervals in order to explore the biomarker
trajectory till disease progression or excessive toxicity, both of which would force a patient
to drop-out of the study. All methods described here consider the activity at a unique
time point. One major limitation of this approach is that we cannot know in advance
which measurement is the most informative, so selection is usually random. Secondly,
by ignoring the time-activity relationship of the biomarker we discard a vital part of the
information.
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Chapter 2
An adaptive design for the
identification of the optimal dose
using joint modeling of continuous
repeated biomarker measurements
and time-to-toxicity
2.1 Introduction
In Chapter 1 we introduced the existing methods for dose-finding in oncology. Discus-
sion also revolved around challenges that we face when designing phase I trials, associated
with cumulative toxicities, repeated measurements of biomarkers of activity as well as
missing data. In this chapter, we attempt to address these important challenges by
introducing a new adaptive design.
The remainder of Chapter 2 is organized as follows. In Section 2.2 we present the
objective of our work along with a motivating example from a clinical trial (Subsec-
tion 2.2.1). Section 2.3 is the methods part, where we introduce the models for toxicity
and activity and we describe the joint modeling framework. We talk about estimation
difficulties, the study design and finally, the decision process for the identification of the
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OD. Section 2.4 is dedicated to the simulation study we conducted in order to test the
robustness and the operating characteristics of our design under various settings. We
analytically present the simulation framework, i.e. how simulation scenarios were devel-
oped using the motivating example. Section 2.5 refers to the simulation results, including
tables and also the sensitivity analysis. Discussion follows in Section 2.6.
2.2 Objective
We propose an adaptive design for the identification of the OD, in phase I/II trials
of MTAs. The OD is defined as the lowest dose, within a range of active doses, that is
below or equal to the MTD. The MTD is the dose with a cumulative risk of toxicity, or
more precisely cumulative risk of DLT, over six cycles that minimizes the distance from
a predefined TTL. The TTL is also defined cumulatively over six cycles. We employ a
recent joint modeling technique of longitudinal continuous biomarker measurements and
time-to-DLT data, using a shared random effect and likelihood approach. The biomarker
is measured on a continuous time scale, whereas DLTs are measured on a discrete time
scale.
2.2.1 Motivating example
This work is motivated by a french multicenter phase IB trial in patients with platinum
resistant epithelial ovarian carcinoma. The aim of this trial is to assess the performance of
the combination of three different agents, immunotherapy, biotherapy, and chemotherapy.
The primary objective of the study is to determine the MTD and the OD that will be
recommended for phase II. Activity of the drug combination is mainly evaluated with
tumor volume and CA 125 measurements. CA 125 is a biomarker routinely used to assess
response and progression in ovarian cancer clinical trials. According to the Gynecological
Cancer Intergroup guidelines (Rustin et al., 2011), response is defined on the basis of a
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reduction in the levels of CA 125. Progression is indicated by progressive serial elevation
of serum CA 125, either above 70 units/ml for patients with normalization of CA 125 or
otherwise above twice the nadir value. Zhou et al. (2016) provide an example of the CA
125 trajectory from a randomized clinical trial on ovarian cancer patients (Figure 2.1).
We have simulated a similar example (Figure 2.2), using a linear mixed effects model,
with a quadratic term for time that we shall use in the following. A maximum of eight
cycles has been planned, with a duration of three weeks each, and a maximum of 42
patients is expected to be included in the study. Once the MTD is determined, then,
based on both toxicity and activity data the OD will be defined. The OD will either be
the same as the MTD or below the MTD, but will not exceed the MTD.
Figure 2.1: CA 125 trajectory plotted against the per-
centage of progression free survival. Red line refers to the
experimental arm and blue line refers to the standard arm.
Figure from a randomized clinical trial (Zhou et al., 2016).
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optimal dose.
2.3 Methods
2.3.1 General framework
Consider a trial of N individuals, i = 1, . . . , N and a total of M planned doses to be
tested D = {d(1), . . . , d(M)}. Patients are sequentially assigned to a specific dose level,
selected based on the data from previous patients. Cycles of treatment are repeatedly
administered until DLT, disease progression, defined by an elevation of the biomarker,
or consent withdrawal. At the end of each cycle study participants are evaluated as to
whether they had a DLT during the cycle or not. We then have discrete time failure
data. During the trial, the biomarker levels are measured at each weekly visit, in order to
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monitor the treatment effect. As a result, for each patient we have repeated continuous
biomarker measurements. One or more doses are considered to be “equally” active to the
MTD if their predicted activity falls within a predefined equivalence range. For example,
Figure 2.2 illustrates such an equivalence range. The minimum biomarker value, reflecting
the maximum activity, of doses 2 and 3 fall within this equivalence range, indicating that
the two doses are “equally” active. The OD is the lowest dose on the range of doses that
are “equally” active to the MTD. If a DLT is observed or the agent is not active, based
on the biomarker data, then the patient is removed from the study, resulting in censored
DLT data and missing at random data (MAR) for the biomarker.
2.3.2 Modeling time-to-DLT
The time-to-DLT is a survival endpoint. Specifically, we are interested in the time of
the first DLT of each patient. As mentioned in Section 1.5.3 DLTs are usually recorded
at the end of a cycle. Consequently, for the toxicity outcome we have a discrete time scale
C = {1, . . . , k}, where k is the total number of treatment cycles. To model this outcome
a probit time-to-DLT model, adjusted for cycle and dose effects, is assumed. Let Si be
the time-to-DLT, so that
P (Si = s|Si > s− 1) = 1− Φ(a0 + a1ci(s−1) + agdi), ci(s−1) ∈ C, (2.1)
where Φ(·) is the cumulative standard normal distribution and a0 and a1 are unknown
parameters and di is the patient’s dose. Cycle ci(s−1) is included in the model, assuming a
linear relationship on the probit scale for the hazard of DLT and the cycle. No time effect
is assumed in the first cycle, as the intercept captures the hazard at the first cycle. In
the spirit of the CRM (O’Quigley et al., 1990), we fix the slope of the dose to a constant
value ag. Given the model, the probability of having a DLT at cycle s is conditional on
having no DLT in all the past cycles.
As mentioned above, the MTD is defined based on the cumulative probability of
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DLT. We consider a total of 6 cycles in the study. The probability of DLT at each cycle
is obtained as follows:
P(l)(Si = s) =

(1− Φ(l)1) s = 1
Φ(l)1Φ(l)2 . . .Φ(l),s−1(1− Φ(l)s) s = 2, . . . , 6
Φ(l)1Φ(l)2 . . .Φ(l),s−1Φ(l)s s > 6,
where 1−Φ(l)s is the hazard function at cycle s and dose level l, l being the index for the
dose. Then, the cumulative probability of DLT at the end of cycle 6 is
P(l)(Si ≤ 6) =
6∑
s=1
P(l)(Si = s).
2.3.3 Modeling activity
For the activity endpoint we suppose a continuous timescale, such that T = (0, k).
Let Yij be the repeated continuous biomarker measurements for the i
th individual, at
times tij ∈ T and j = 1, . . . , n represents the visit number. The model structure is
motivated by the activity trend over time, shown in Figure 2.2. We assume that doses of
treatment modify the course of CA 125 as follows
yij = β0 + β1t
2
ij + β2tijdi + β3tijlog(
√
di + 1) + Uitij + rij, (2.2)
where β0, β1, β2, and β3 are unknown parameters to be estimated and di, as before, is
the dose. Ui refers to the random effect associated with the time of the longitudinal
measurements and Ui ∼ N(0, σ21). The model residuals, Rij, are mutually independent
and follow a Gaussian distribution, MVN(0, σ22I), with I being the identity matrix.
Within our model we do not include a main effect for the dose, since baseline activity is
not associated with the dose level, to which a patient is allocated to. Furthermore, we
have adjusted the model for two interaction terms. The first one, tijdi is used to capture
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the dose-time interaction, usually present in a clinical trial, whereas the second one
tijlog(
√
(di) + 1) permits for a smoother dose-activity relationship. In other words, the
log square root gives a curve that approximates a plateau in the dose-activity relationship.
Regarding the biomarker trajectory over time, we selected the square of the time t2ij, to
model the parabolic time-activity relationship (Figure 2.1). This is no the first time that
a model like 2.2 is used for a biomarker. For example, Rizopoulos (2012) modeled the
level of serum bilirubin accounting for a quadratic time-trend, as well as for interactions
with t and t2, in order to capture the biomarker evolution in time. Phase I patients might
respond to the treatment but will eventually progress, due to advanced disease, and the
biomarker will increase back to the initial values or even higher. This is also clear by
the CA 125 guidelines that state that patients should be censored, due to lack of activity
once their biomarker values increase above a certain threshold.
In principle, the timing of the individual measurements can differ per patient, but in
our design we assume fixed time points tij. It is implicit that the number of measurements
varies per subject due to censoring. The dose parametrization makes the model suitable
for monotonic or plateau shaped dose-activity relationship, but not for a parabolic one.
In this design we make the assumption that patient discontinuation is solely related to
the set of observed responses. That could refer to either disease progression or occurrence
of a DLT. Thus, missing responses correspond to MAR. Longitudinal models, estimated
with maximum likelihood estimation, provide valid inferences under MAR given the fact
that they are correctly specified (Rizopoulos, 2012) .
2.3.4 Joint modeling
When implementing a survival model the main focus is to investigate how certain
factors can affect the overall survival. These factors are usually constant during the
follow-up and are measured at baseline. An example of such a variable is the dose
administered to each patient, in model 2.1 that is not modified during the course of
the trial. Furthermore, in oncology, we know that toxicity is associated to drug activity
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(Abola et al., 2014). Patients who respond to the treatment are more likely to present
with a DLT. Therefore, when estimating the probability of toxicity, it is of interest to
take into account this association. However, activity is a time-dependent variable. Time-
dependent is a covariate that changes in time and this change may have an impact on
the outcome. There are two types of time-dependent variables; the exogenous and the
endogenous. Exogenous is a variable that can be measured at any time s. An example
of an exogenous variable is the air pollution or the seasonal patterns that are associated
with allergies or asthma attacks. Irrespectively of the event of interest or the subject
under study, at any time we can measure the levels of the air pollution. On the other
hand an endogenous variable cannot be measured at any time s. The main reason is its
dependence on the subjects under study. In this study CA 125 biomarker measurements is
an endogenous variable. CA 125 is an indicator of activity and patients are removed from
the study after CA 125 increase, suggesting disease progression. Biomarker measurements
are directly connected to patients, therefore if the latter are out of study information is
no longer available. Consequently, there is missing data in the time-to-DLT outcome due
to a factor not directly related to toxicity. An endogenous variable requires the survival
of the subject for its existence and adjusting for it is not enough to capture its effect.
That being said it is clear that measuring the effect of these variables requires alternative
methods.
When the primary focus of an analysis is to investigate the association of a survival
outcome with time-dependent endogenous variables, an alternative framework has been
proposed known as joint modeling. The main idea behind this approach is that the out-
comes of interest are estimated using a joint distribution (Schluchter, 1992; Faucett and
Thomas, 1996; Wulfsohn and Tsiatis, 1997; Henderson et al., 2000; Tsiatis and David-
ian, 2004; Rizopoulos, 2012). An idea of joint models is given in Figure 2.3 (Rizopoulos,
2012). In the top panel we have a hazard funtion that describes how the risk of an event,
here toxicity, changes in time. In the bottom panel we see the longitudinal process. The
asterisks are the longitudinal measurements, here the biomarker measurements, and the
green line delineates the fitted model. Joint models posit that the hazard function at
any time point is associated with the value of the longitudinal process at the same time
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point. Several joint models have been proposed in the current literature, such as the
joint models with shared random effects or joint latent class models (Ibrahim et al., 2010;
Mccrink et al., 2013; Proust-Lima et al., 2014; Lawrence Gould et al., 2015). Estimation
of these models can be achieved under both the maximum likelihood or the Bayesian
framework.
Figure 2.3: Top panel: Hazard funtion for the time-to-event outcome. Bottom
panel: Longitudinal process (Rizopoulos, 2012).
Joint models have significantly gained ground over the past years because they benefit
the analysis of both longitudinal and survival outcomes. To begin with, the use of the
longitudinal model to incorporate the effect of the time-dependent variable on the sur-
vival outcome has been shown to provide less bias estimates than independent or separate
model estimation (Ibrahim et al., 2010). Furthermore, integration of the survival infor-
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mation into the evaluation of the longitudinal process directly embodies the effect of an
informative missing-data mechanism. Joint models provide accurate inference, especially
in the case where outcomes are strongly associated.
Returning to our framework, we shall focus on a joint modeling technique with a
shared random effect, proposed by Barrett et al. (2015). This technique makes use of a
probit time-to-DLT model 2.1 and a linear mixed effects model 2.2 that share the random
effect that comes from the latter. Hence, model 2.1 takes the form
P (Si = s|Si > s− 1, Ui) = 1− Φ(a0 + a1ci(s−1) + agdi + γUi), ci(s−1) ∈ C, (2.3)
where Ui, as before, is the random effect of the activity model and γ is the parameter
associating the time-to-DLT outcome with the random effect. The underlying assumption
of a shared random effect model is that repeated measurements and DLT times are
independent conditionally on Ui.
A major challenge when jointly modeling time-to-event and longitudinal data is over-
coming estimation difficulties, especially with small sample sizes. As underlined by Ri-
zopoulos (2012), parameter estimation of shared random effect approaches for longitudi-
nal and survival data is impeded by both numerical approximation of the log-likelihood
integrals and numerical optimization. An attractive and elegant feature, of the joint
modeling technique we use, is that it allows for likelihood inference. Barrett et al. (2015)
chose the probit and the linear mixed effects model to take advantage of specific prop-
erties of the skew normal distribution (Azzalini, 2005; Arnold, 2009). Their aim was to
express the joint likelihood in a closed form, by integrating out the random effects. They
called it exact likelihood. Hence, the estimates of the model parameters are obtained
directly from the numerical maximization of the likelihood.
Hereafter, for the notation we remain as close as possible to Barrett et al. (2015), thus,
we omit the subscript i from the notation. Suppose now that there is an indicator δ, for
the survival events, such that δ = 1 for DLT and δ = 0 for censoring. Define two vectors
that summarize the model parameters, β = (β0, β1, β2, β3) and a = (a0, a1, ag) of the
longitudinal and the survival model, respectively. Moreover, let X summarize covariates
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that are operative on Y , i.e. time visits and dose and similarly let X˜s be an s× 2 matrix
summarizing covariates up to time s, i.e. cycle and dose. Here, we make the assumption
that survival variables are not time dependent. For simplicity purposes let θ be a vector
containing all unknown parameters and y be the realization of Y . After integrating out
the random effects, the joint likelihood takes the form:
L(θ; y, s, δ) = L1(θ; y)L2(θ; y, s, δ). (2.4)
The first term of the right part of expression (2.4), L1, corresponds to the longitudinal
model and is expressed as
L1(θ; y) =
1
(2pi)n/2σn2 |σ21H|1/2
exp{−(y −Xβ)
T (y −Xβ)
2σ22
+
hTHh
2
},
where
H =
tT t
σ22
+ (σ21)
−1, h =
H−1tT (y −Xβ)
σ22
, and t = (t1, . . . , tn)
T .
The second term of expression (2.4), L2, is related to the event time model. Let Γs be an
s× 1 matrix that takes the value of γ and denotes the first s rows. Then L2 for a single
random effect can be written as
L2(θ; y, s, δ) =

Φ(s){X˜sa + Γsh; 0, I + ΓsH−1ΓTs } for δ = 0,
Φ(s−1){X˜s−1a + Γs−1h; 0, I + Γs−1H−1ΓTs−1}
−Φ(s){X˜sa + Γsh; 0, I + ΓsH−1ΓTs } for δ = 1,
where Φ(s) is the s-dimensional cumulative normal distribution. The process to reach the
analytical expression of the above relationships can be found in Barrett et al. (2015).
This method is highly robust in terms of parameter estimation and the authors demon-
strate good mean square error and coverage. However, because of the small sample sizes
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in phase I trials, we further examined its robustness under six different sample sizes,
N1 = 15, N2 = 20, N3 = 25, N4 = 30, N5 = 40, and N6 = 60 and under the case of
unbalanced data over time. We concluded to satisfactory bias and coverage. Results can
be found in Table A.1 (Appendix A).
2.3.5 Study design
To maximize the likelihood, it should be non-monotone, so that the estimates do
not arise on the boundary of the parameter space. In other words, we cannot proceed
with the parameter estimation before some heterogeneity is encountered in the responses
(O’Quigley and Shen, 1996). Even then, certain issues may arise when estimating the
Hessian matrix for the standard errors. These difficulties are usually related to the small
sample size. Even if optimization criteria are satisfied, the Hessian matrix may not be
positive definite due to zero or negative eigenvalues. We then considered that fitting the
joint model was possible only if certain criteria were satisfied; 1) at least 16 patients had
been enrolled, 2) the standard errors of all joint model parameter estimates were below
20, and 3) the Hessian matrix was positive definite. Therefore, we split the design into
two stages (Figure 2.4): for the first one dose escalation proceeds based on toxicity only
and for the second one patient allocation is based on both outcomes and we identify the
OD.
For the first stage, we introduce an escalation scheme that relies on a rule-based
design, the ‘2+2’ design. Patients enter the study in cohorts of two and dose escalation
starts from the lowest dose level. In this stage interest lies on the toxicity observed in
the first treatment cycle only. First, a cohort is assigned to dose level d(l). Then, at the
end of a treatment cycle if no DLT has occurred the next cohort will be allocated to dose
d(l+1) and if two DLTs have occurred then we de-escalate to dose d(l−1). Finally, if one
DLT is observed then we remain at the same dose level.
When two DLTs and two non-DLTs have occurred, we stop the ‘2+2’. If all 3 criteria,
mentioned above, are satisfied, we switch to the joint modeling stage. If not, then we rely
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on a probit time-to-DLT CRM to guide dose-escalation. This approach, an extension of
the CRM, is very similar to the one proposed by Sinclair and Whitehead (2014). Patients
are sequentially enrolled in the trial at the best current estimate of the MTD, defined as
the dose associated with some cumulative risk of DLT over six cycles. During this stage
we accumulate the toxicity data from all treatment cycles and update the information
before the entry of a new patient. Estimation relies on the same model 2.1 of the toxicity
outcome
P (S = s|S > s− 1) = 1− Φ(a0 + a1c(s−1) + agd), c(s−1) ∈ C. (2.5)
Two DLTs and two non-DLTs, in two different cycles, are the minimum requirement for
parameter estimation of model 2.5. We continue with the CRM until we can switch to the
joint modeling. The ‘2+2’ and the CRM constitute the first stage of the design, where
dose escalation depends solely on toxicity. Of note, any design could be applied in order
to collect enough data to fit the joint model.
Finally, when all 3 criteria are met, we initiate the second stage and we update activity
and toxicity estimates after each new patient, using joint modeling. Patients may enter
into the study even if previous patients have not completed their six-cycle treatment
period. Based on those estimates, we determine the MTD and the OD that is the dose
the new patient will be allocated to. The OD allocated to the last patient in the trial
is the dose recommended for phase II or III trials. For safety reasons dose skipping is
not allowed. The trial ends either after all planned patients have been treated or due to
excessive toxicity at the first dose level.
To avoid treating patients with a drug that would be excessively toxic at all dose
levels, we implemented an early stopping rule, proposed by Ivanova et al. (2005). We
generated a Pocock-type boundary for repeated testing of the toxicity, occurring at the
first treatment cycle. A probability above 35% at the 10% level (one-sided) led to stop
the trial. During the ‘2+2’ it is not possible to estimate the probability of DLT using
model 2.3, thus we chose a non-parametric stopping rule that is applicable to both the
‘2+2’ and the CRM. We only considered DLTs at the first cycle of treatment for similar
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‘2+2’  
2 DLTs and 2 non-DLTs 
If SE>20 or Hessian matrix 
is not  positive definite 
 
Time-to-DLT 
CRM 
 
Try 
Joint Modeling 
    If i≥16      If i<16  
If SE≤20 and Hessian matrix 
is positive definite 
Joint Modeling 
    If i≥16  
Figure 2.4: Representation of the study design described in Section 2.3.5. Abbre-
viations: DLTs, Dose Limiting Toxicities; i, index for the patient; SE, Standard
Error; CRM, Continual Reassessment Method.
reasons. The explicit boundaries can be found in Table A.2 .
2.3.6 Decision process
Based on the joint model estimates, we determine the MTD and the OD. We start
from the MTD. Taking the conditional probability of toxicity for U = 0 we minimize over
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all dose levels
MTD = min
(l)
|− P(l)(S ≤ 6|U = 0)|,
where  is the TTL. Then the MTD is used to select a subset of safe doses B. This subset
contains the MTD and all doses below the MTD, if the MTD is not the first dose level.
Then, from B we eventually select the OD, that is the lowest dose, from a range of
doses, Λ, where Λ ⊆ B, that are “equally” active as the MTD. Particularly, for every
d(l) ∈ B we estimate, at each time visit tj and for each dose level l, the conditional
predicted biomarker activity
yˆj(l) = βˆ0 + βˆ1t
2
j + βˆ2tjd(l) + βˆ3tjlog(
√
d(l) + 1).
The maximum drug activity is associated with the minimum biomarker measurement
over time, thus, for each dose we select the minimum of the predicted values yˆmin(l). We
identify doses that are “equally” active to the MTD as follows,
|yˆmin(MTD) − yˆmin(l)| ≤ ζ,
where ζ is the equivalence range. The lowest dose in Λ is selected for the next patient.
Estimation of the MTD and the OD is repeated before the enrollment of a new patient.
For a better understanding, we summarize the above procedure by simulating an
example. Consider a trial of k = 4 treatment cycles, one patient visit per cycle, so
n = 4 and M = 4 planned doses. The estimations of the joint model parameters, serve
to estimate the cumulative probability of DLT, over 4 cycles at each dose, as shown
in Table 2.1. If we assume that the target is  = 0.40, then MTD=d(3), Figure 2.2.
Consequently, the safe subset of doses is B = {d(1), d(2), d(3)}. Next, for every d(l) ∈ B
we select the minimum predicted value in time, yˆmin(l), which is depicted in bold in
Table 2.2. We define ζ = 20, that is any dose d(l) ∈ Λ to be “equally” active to the MTD, if
|yˆmin(MTD)−yˆmin(l)| ≤ 20. For instance, for dose level 2 we have |yˆmin(MTD)−yˆmin(2)| = 13,
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meaning that d(2) and the MTD are “equally” active. On the contrary, for dose level 1
|yˆmin(MTD) − yˆmin(2)| = 24, thus, d(1) and the MTD are not “equally” active. Therefore,
the OD is d(2). This can be seen in Figure 2.2, where the two horizontal lines delineate
the range where doses are not clinically different from the MTD.
Table 2.1: Probability of DLT at each cycle P (S = s) and cu-
mulative probability of DLT over 4 cycles P (S ≤ 4) per dose
level.
P (S = 1) P (S = 2) P (S = 3) P (S = 4) P (S ≤ 4)
d(1) 0.05 0.03 0.01 0.01 0.10
d(2) 0.12 0.07 0.04 0.02 0.25
d(3) 0.22 0.11 0.08 0.04 0.45
d(4) 0.30 0.20 0.14 0.06 0.70
Table 2.2: Predicted biomarker activity yˆmin(l) per cycle and per
dose level. Bold values indicate the minimum predicted value
over all cycles and for the safe doses only.
yˆmin(1) yˆmin(2) yˆmin(3) yˆmin(4)
d(1) 102 85 88 110
d(2) 100 77 74 91
d(3) 98 70 61 73
d(4) 96 62 48 54
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2.3.7 Estimands
Joint model with shared random effect is used to obtain unbiased estimates of the
expectation of the biomarker effect over time, while accounting for attrition due to severe
toxicity and vice versa. The immortal cohort is not very different from the intent to treat
population in phase III trials. In fact, in phase II or in phase III clinical trials, patients
suffering from serious adverse events would probably receive co-medication and continue
treatment. Therefore, this population is hypothetical but may exist. Conversely, one
could be interested in the expectation of the marker given that the subjects had no DLT
at a given time point, also called the partly conditional expectation.
Following Rouanet et al. (2017), if we assume that missingness for DLT is independent
of the current marker value, then to obtain the expected activity under both the immortal
cohort and given that subjects had no DLT we should estimate
E(Yij|Xij, Ui, Si > s− 1) = XTijβ + γE(Ui|Xij, Si > s− 1) + E(rij|Xij, Ui, Si > s− 1).
In fact E(rij|Xij, Ui, Si > s − 1) is negligible (Rouanet et al., 2017). For the immortal
cohort E(Ui|Xij, Si > s−1) = 0, whereas given that subjects had no DLT E(Ui|Xij, Si >
s− 1) 6= 0. For the estimation of E(Ui|Xij, Si > s− 1), Mcculloch et al. (2016) proposed
an approximation based on a log-linear time to event model, which does not lead to
similar flexibility in the modeling of the variation of the hazard in time.
2.4 Simulation settings and evaluation criteria
2.4.1 Framework
In order to assess the performance of our design we conducted a set of extensive
simulations, covering a wide variety of scenarios. Several aspects of our simulations
matched the ovarian cancer trial, introduced in Section 2.2.1, such as time intervals,
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CA 125 biomarker measurements, and censoring process. To that end, we simulated a
trial of six doses (1.2, 1.4, 1.6, 1.8, 2.0, 2.2) and a total of 60 patients. Eight principal
scenarios were investigated (Table 2.3). Scenarios covered cases where the OD and the
MTD coincided, the OD was below the MTD, and finally all doses were highly toxic. The
parameters used for data generation of these scenarios are provided in Table A.3. Some
of these scenarios served for our sensitivity analysis (Tables A.4-A.5).
2.4.2 Time-to-DLT
For the time-to-DLT outcome, we considered a maximum of six treatment cycles.
This number stemmed from the DLT-TARGETT group (Postel-Vinay et al., 2014), who
showed that severe toxicities occurred quite often after cycle 1 and were almost null
after cycle 6. We assumed that the hazard decreased over time (Postel-Vinay et al.,
2011, 2014). Typically, the target toxicity level over one treatment cycle is between 20%
and 33%, so over six treatment cycles setting the target at 40% was quite a realistic
choice. In the principal scenarios, data was generated from the model of analysis. For
the analysis model, the dose slope was fixed, across all scenarios, at ag = −3.29 and for
data generation we changed this specific value assuming a maximum change of 0.7 units.
Parameter ag = −3.29 provided satisfactory operating characteristics in capturing the
monotonic dose-toxicity relationship. Administrative censoring was at cycle 6.
2.4.3 Activity
For the activity endpoint, following the Gynecological Cancer Intergroup guidelines
(Rustin et al., 2004), we simulated CA 125 patient data at fixed time intervals with
baseline values being at least twice the upper limit of the reference range, [0, 35] units/ml.
The marker was measured once a week, corresponding to three measurements per cycle,
so participants could have a maximum of n = 18 measurements at the end of the trial.
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Along with the time-to-DLT model, that gave a total of nine parameters to estimate in
the joint model. One dose was considered “equally” active to the MTD if their minimum
biomarker measurements did not differ by more than 20 units/ml, so ζ = 20.
2.4.4 Missing data
Patients remained in the study until DLT occurrence, disease progression, consent
withdrawal or completion of the 6 cycles of treatment. In fact, in phase I around 93% of
study participants leave the study by the end of cycle 6 (Postel-Vinay et al., 2011). In our
simulations all censoring takes place at the end of the corresponding cycle. The first cause
of missingness was DLT occurrence. After a DLT patients did not contribute biomarker
data. The second cause was disease progression and that led to information missing
regarding the toxicity profile. Disease progression was defined with respect to Rustin et al.
(2011) stating that: a) patients with elevated CA 125 pretreatment and normalization of
CA 125 must show evidence of CA 125 greater than, or equal to, twice the upper limit
of the reference range and b) patients with elevated CA 125 pretreatment, which never
normalizes, must show evidence of CA 125 greater than, or equal to, twice the nadir value.
These two missingness mechanisms can be seen as at random. We assumed that patients
consent withdrawal, the third cause of missing data, was independent of both toxicity
and activity and may occur with a 8% probability at each treatment cycle. Finally, we
accounted for 7% intermittent missing responses for each biomarker measurement, that
entailed missing data but not censoring.
2.4.5 Main analysis
A total of 2000 simulations were replicated for each scenario. Interest lay in evaluating
the percentage of correct OD identification, which corresponded to the dose administered
to the last patient in the trial and the mean number of patients allocated over the dose
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range in the study. Furthermore, we explored the percentage of simulations where joint
modeling could not be fitted. Convergence criteria for likelihood maximum were based
on the gradient function, with an absolute error tolerance of 10−3.
2.4.6 Sensitivity analysis
A sensitivity analysis was performed assessing the robustness of the proposed design,
under various conditions including also different dose-activity and time-activity relation-
ships than the ones investigated in the principal scenarios. First, we have simulated two
scenarios (Table 2.4) where hazard was increasing at each successive cycle, inducing cu-
mulative toxicities. For the cycle effect we assumed both a steep and a smooth slope,
scenarios 4.1 and 4.2 respectively. Till now, we assumed that the time-activity relation-
ship had a parabolic shape and that doses were ordered. However, we were interested in
investigating the model behavior under various biomarker trajectories over time. To that
end, we simulated one scenario in which the above relationship reached a plateau and
another one where doses crossed in time, see Figures 2.5 a)-b) accordingly. Additionally,
we explored scenarios (Table 2.5) with various degrees of misspecification; toxicity data
was generated based on a logistic model, whereas for activity a saturated dose-biomarker
relationship 2.6 was simulated, with a separate parameter for every dose level,
yij(l) = β0 + β1t
2
ij + β2tijd(1) + β3tijd(2) + β4tijd(3) + β5tijd(4)
+ β6tijd(5) + β7tijd(6) + Uitij + rij. (2.6)
Analysis models were not modified.
The principal scenarios (Table 2.3) were also evaluated under the case of larger vari-
ances (Table A.4), smaller sample size and larger variances (Table A.5) and different dis-
tributions for the random effects between the two models (Table 2.5). We assumed that
for the activity model, random effects followed a gamma distribution U ∼ Gamma(2, 2)
and for the toxicity model, the standard normal distribution U ∼ N(0, 1). In order to
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Figure 2.5: Non-linear biomarker trajectories over time.
assess which of the two models, toxicity or activity, has a stronger effect when being
misspecified, we generated data where either one of the two models was modified. More
specifically, for scenarios A.6.1-A.6.3 data was generated from a saturated linear mixed
effects model for activity and the probit model for toxicity, whereas for scenarios A.6.4-
A.6.6 data was generated from the linear mixed effects model for activity and a logistic
model for toxicity (Table A.6). What is more, we considered a different biomarker-time
relationship that corresponds to that depicted in Figure A.1. This trajectory refers to
biomarkers, discussed in section 2.2.1, that reflect the direct action of the treatment such
as the plasma concentration or the level of antibodies binding to their target. When
patients respond to the treatment the levels of the biomarker increase with time and
when they progress the levels decrease. We have explored our design under these types of
biomarkers by simulating two additional scenarios (Table A.7). Data for the biomarker
was generated from the same linear mixed effects model 2.2 that we introduced in sec-
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tion 2.3.3. Scenarios A.7.1 and A.7.2 were generated in a such a way to match scenarios
5 and 2, respectively, from Table 2.3, at least in terms of toxicity and OD. Patients were
censored due to lack of activity when their biomarker measurements decreased by more
than 20 units/ml, after reaching the maximum activity. To further test the robustness
of the joint model with one random effect, we replicated scenarios in which biomarker
data was generated from a linear mixed effects model with both a random intercept, with
variance σ23 and a random slope and these two were highly correlated ρσ1,σ3 (Table A.8).
Finally, we explored a case where activity data was generated assuming both a linear
and a quadratic term for time (Table A.9). Scenario A.9.1 was created in such a way to
match scenario 1 in Table 2.3, so as to allow for comparison of the two.
2.5 Results
2.5.1 Main results
Table 2.3 summarizes the main results. The percentage of correct selection for sce-
narios 1-7 was 97.3%, 79.5%, 98.4%, 90.9%, 99.5%, 94.8% and 86.5% accordingly. That
was usually higher when the true OD was one of the extreme dose levels, so for instance
scenarios 3, 5, and 6 and lower when the OD was in the middle of the dose range. The
mean number of patients allocated to the OD ranged from 30 to 51 out of 60, depending
on whether it coincided with the MTD. Regarding safety, a dose was recommended above
the MTD for scenarios 1 and 3 in 1.5% and 0.2% of the simulations, accordingly. Gen-
erally, patients were not exposed to highly toxic doses, or to doses that could eventually
be subtherapeutic. For scenarios 1-7, the median number of patients treated before the
joint modeling initiation ranged from 17 to 28. For scenario 8, all doses were assumed to
be highly toxic. The simulated trials came to an early halt in 83.3% of the simulations.
In our simulations, we observed a low rate of convergence failure, indicating that joint
modeling could not be fitted. For scenarios 1,2,4,5, and 7, that rate was less than 0.44%,
whereas for scenario 6 it slightly increased to 2.75%. Only in scenario 3, where dose 1 was
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Table 2.3: Simulation results: Percentage of dose selection at the end of the trial (P%) and
mean number of patients assigned to each dose level (N¯pat). Activity data correspond to
that presented in Figure 2.2. The optimal dose is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
1 (Y(l),min, pl) (200, 0.00) (176, 0.00) (147, 0.02) (115, 0.12) (79, 0.38) (40, 0.75)
P% 0.0 0.0 0.0 1.2 97.3 1.5 0.0
N¯pat 2.0 2.0 2.2 5.4 40.5 7.9
2 (Y(l),min, pl) (71, 0.00) (64, 0.00) (57, 0.03) (49, 0.12) (39, 0.38) (29, 0.75)
P% 0.2 11.0 79.5 8.9 0.4 0.0 0.0
N¯pat 2.2 7.4 31.4 8.4 5.6 5.0
3 (Y(l),min, pl) (87, 0.32) (78, 0.71) (67, 0.96) (55, 0.99) (41, 0.99) (26, 0.99)
P% 98.4 0.2 0.1 0.0 0.0 0.0 1.3
N¯pat 51.3 6.5 2.0 0.2 0.0 0.0
4 (Y(l),min, pl) (87, 0.00) (78, 0.00) (67, 0.03) (55, 0.12) (41, 0.38) (26, 0.75)
P% 0.0 0.0 3.8 90.9 5.3 0.0 0.0
N¯pat 2.0 2.1 5.6 35.8 9.3 5.3
5 (Y(l),min, pl) (71, 0.02) (68, 0.07) (65, 0.20) (61, 0.43) (57, 0.68) (52, 0.88)
P% 99.5 0.1 0.0 0.4 0.0 0.0 0.0
N¯pat 30.0 3.6 6.3 11.4 7.4 1.3
6 (Y(l),min, pl) (200, 0.00) (176, 0.00) (147, 0.01) (115, 0.04) (79, 0.16) (40, 0.41)
P% 0.0 0.0 0.0 0.0 5.2 94.8 0.0
N¯pat 2.0 2.0 2.0 2.4 8.0 43.6
7 (Y(l),min, pl) (84, 0.00) (73, 0.00) (61, 0.01) (48, 0.04) (32, 0.16) (16, 0.41)
P% 0.0 0.0 0.0 13.1 86.5 0.4 0.0
N¯pat 2.0 2.0 2.2 9.0 34.2 10.6
8 (Y(l),min, pl) (71, 0.71) (64, 0.88) (57, 0.97) (49, 0.99) (39, 0.99) (29, 0.99)
P% 16.7 0.0 0.0 0.0 0.0 0.0 83.3
N¯pat 14.9 0.9 0.0 0.0 0.0 0.0
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both the OD and the MTD, joint model could not be fitted in 6.47% of the simulations.
Thus, these simulations were conducted with the probit CRM exclusively. However, that
could be expected as on average 57 patients were assigned to dose level 1, which made
it harder to estimate parameters related to dose in the longitudinal model. Nonetheless,
patients were still allocated to the correct OD.
2.5.2 Sensitivity analysis results
Results from the sensitivity analysis can be seen, first, in Table 2.4. For scenarios 4.1
and 4.2 we assumed a cumulative risk of toxicity. In case of cumulative toxicity, when
no or low toxicity is observed in the first cycles and data is missing at later cycles due
to censoring, estimating the true probability of toxicity can be challenging. We can see
that by comparing the rate of OD identification of scenarios 4.1 and 2, of Table 2.3, that
are almost identical. The power to detect a time-trend was 97% and 47% for scenarios
4.1 and 4.2, accordingly, illustrating the additional information that can be drawn from
the sequential probit model regarding the risk of cumulative toxicity over time. The
conditional risk of DLT on the MTD, for scenarios 4.1 and 4.2, increased from 0.01% to
21% and from 3% to 10%, respectively. An increasing hazard would probably be com-
patible with long drug administration. For scenarios 4.3 and 4.4, we simulated different
biomarker trajectories over time (Figure 2.5 a)-b)). Our design is somehow sensitive when
the time-activity relationship reaches a plateau, but not when doses cross over time (65%
and 95.3% correct OD selection, respectively). In Table 2.5, there are five scenarios, for
which data was generated from different models than the ones used for the analysis. The
rate of correct OD identification for scenarios 5.1 to 5.5 was 74.8%, 54.2%, 99.2%, 97.4%
and 92.7%, respectively. As expected, that rate was lower than the one from Table 2.3.
It is worth mentioning, though, that for these simulations, doses were quite close in terms
of probability of toxicity, which makes it harder for any algorithm to correctly identify
the MTD and subsequently the OD.
The last part of our sensitivity analysis can be found in Appendix A. Increasing the
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variance (Table A.4) or altering the random effects between the two models (Table A.5)
did not affect the rate of correct OD selection. Increasing the variance and setting
the sample size at 40 (Table A.5) was associated with a 7% lower rate of correct OD
selection. Scenarios, for which either one of the two models was misspecified, are presented
in Table A.6. Trials reach the true OD more frequently when the activity model is
misspecified, rather than the toxicity, which is expected given the amount of information
resulting from the repeated measurements. The percentage of correct OD selection was
the same for scenarios A.7.1 and 5 from Table 2.3 and differed by 6% for A.7.2 and
2 (Table A.7). Thus, we conclude that there are no substantial differences stemming
from the increasing or decreasing pattern of the biomarker over time. Assuming activity
data with both random intercept and random slope did not affect the results, unless we
increase the random intercept variance. More precisely, when the variance increased the
correct OD selection drop from 80.3% to 67.9% (Scenarios A.8.1 and A.8.2 Table A.8).
Finally, when activity data generation included both a linear and a quadratic term for
time did not seem to impact the OD identification (Table A.9). In fact the observed rate
in scenario A.9.1 is almost identical to that of scenario 1 in Table 2.3.
2.6 Discussion
In this chapter, we presented an adaptive design for the identification of the OD in
phase I/II trials of MTAs in oncology. We considered a discrete time failure model to
match the data usually collected in phase I and to evaluate modification of the hazard of
toxicity over time as well as cumulative toxicities. Allowing for a longer DLT evaluation
period, instead of per cycle modeling, could be an alternative but that would lead to
patients dropping out. Nevertheless, in the case of patient reported outcomes, where the
exact time of the DLT is known, the approach of Rizopoulos (2012) could be applied,
assuming that approximation of the likelihood is feasible under small sample sizes. We
believe in the importance of joint modeling for two major reasons. First, we tackled the
issues of missing at random data, due to DLTs and lack of activity, as well as intermittent
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Table 2.4: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). For scenarios 4.1 − 4.2 toxicity data was generated assuming increasing
hazard at each successive treatment cycle. For scenarios 4.3 − 4.4 data was generated for
different biomarker trajectories over time, as shown in Figure 2.5 a) and Figure 2.5 b),
respectively. The optimal dose is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
4.1 (Y(l),min, pl) (71, 0.00) (64, 0.01) (57, 0.03) (49, 0.14) (39, 0.38) (29, 0.72)
P% 10.7 14.6 64.2 9.7 0.8 0.0 0.0
N¯pat 5.2 8.0 19.8 6.6 3.7 16.7
4.2 (Y(l),min, pl) (168, 0.00) (151, 0.00) (132, 0.00) (112, 0.03) (89, 0.14) (63, 0.42)
P% 0.8 0.0 0.1 0.0 6.4 92.7 0.0
N¯pat 2.2 2.0 2.1 2.4 8.1 43.2
4.3 (Y(l),min, pl) (81, 0.04) (76, 0.13) (70, 0.35) (65, 0.65) (59, 0.89) (53, 0.98)
P% 65.0 17.7 16.8 0.5 0.0 0.0 0.0
N¯pat 19.7 12.7 17.5 8.3 1.7 0.1
4.4 (Y(l),min, pl) (84, 0.00) (80, 0.00) (76, 0.03) (72, 0.12) (68, 0.38) (65, 0.75)
P% 95.3 0.9 0.0 0.0 3.8 0.0 0.0
N¯pat 34.8 5.2 3.3 4.1 7.3 5.3
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Table 2.5: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). Data generation from a saturated linear mixed effects model for activity
and a logistic model for toxicity. The optimal is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
5.1 (Y(l),min, pl) (86, 0.02) (73, 0.04) (69, 0.08) (66, 0.13) (64, 0.22) (58, 0.34)
P% 20.8 74.8 3.8 0.6 0.0 0.0 0.0
N¯pat 8.9 27.1 7.0 3.9 3.8 9.3
5.2 (Y(l),min, pl) (119, 0.09) (113, 0.14) (88, 0.23) (80, 0.35) (65, 0.51) (46, 0.69)
P% 8.0 18.8 54.2 12.3 6.2 0.5 0.0
N¯pat 5.5 10.4 22.4 10.8 7.6 3.3
5.3 (Y(l),min, pl) (79, 0.22) (77, 0.33) (74, 0.48) (72, 0.65) (70, 0.80) (66, 0.91)
P% 99.2 0.5 0.2 0.0 0.0 0.0 0.1
N¯pat 44.4 6.6 5.1 2.8 0.9 0.2
5.4 (Y(l),min, pl) (79, 0.02) (77, 0.04) (74, 0.07) (72, 0.12) (70, 0.19) (66, 0.30)
P% 97.4 0.0 0.0 0.0 0.2 2.4 0.0
N¯pat 34.5 3.1 3.3 3.6 4.0 11.5
5.5 (Y(l),min, pl) (175, 0.02) (160, 0.04) (138, 0.07) (109, 0.12) (84, 0.19) (53, 0.30)
P% 1.0 0.0 0.0 0.2 6.1 92.7 0.0
N¯pat 2.4 2.2 2.4 3.1 7.8 42.1
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missing responses. Second, patients in the study were allocated to the OD that is not
necessarily the MTD, as it would be the case if only toxicity data was considered. Our
principal goal was to integrate all the information collected during the trial, without
being restricted to the first treatment cycle only and without loss of information due to
dichotomization of the activity measurements.
The design was evaluated on diverse settings, showing a percentage of correct OD se-
lection particularly high and good operating characteristics. Most importantly, simulated
subjects were rarely exposed to doses above the MTD and a large fraction of them was
not undertreated. Even under convergence failure of the joint modeling, with the aid of
CRM, patients were still administered to safe and highly active doses.
A limitation of our model is associated to the type of plateau it can capture. When
either of the dose-activity or time-activity relationships reaches a steep plateau, our
design might be less robust. Strictly speaking, this refers to the case where biomarker
measurements on the plateau have exactly the same value and are not just “equally”
active as per our definition. Under this scenario, for the dose-activity relationship, for
instance, the OD would be located on the beginning of the plateau, since with further
escalation only toxicity would be gained. Even though determination of the MTD does
not pose a problem, the model cannot properly identify the OD, and as a corollary the
recommended dose at the end of the trial is usually closer to the MTD. In practice, that
does not constitute an issue, since the dose selected is between the true OD and the
MTD, meaning that it has the maximum possible activity, and yet is safe.
This specific design is quite flexible and can be applied to any biomarker that has a
monotonic or plateau type relationship with the dose, irrespectively of the increasing or
decreasing pattern over time. It can be adapted by researchers to include as many cycles
and biomarker measurements as needed, and additionally to allow for non-balanced data.
For the decision process, alternative criteria can be considered, such as a toxicity-activity
trade-off (Thall and Cook, 2004). Overall, we consider that the inclusion of multiple
and continuous biomarker measurements may play a pivotal role in integrating all the
information gathered during a clinical trial.
Chapter 3
Optimal dose selection considering
both toxicity and activity data;
plateau detection for molecularly
targeted agents
3.1 Introduction
In the previous chapter, we presented an adaptive design for the identification of the
OD. We explored several scenarios, showing that our method is robust, under diverse
settings. At the end, we discussed a limitation of the design regarding the case of a steep
plateau, in which doses would have exactly the same biomarker value and consequently
exactly the same activity. In that case, our method was not very efficacious in identifying
at which dose is located the beginning of the plateau. Although the algorithm could
still propose a dose as “active” as the MTD, we may need a method that can identify
the beginning of the plateau. A major benefit of such an approach would be for cases
where many doses have exactly the same activity and the MTD is far from the OD.
Identification of the beginning of the plateau could help select a dose “equally” active to
MTD and yet a lot less toxic.
Furthermore, a significant part of our adaptive design relies on the joint modeling
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technique. In the previous chapter, we mentioned that several authors have shown in
simulation studies the importance of implementing joint models, when two outcomes are
believed to be associated. This is due to the fact that joint models reduce the bias, leading
to more robust estimations. However, an important question is whether reducing the
estimation bias through joint modeling could help improve the dose selection, as compared
to implementing independent modeling, i.e. considering independently the activity and
the toxicity model. Cunanan and Koopmeiners (2014) performed a simulation study,
investigating whether operating characteristics of a phase I/II clinical trial improved
after the implementation of joint modeling. For their study, they used a copula model,
where both toxicity and activity were considered as binary endpoints. They found that
both approaches performed just as well due to difficulty in estimating the copula model
correlation parameters from binary data. Nonetheless, there is merit in examining if this
is the case in the presence of continuous and repeated biomarker measurements that are
richer in information and under the likelihood inference.
In this chapter, we propose an extension of the adaptive design described in Chapter 2.
We rely on the same joint modeling technique of longitudinal continuous biomarker mea-
surements and time-to-DLT data, using a shared random effect and likelihood approach.
We use the same model for toxicity and a change-point model for activity. Specifically,
for the biomarker measurements, we employ a linear mixed effects model that can ac-
count for either a plateau or a linear dose-activity relationship (Figure 3.1). Every time
we fit the joint model, the algorithm selects the activity model (plateau or linear) that
best fits the observed data. Similar to the previous design, the MTD is the dose with
a cumulative risk of DLT, over six cycles that minimizes the distance from a predefined
TTL. The OD is defined as the lowest dose, within a range of highly active doses, that
is below or equal to the beginning of the plateau, if the beginning of the plateau is be-
low the MTD. If the MTD is a dose below the plateau beginning, then the OD is the
lowest dose, within a range of highly active doses, that is below or equal to the MTD.
The motivating example of our design is the multicenter phase IB trial in patients with
platinum resistant epithelial ovarian carcinoma, described in Section 2.2.1. Finally, we
investigated the contribution of joint modeling versus independent modeling in the case
Plateau detection 75
of a phase I/II clinical trial.
The remainder of Chapter 3 is organized as follows. In Section 3.2, we introduce the
models for toxicity and activity, the study design and the decision process for the identifi-
cation of the OD. In Section 3.3, we describe the simulation framework and the scenarios
that were investigated. In Section 3.4, we comment on the results of the simulation study
and we compare this design with the one described in Chapter 2. Section 3.4.3 is de-
voted to the results obtained from the comparison of joint modeling with independent
modeling. Discussion follows in Section 3.5.
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Figure 3.1: Dose-biomarker relations.
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3.2 Methods
3.2.1 General framework
First, we shall briefly recap some basic notation of Chapter 2. Consider a trial of N
individuals, i = 1, . . . , N and a total ofM planned doses to be testedD = {d(1), . . . , d(M)}.
Patients are sequentially assigned to a specific dose level, selected based on the data from
previous patients. Cycles of treatment are repeatedly administered until DLT, disease
progression, defined by some elevation of the biomarker, or consent withdrawal. At
the end of each cycle study participants are evaluated as to whether they had a DLT
during the cycle or not. Therefore, for the time-to-DLT we consider a discrete time scale,
C = {1, . . . , k}, where k is the total number of treatment cycles. As before, we consider
a total of six treatment cycles k = 6. The biomarker levels are measured at each weekly
visit, in order to determine if and when patients respond to the treatment and when
they progress. For the biomarker measurements, we have continuous measurements on a
continuous time scale T = (0, k). If a DLT is observed or the agent is not active, based
on the biomarker data, then the patient is removed from the study, resulting in censored
DLT data and MAR for the biomarker.
3.2.2 Modeling time-to-DLT
Let Si be the time-to-DLT. In this design, for the time-to-DLT outcome we consider
the same probit model 2.3,
P (Si = s|Si > s− 1, Ui) = 1− Φ(a0 + a1ci(s−1) + agdi + γUi), ci(s−1) ∈ C,
where Φ(·) is the cumulative standard normal distribution, a0 and a1 are unknown pa-
rameters, di is the patient’s dose and ci(s−1) is the administered cycle. Once again we fix
the slope of the dose to a constant value ag. Ui ∼ N(0, σ21) is the shared random effect
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that comes from the activity model and γ is the corresponding parameter for estimation.
We remind that the probability of having a DLT at cycle s is conditional on having no
DLT in all the past cycles.
The probability of DLT for a given patient at each cycle is obtained as follows:
P(l)(Si = s|Ui) =

(1− Φ(l)1) s = 1
Φ(l)1Φ(l)2 . . .Φ(l),s−1(1− Φ(l)s) s = 2, . . . , 6
Φ(l)1Φ(l)2 . . .Φ(l),s−1Φ(l)s s > 6,
where 1−Φ(l)s is the hazard function at cycle s and dose level l, l being the index for the
dose. Then, the cumulative probability of DLT at the end of cycle 6 is
P(l)(Si ≤ 6|Ui) =
6∑
s=1
P(l)(Si = s|Ui).
3.2.3 Modeling activity
Let Yij(l) be the repeated continuous biomarker measurements for the i
th individual,
at times tij ∈ T , j = 1, . . . , n represents the visit number, and at dose level l. Now,
we shall consider an activity model different from the one presented in Chapter 2. The
model structure, regarding the time-biomarker relationship remains the same, motivated
by the activity trend over time, shown in Figure 2.2. However, for the dose-biomarker
relationship we allow for more flexibility. Let pl be an integer that takes values from 1
to M − 1, indicating the dose level that is the beginning of the plateau and 1 be the
indicator function. Then, doses of treatment modify the course of CA 125 as follows
yij(l) = β0 + β1t
2
ij + β2tij(di(l)1(l < pl) + di(pl)1(l ≥ pl)) + Uitij + rij, (3.1)
where β0, β1, and β2 are unknown parameters and di(l) is the dose. Ui refers to the
random effect associated with the time of the longitudinal measurements and Rij are
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the model residuals that are mutually independent and follow a Gaussian distribution,
MVN(0, σ22I), with I being the identity matrix. Model 3.1 makes the assumption that
dose modifies the biomarker trajectory linearly and after a certain dose level the biomarker
reaches a plateau. This plateau is observed at a specific time point for each patient and
this time can vary among patients. Therefore, when the dose level is lower than pl, the
dose-biomarker relationship monotonically decreases, and when the dose level is equal
to or higher than pl, the dose-biomarker relationship plateaus. This model is similar to
the one proposed by Riviere et al. (2016). Doses on the plateau have exactly the same
biomarker value. In case where the dose-activity relationship is strictly monotonic and
there is no plateau model 3.1 becomes
yij(l) = β0 + β1t
2
ij + β2tijdi(l) + Uitij + rij. (3.2)
An example is illustrated in Figure 3.1. The orange and the violet curves are two
examples of model 3.1, in which the dose-activity relationship monotonically decreases
and then plateau begins at dose level 2 and 4, respectively. On the other hand, the blue
curve delineates the monotonic relationship, described by model 3.2. Hence, for the 6 dose
levels pl takes values between 1 and 5. Value 1 is for the monotonic relationship, whereas
values 2 to 5 are the possible dose levels that could indicate the beginning of a plateau.
Every time we apply the joint modeling, we investigate all of the 5 candidate models.
In particular, we estimate each of the five joint models for the different dose-activity
relationships and we select the one that best fits the data using the Akaike information
criterion (AIC) (Akaike, 1973). Let ξθ be the number of parameters we estimate for each
model. Then taking the likelihood 2.4, described in Section 2.3.4, the AIC is
AIC = 2 ∗ ξθ − (2 ∗ (−log(L(θ; y, s, δ))).
We select the joint model with the minimum value for the AIC.
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3.2.4 Study design
The study design is very similar to the one described in Section 2.3.5. As before
we split the design into two stages. For the first one dose escalation proceeds based on
toxicity only and for the second one, we identify the OD based on both outcomes. We
start with a ‘2+2’ design, where cohorts of patients escalate, de-escalate or remain at the
same dose based on the DLTs observed in the first treatment cycle. When two DLTs and
two non-DLTs have occurred, we stop the ‘2+2’. If all 3 criteria, 1) at least 16 patients
have been enrolled, 2) the standard errors of all joint model parameter estimates are
below 20, and 3) the Hessian matrix is positive definite, are satisfied, we switch to the
joint modeling stage. If not, then we implement the probit time-to-DLT CRM 2.5 to
guide dose-escalation. We continue with the CRM until all 3 criteria are satisfied and
then we switch to the joint modeling. Recall Figure 3.2 that depicts the study design
procedure.
Finally, when all 3 criteria are met, we initiate the second stage and we update activity
and toxicity estimates after each new patient, using joint modeling. It is in the second
stage, where we consider both toxicity and activity data that this design defers from the
previous one. This is due to the fact that every time we apply the joint modeling, we
investigate several models for the biomarker measurements and we are not restricted to
a single one. Based on the model selected with AIC, we determine the MTD and the
OD that is the dose the new patient will be allocated to. We repeat this procedure every
time there is a new patient in the study. The model selected after each new patient is not
necessarily the same. Nevertheless, after a certain number of patients has been enrolled
in the trial, we expect it to eventually converge to one of the five candidate models. As
before, for safety reasons dose skipping is not allowed.
Finally, we implemented the same early stopping rule for excessive toxicity at dose
level 1, proposed by Ivanova et al. (2005). We generated a Pocock-type boundary for
repeated testing of the toxicity at the first treatment cycle. A probability of DLT above
35% at the 10% level (one-sided) led to stop the trial.
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‘2+2’  
2 DLTs and 2 non-DLTs 
If SE>20 or Hessian matrix 
is not  positive definite 
 
Time-to-DLT 
CRM 
 
Try 
Joint Modeling 
    If i≥16      If i<16  
If SE≤20 and Hessian matrix 
is positive definite 
Joint Modeling 
    If i≥16  
Figure 3.2: Representation of the study design described in Section 2.3.5. Abbre-
viations: DLTs, Dose Limiting Toxicities; i, index for the patient; SE, Standard
Error; CRM, Continual Reassessment Method.
3.2.5 Decision process
Based on the joint model estimates, we determine the MTD and the OD. Similarly
to our previous adaptive design, we start from the MTD, which is defined cumulatively
over six cycles. Taking the conditional probability for U = 0 we minimize over all dose
levels
MTD = min
(l)
|− P(l)(S ≤ 6|U = 0)|,
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where  is the TTL. Then the MTD is used to select a subset of safe doses B. This subset
contains the MTD and all doses below the MTD, if the MTD is not the first dose level.
The OD is defined as the lowest dose, within a range of highly active doses. We
remind that if the biomarker measurements reach a plateau, then all doses located on
that plateau are considered to have exactly the same biomarker activity. Therefore, for
the selection of the OD we identify two cases; 1) the MTD is a dose higher than the dose
indicating the beginning of the plateau and 2) the MTD is a dose equal or lower to the
beginning of the plateau.
For the first case, the OD is defined as the lowest dose, within a range of highly active
doses, below or equal to the dose indicating the beginning of the plateau. Define M to
be a subset of doses below or equal to the plateau beginning and M ⊆ B. Then, for
every d(l) ∈M we estimate, at each time visit tj and for each dose level l, the conditional
predicted biomarker activity
yˆj(l) = βˆ0 + βˆ1t
2
j + βˆ2tj(d(l)1(l < pl) + d(pl)1(l ≥ pl)). (3.3)
As before, the maximum drug activity is associated with the minimum biomarker mea-
surement over time, thus, for each dose we select the minimum of the predicted values
yˆmin,(l). We identify doses that are “equally” active to the dose located on the beginning
of the plateau as follows,
|yˆmin(pl) − yˆmin(l)| ≤ ζ,
where ζ is the equivalence range. The lowest dose in M is selected for the next patient.
An example of such a case is illustrated in Figure 3.3 a). In this example, the MTD
is dose level 6 and the beginning of the plateau is located at dose level 4. Imagine, for
the purpose of this example and without loss of generality that the minimum biomarker
measurement of every dose is at the same time visit, as shown in Figure 3.3 a). Then,
Ω = {d(1), d(2), d(3), d(4)} and ζ = 20 that is any dose d(l) ∈ M to be “equally” ac-
tive to the plateau, if |yˆmin(pl) − yˆmin(l)| ≤ 20. For instance, for dose level 3, we have
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|yˆmin(pl) − yˆmin(3)| = 17, meaning that d(3) is “equally” active to d(4) that corresponds to
the beginning of the plateau. Therefore, the OD is d(3).
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Figure 3.3: Dose-activity relationships.
For the second case, the OD is defined as the lowest dose, within a range of highly
active doses, below or equal to the MTD. Then, for every d(l) ∈ B we estimate, at each
time visit tj and for each dose level l, the predicted biomarker activity, using model 3.3.
We identify doses that are “equally” active to the MTD as follows,
|yˆmin(MTD) − yˆmin(l)| ≤ ζ.
Define Λ to be a subset including all doses that are “equally” active to the MTD. The
lowest dose in Λ is selected for the next patient. Figure 3.3 b) is an example of such a
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scenario. Here, the MTD is dose level 3 and the beginning of the plateau is located at
dose level 4. Then, B = {d(1), d(2), d(3)} and as earlier ζ = 20. In this example the MTD
is also the OD, since for dose level 2 we have |yˆmin(MTD) − yˆmin(2)| = 25, meaning that
d(2) is not “equally” active to the MTD.
Estimation of the MTD and the OD is repeated after every new patient. When
the MTD is a dose higher than the start of the plateau, this OD definition is slightly
different from that described in Section 2.3.6. When we consider the case of plateau, the
two different decision process algorithms could potentially lead to different results. An
example of such a case is discussed in Section 3.4.2.
3.2.6 Independent modeling
For the independent modeling approach, we considered the same toxicity and activity
models that were presented in sections 3.2.2 and 3.2.3. For the toxicity outcome and after
removing the random effects we get
P (Si = s|Si > s− 1) = 1− Φ(a0 + a1ci(s−1) + agdi), ci(s−1) ∈ C.
For the activity outcome model 3.1 was used.
3.3 Simulation settings and evaluation criteria
3.3.1 Framework
To assess the performance of this design, we conducted a set of extensive simulations,
covering a wide variety of scenarios. The simulation framework was similar to that pre-
sented in Section 2.4, so as to compare this design with the one described in Chapter 2.
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Scenarios covered cases where the OD, the MTD, and the beginning of the plateau coin-
cided, the OD was below the MTD and the beginning of the plateau, and finally all doses
were highly toxic.
We rapidly remind the main characteristics of the simulated trials. We assumed a
trial of six doses (1.2, 1.4, 1.6, 1.8, 2.0, 2.2) and a total of 60 patients. For the toxicity
endpoint, we considered a maximum of six treatment cycles. We supposed that the risk
of DLT decreased at each treatment cycle and that the TTL after 6 cycles was 40%. For
the analysis model, the dose slope was fixed, across all scenarios, at ag = −3.29. For
the activity endpoint, following the Gynecological Cancer Intergroup guidelines (Rustin
et al., 2004), we simulated CA 125 patient data at fixed time intervals with baseline
values being at least twice the upper limit of the reference range, [0, 35] units/ml. The
marker was measured once a week, corresponding to three measurements per cycle, so
participants could have a maximum of n = 18 measurements at the end of the trial.
As before, one dose was considered “equally” active to the MTD or to the beginning of
the plateau if their minimum biomarker measurements did not differ by more than 20
units/ml, so ζ = 20.
In our simulations all censoring takes place at the end of the corresponding cycle. The
first cause of missingness was DLT occurrence. After a DLT patients did not contribute
data anymore on the biomarker. The second cause was disease progression and that led to
information missing regarding the toxicity profile. Censoring due to disease progression
was applied with respect to Rustin et al. (2011). Administrative censoring was at cycle
6. We assumed that patients consent withdrawal, the third cause of missing data, was
independent of both toxicity and activity and may occur with a 8% probability at each
treatment cycle. Finally, we accounted for 7% intermittent missing responses for each
biomarker measurement, that entailed missing data but not censoring.
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3.3.2 Main analysis
For the main analysis, we investigated five principal scenarios (Table 3.1). A total
of 1000 simulations were replicated for each scenario. Interest lay in evaluating the
percentage of correct OD identification, which corresponded to the dose administered to
the last patient in the trial and the mean number of patients allocated over the dose
range in the study. Another aspect under investigation was the percentage of simulations
where joint modeling could not be fitted. Particularly, we assessed whether the use of a
more flexible activity model could help resolve convergence issues observed in the previous
design. Convergence criteria for likelihood maximum were based on the gradient function,
with an absolute error tolerance of 10−3. The parameters used for data generation of these
scenarios are provided in Table B.1. For the principal scenarios, data was generated from
the model of analysis.
3.3.3 Sensitivity analysis
In order to assess the robustness of the proposed design, a sensitivity analysis was
performed, accounting for various degrees of model misspecification. To begin with,
we explored scenarios in which toxicity data was generated based on a logistic model
(Table 3.2). For the activity, data was simulated from the saturated dose-biomarker
relationship 2.6, presented in Section 2.4.6, with a separate parameter for every dose level.
Additionally, we compared this design with the previous one, by simulating activity data
with the log model 2.2 (Table 3.3). More specifically, for data generation we selected four
from the eight principal scenarios, investigated in Table 2.3, and we analyzed them with
the plateau model. The aim was first to investigate the model behavior under model
misspecification and second to examine if the percentage of convergence failure would
diminish, given the model flexibility.
Next, the principal scenarios (Table 3.1) were also evaluated under the case of larger
variances with smaller sample size and smaller sample size with different random effects
distributions between the two models (Table B.2). In particular, we assumed that for
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the activity model, random effects followed a gamma distribution U ∼ Gamma(2, 2) and
for the toxicity model, the standard normal distribution U ∼ N(0, 1). Furthermore, we
investigated two scenarios (Table B.3), where hazard was increasing at each successive
cycle, inducing cumulative toxicities. For the cycle effect we assumed both a steep and
a smooth slope, scenarios B.3.1 and B.3.2, respectively. In the preceding simulations, we
had accounted for scenarios, in which biomarker data was generated from a linear mixed
effects model with both a random intercept and a random slope. Here, we considered
this setting and additionally, activity data was generated from the log model 2.2. The
investigated scenarios (Table B.4) were exactly the same as those presented in Table A.8,
allowing for direct comparison of the two approaches.
Analysis models were not modified.
3.3.4 Comparison of joint modeling and independent modeling
In order to compare the joint modeling with the independent modeling approach, we
generated two different types of scenarios. For the first one, we assumed that simulated
data was correlated with an increasing degree of correlation between the toxicity and the
activity model (Figure 3.5 and Figure 3.6). Given the correlated data, we varied the
sample size, the residual and random effect variance and additionally, generated toxicity
data from the previously described logistic model. For the second type of scenarios, we
assumed that toxicity and activity data was not correlated, γ = 0, and similarly, we
investigated the model behavior under diverse sample sizes, variances and misspecified
models (Figure 3.7 and Figure 3.8). Data was analyzed with both approaches, so as to
determine whether joint modeling is more robust than independent modeling concerning
correct dose selection. Since for the OD selection the first step is to correctly identify the
MTD, the main focus of these simulations was the percentage of correct MTD selection.
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3.4 Results
3.4.1 Main results
Table 3.1 summarizes the main results. The percentage of correct OD selection for
scenarios 1-4 was 99.2%, 99.2%, 99.7%, and 86.3% accordingly. The mean number of
patients allocated to the OD ranged from 27 to 43 out of 60, depending on whether it
coincided with the MTD. As far as safety is concerned, no dose was ever recommended
at the end of the trial that was above the MTD. Therefore, patients were not exposed to
highly toxic doses. We can also see that most patients were allocated to doses close to
the MTD or the OD, an indication that they were not exposed to subtherapeutic doses
either. For scenarios 1-4, the median number of patients treated before the joint modeling
initiation ranged from 18 to 28. These numbers were almost identical to those presented
in Section 2.5.1, for scenarios 1-7 of Table 2.3. For scenario 5, all doses were assumed to
be highly toxic. The simulated trials came to an early halt in 81.9% of the simulations.
In the Chapter 2, we discussed the issue of convergence failure, i.e. the cases where
the joint model could not be fitted. For scenarios 1-4 the failure rate was 0% in all our
simulations. Therefore, all simulations proceeded with the joint modeling. We believe
that this could be the result of the more flexible activity model and the fact that at each
new patient entry the algorithm selects the activity model that best fits the data, without
being restricted to a single model.
3.4.2 Sensitivity analysis results
In Table 3.2, there are four scenarios, for which data was generated from different
models than the ones used for the analysis. The rates of correct OD identification for
scenarios 2.1 to 2.4 were 73.4%, 78.5%, 99.5%, and 53.3%, respectively. As expected, these
rates were lower than the ones from Table 2.3. Nonetheless, that was expected, since doses
were quite close to each other, in terms of probability of toxicity and simulated models
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Table 3.1: Main analysis: Percentage of dose selection at the end of the trial (P%) and
mean number of patients assigned to each dose level (N¯pat). The optimal dose is in bold,
the MTD in italic and the beginning of the plateau is underlined.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
1 (Y(l),min, pl) (92, 0.02) (68, 0.07) (40, 0.20) (40, 0.43) (40, 0.68) (40, 0.88)
P% 0.0 0.8 99.2 0.0 0.0 0.0 0.0
N¯pat 2.1 2.8 34.7 11.3 7.7 1.4
2 (Y(l),min, pl) (140, 0.00) (118, 0.00) (92, 0.03) (64, 0.12) (32, 0.38) (32, 0.75)
P% 0.1 0.0 0.0 0.7 99.2 0.0 0.0
N¯pat 2.0 2.0 2.2 5.8 42.7 5.2
3 (Y(l),min, pl) (78, 0.07) (74, 0.19) (69, 0.39) (63, 0.64) (57, 0.84) (50, 0.96)
P% 99.7 0.3 0.0 0.0 0.0 0.0 0.0
N¯pat 31.8 6.0 11.0 9.1 2.0 0.1
4 (Y(l),min, pl) (96, 0.02) (88, 0.07) (80, 0.20) (71, 0.43) (71, 0.68) (71, 0.88)
P% 13.6 86.3 0.1 0.0 0.0 0.0 0.0
N¯pat 6.4 26.9 6.3 11.2 7.8 1.4
5 (Y(l),min, pl) (78, 0.71) (74, 0.88) (69, 0.97) (63, 0.99) (57, 0.99) (50, 0.99)
P% 18.1 0.0 0.0 0.0 0.0 0.0 81.9
N¯pat 17.5 1.1 0.0 0.0 0.0 0.0
were misspecified. It was previously pointed out that due to small differences in the dose
finding algorithm, it is possible that the two approaches (Chapter 2 and Chapter 3) can
identify different doses as the OD. An example of such a case is scenario 2.1. With the
previous design, the OD would be dose level 2, since we would be interested in a difference
of 20 units/ml from the MTD, which is dose level 6. However, with the new design, there
is a plateau that starts at dose level 2 and therefore, the OD was dose level 1 that did
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not differ by more than 20 units/ml from the plateau. Due to the model misspecification,
it is not clear where the plateau begins and for that reason the dose-activity relationship
of scenario 2.1 is illustrated in Figure 3.4.
Table 3.2: Sensitivity analysis of 1000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). Data generation from a saturated linear mixed effects model 2.6 for
activity and a logistic model for toxicity. The optimal dose is in bold, the MTD in italic
and the beginning of the plateau is underlined.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
2.1 (Y(l),min, pl) (86, 0.03) (73, 0.04) (69, 0.08) (66, 0.13) (64, 0.22) (58, 0.34)
P% 73.4 19.8 6.8 0.0 0.0 0.0 0.0
N¯pat 23.7 11.7 8.0 3.5 3.8 9.3
2.2 (Y(l),min, pl) (119, 0.09) (113, 0.14) (88, 0.23) (80, 0.35) (65, 0.51) (46, 0.69)
P% 8.9 2.9 78.5 1.4 8.3 0.0 0.0
N¯pat 5.5 10.4 22.4 10.8 7.6 3.3
2.3 (Y(l),min, pl) (79, 0.22) (77, 0.33) (74, 0.48) (72, 0.65) (70, 0.80) (66, 0.91)
P% 99.5 0.0 0.0 0.0 0.0 0.0 0.5
N¯pat 45.6 5.5 4.6 3.0 1.1 0.2
2.4 (Y(l),min, pl) (175, 0.02) (160, 0.04) (138, 0.07) (109, 0.12) (92, 0.19) (74, 0.30)
P% 1.6 0.2 3.2 53.3 41.7 0.0 0.0
N¯pat 2.8 2.5 3.9 26.6 14.0 10.2
Table 3.3 presents the results of the comparison of the two designs. Even though
the activity data was simulated from the log model, the plateau model gave the same
percentage of correct OD selection in all four scenarios. Most importantly, for scenario
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Figure 3.4: Dose-biomarker relationship for three different time vis-
its. This relationship was generated by model 2.6.
3.2, the log model had 6.47% convergence failure, i.e. these simulations were conducted
with the probit CRM alone. On the contrary, for the plateau model, all simulations
proceeded with the joint modeling, meaning that there was 0% convergence failure.
The remaining of the sensitivity analysis can be found in Appendix B. Increasing the
variance and setting the sample size at 40 (Table B.2) was associated with a small change
in the percentage of OD identification, compared to Table 3.1. More precisely, correct OD
selection was between 2%− 7% lower for these scenarios. Similarly, altering the random
effects distribution for the activity and toxicity model and setting again the sample size
at 40 (Table B.2) did not seem to have a significant impact on the results. Correct OD
selection was 0% − 5% lower for these scenarios than those of Table 3.1. For scenarios
B.3.1 and B.3.2 (Table B.3), we assumed a cumulative risk of toxicity. The percentage
of correct OD selection for the two scenarios was 100% and 93.5%. For the toxicity
outcome, we selected similar scenarios to those presented in Table 2.4. Surprisingly, this
design had a higher rate of OD identification when the OD was in the middle of the
dose range (scenario B.3.1 versus 4.1). When the OD was on the tail of the dose range
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both designs produced similar results. Finally, in Table B.4, we have two more scenarios
comparing the two designs. If we assume activity data with both a random intercept and
a random slope, and simulated from the log model, both designs perform well. However,
if we increase the variance the plateau model seems to outperform the log model (67.9%
versus 73.9%). The good performance of the plateau model, under the case of larger
variances, could be related to the model flexibility.
3.4.3 Comparison of joint modeling and independent modeling
Figures 3.5 and 3.6 summarize the simulation results, assuming that the activity and
toxicity data is correlated. If we assume small variance and 60 patients (Figure 3.5 a)),
the two approaches perform relatively the same way and when the correlation increases,
γ ≥ 0.6, the joint modeling approach has a 6% higher rate of correct MTD identification.
When increasing both the residual and the random effect variance (Figure 3.5 b)) joint
modeling has a better performance in correctly selecting the MTD that ranges from
11% to 18%, when the correlation increases from 0.4 to 0.8. Further increase of the
random effect variance (Figure 3.5 c)), leads to a better performance of the joint modeling
approach ranging from 11% up to 21%, when the correlation increases from 0.2 to 0.8.
Finally, after increasing the overall variance and setting the sample size at 40 patients,
joint modeling outperforms the independent modeling approach by 7% to 11%, when the
correlation increases from 0.6 to 0.8.
Figure 3.6 illustrates similar scenarios to those presented in Figure 3.5, with the
difference that data for the toxicity model come from a logistic model. Overall, the two
approaches perform similarly. Joint modeling outperforms independent modeling by 8%
to 11% (Figure 3.6 b), d)) when increasing the residual and random effect variance.
Figures 3.7 and 3.8 summarize the simulation results, assuming that the activity and
toxicity data is not correlated. Under the case of increasing variance and irrespectively
of the sample size, 60 patients (Figure 3.7 a)) or 40 patients (Figure 3.7 b)), the two
approaches produce identical results. Finally, the only case we identified, where indepen-
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Figure 3.5: Percentage of correct MTD selection in the presence of increasing
correlation between the activity and toxicity data. a) Variance (σ1 = 1 and
σ2 = 3) and N=60 patients. b) Variance (σ1 = 2 and σ2 = 5) and N=60 patients.
c) Variance (σ1 = 4 and σ2 = 3) and N=60 patients. d) Variance (σ1 = 2 and
σ2 = 5) and N=40 patients.
dent modeling outperforms the joint modeling by 6%, is under model misspecification
and small overall variance ((Figure 3.8 a))).
3.5 Discussion
In this chapter, we proposed an extension of the adaptive design for the identification
of the OD, presented in Chapter 2. The principal goal was to improve the previous
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Figure 3.6: Percentage of correct MTD selection in the presence of increasing
correlation between the activity and toxicity data. Toxicity data was generated
under a logistic model. a) Variance (σ1 = 1 and σ2 = 3) and N=60 patients. b)
Variance (σ1 = 2 and σ2 = 5) and N=60 patients. c) Variance (σ1 = 2 and σ2 = 5)
and N=40 patients. d) Variance (σ1 = 2 and σ2 = 5) and N=40 patients.
design, mainly in terms of dose-activity relationship. As before, for the toxicity outcome,
we considered a discrete time failure model in order to evaluate the modification of the
hazard, during the course of a phase I trial, as well as the cumulative toxicities. For the
biomarker measurements, we employed a linear mixed effects model that allowed for both
monotonic and plateau dose-activity relationships, but not parabolic ones. Furthermore,
we addressed the important case of missing at random data, due to DLTs and lack of
activity, as well as intermittent missing responses. Finally, we investigated the impact
of using joint modeling in the presence or not of correlated toxicity and activity data,
versus independent modeling.
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Figure 3.7: Percentage of correct MTD selection in the presence of increasing
variance. Absence of correlation between the activity and toxicity data. a) N=60
patients. b) N=40 patients.
This design was assessed under various settings and was also compared to the prece-
dent design. We observed a high rate of correct OD selection and study participants were
most often not exposed to highly toxic or to subtherapeutic doses. The structure of the
activity model, due to its flexibility, allowed to capture several biomarker trajectories,
including the one of the log model. Most importantly, because of selecting the model that
best fits the data, we were able to tackle the issue of convergence failure and to conduct
all simulations with the joint modeling algorithm. Comparing the two approaches showed
that in most of the scenarios both designs performed equally good and in one scenario
the plateau model outperformed the log. Nonetheless, the two designs were not always
directly comparable, due to the nature of the dose finding algorithm.
In theory, any linear model could be applied for the activity outcome. Increasing the
number of the investigated models could help increase the robustness of the design, since
it would be feasible to select a model closer to the observed data. Likewise, for the dose
finding algorithm it could be possible to restrict the OD selection on the dose located on
the beginning of the plateau and remove the definition of “equally” active doses. Finally,
Plateau detection 95
10 20 30 40
0
20
40
60
80
100
Co
rr
ec
t M
TD
 s
el
ec
tio
n 
(%
)
Variance
a)
Joint modeling
Independent modeling
10 20 30 40
0
20
40
60
80
100
Co
rr
ec
t M
TD
 s
el
ec
tio
n 
(%
)
Variance
b)
Joint modeling
Independent modeling
Figure 3.8: Percentage of correct MTD selection in the presence of increasing
variance. Absence of correlation between the activity and toxicity data. Toxicity
data was generated under a logistic model. a) N=60 patients. b) N=40 patients.
alternative dose escalation schemes, for the trial initiation, could be considered.
The performance of joint modeling versus independent modeling was evaluated under
certain settings, showing that in the presence of large variances, the former outperforms
the latter. Even in the absence of correlated toxicity and activity data the two approaches
performed similarly. Hence, we conclude that the estimation of the additional association
parameter γ does not impede the correct MTD identification, but on the contrary, in the
presence of correlation it can enhance it.
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Table 3.3: Sensitivity analysis of 1000 replicates and a sample size of 60. Percentage
of dose selection at the end of the trial (P%) and mean number of patients assigned to
each dose level (N¯pat). Data was generated from the models described in Chapter 2. The
optimal dose is in bold and the MTD in italic.
Model Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
3.1 (Y(l),min, pl) (71, 0.00) (64, 0.00) (57, 0.03) (49, 0.12) (39, 0.38) (29, 0.75)
log
P% 0.2 11.0 79.5 8.9 0.4 0.0 0.0
N¯pat 2.2 7.4 31.4 8.4 5.6 5.0
plateau
P% 2.0 12.1 79.5 3.4 3.0 0.0 0.0
N¯pat 3.0 7.5 31.6 5.7 7.2 7.2
3.2 (Y(l),min, pl) (87, 0.32) (78, 0.71) (67, 0.96) (55, 0.99) (41, 0.99) (26, 0.99)
log
P% 98.4 0.2 0.1 0.0 0.0 0.0 1.3
N¯pat 51.3 6.5 2.0 0.2 0.0 0.0
plateau
P% 98.7 0.1 0.0 0.0 0.0 0.0 1.2
N¯pat 51.4 5.9 1.9 0.1 0.0 0.0
3.3 (Y(l),min, pl) (71, 0.02) (68, 0.07) (65, 0.20) (61, 0.43) (57, 0.68) (52, 0.88)
log
P% 99.5 0.1 0.0 0.4 0.0 0.0 0.0
N¯pat 30.0 3.6 6.3 11.4 7.4 1.3
plateau
P% 100.0 0.0 0.0 0.0 0.0 0.0 0.0
N¯pat 29.9 3.5 6.1 11.0 7.9 1.5
3.4 (Y(l),min, pl) (84, 0.00) (73, 0.00) (61, 0.01) (48, 0.04) (32, 0.16) (16, 0.41)
log
P% 0.0 0.0 0.0 13.1 86.5 0.4 0.0
N¯pat 2.0 2.0 2.2 9.0 34.2 10.6
plateau
P% 0.2 0.0 0.0 13.6 86.2 0.0 0.0
N¯pat 2.1 2.0 2.2 9.8 34.1 9.8
Chapter 4
Impact of cumulative toxicity in
phase I trials. What should we
expect at the recommended phase II
dose?
4.1 Introduction
In Chapters 1, 2, and 3 we discussed the importance of considering time, in dose-
finding methods, for the selection of the MTD and the OD and we presented designs
to that end. What we called OD in the precious chapters, here it will be referred to
as RP2D. As mentioned earlier the EMA (European Medicines Agency, 2016) pointed
out the significance to improve phase I designs of MTAs, by changing the definition of
the MTD, allowing for a broader DLT-evaluation period and finally considering AEs of
several treatment cycles for the RP2D assessment. This requirement is even stronger
with immune-toxic side effects, for which the median time varies from 5 to 15 weeks,
which is beyond the usual DLT assessment period (3-4 weeks) (Champiat et al., 2016).
In Chapters 2 and 3 we used a definition of the MTD cumulatively over 6 treatment
cycles assuming a TTL of 40%. However, whilst for guiding dose-escalation, the notion
of what constitutes an acceptable rate of acute toxicity is rather well-defined, when it
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comes to guiding the RP2D recommendation, no such definition of what constitutes
an acceptable cumulative and per-cycle rate of toxicity, in single-agent administration,
exists. Considering cumulative toxicity is even of greater importance when the per-cycle
risk of toxicity increases, indicating that the repeated administration of an agent could
potentially be life-threatening. In particular, when 20% of acute toxicity is observed at
the MTD, what cumulative toxicity rate should we expect over several treatment cycles?
Another major aspect when evaluating the MTD and the RP2D is related to the
type of toxicity we observe. Two large classes of toxicity are the hematologic and the
non-hematologic ones. These toxicities do not have the same impact on the human body.
More precisely, hematologic toxicities have a shorter duration, are less hazardous and are
usually more easily treated than the non-hematologic ones. Therefore, it is important to
consider them separately since the acceptable risk of AEs per-cycle and cumulatively for
these two classes of toxicity is not necessarily the same.
The remainder of Chapter 4 is organized as follows. In Section 4.2, we present the
objective of this work. Section 4.3 is the methods part, where we introduce our data, the
models and the various analyses. In Section 4.4 we describe our data and the results of
our analyses, complemented by figures and tables. Discussion follows in Section 4.5.
4.2 Objective
The aim of the present work is to provide an overview of the risk of first-severe toxicity
per treatment cycle and of the corresponding cumulative incidence function (CIF) over
up to six treatment cycles. We estimated these risks based on 26 phase I clinical trials
of MTAs administered as single agents, from the Cancer Therapy Evaluation Program
(CTEP) of the US NCI. A secondary objective is to document the relation between time-
on-treatment and the risk of severe toxicity. We provide a nomogram that relates the risk
of severe toxicity at cycle 1 with estimations of the CIF expected over up to six cycles of
treatment. Finally, we investigate the CIFs of non-hematologic and hematologic severe
toxicity, within the competing risks framework.
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4.3 Methods
4.3.1 Trials and patients characteristics
This retrospective analysis included single agent phase I studies that reached the
MTD and were provided to the DLT-TARGETT group. The DLT-TARGETT group is
a European Organisation for Research and Treatment of Cancer (EORTC)-led initiative.
The aim was to provide a comprehensive description of all drug-related toxicities reported
in phase I trials of MTAs (in terms of type, grade, cycle of occurrence) and to ultimately
propose recommendations for DLT definition and phase II dose recommendation process,
customized for phase I trials of novel MTAs. Collected trials dated from 1997 to 2013.
Information recorded included treatment arms, agent under investigation, method of
treatment administration, duration of treatment cycle, the MTD, etc. All adult patients
with solid tumors or lymphomas who received at least one cycle of treatment were eligi-
ble for the analysis. Individual data, provided to the DLT-TARGETT group, recorded
for each patient the number of treatment cycles, the dose administered, the follow up,
observed toxicities per cycle and grade, and DLTs, as defined per study protocol, among
others. Administered doses were measured in different units among studies, therefore,
we standardized them, by dividing the amount of the dose by the corresponding trial’s
MTD.
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4.3.2 Toxicity data
For the analysis we considered data up to six treatment cycles. As for Chapters 2 and 3,
this number was motivated by Postel-Vinay et al. (2014), who showed that severe tox-
icities occurred quite often after cycle 1 and were almost null after cycle 6. All AEs at
least potentially related to the treatment that were not present at baseline at the same
or higher grade were extracted. In the beginning of the thesis we call attention to the
fact that DLTs are defined for the first treatment cycle only. DLTs are usually associated
to severe toxicities of grade 3, 4 or 5. Thus, since DLTs are not documented after cycle
1, the outcome of interest is severe toxicity of grade 3,4, or 5. Toxicity severity was har-
monized across studies using the NCI Common Terminology Criteria of Adverse Events,
version 3.0. Severe toxicities were further divided into hematologic and non-hematologic,
according to Medical Dictionary for Regulatory Activities 15.
4.3.3 Main statistical analysis
A treatment cycle as defined per protocol was used as time unit, irrespectively of the
duration in days. As for our previous analyses, we considered a discrete time scale with
a maximum of 6 cycles C = {1, . . . , 6}. The event of interest was the time-to-first severe
toxicity (grade 3, 4 or 5). The per-cycle risk of having an AE was estimated for those
still at risk at the cycle initiation (i.e. the hazard function). For all analyses we relied
on a probit model similar to that introduced in Section 2.3.2. Let Si be the time-to-first
severe toxicity, for the ith individual, at time s given that no toxicity occurred at time
s− 1. Then,
P (Si = s|Si > s− 1) = 1− Φ(a0 + a1ci(s−1) + a2di), ci(s−1) ∈ C, (4.1)
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where Φ(·) is the cumulative standard normal distribution, a0, a1, and a2 are unknown
parameters, di is the dose administered to the i
th patient and ci(s−1) is the cycle variable.
For the estimation of the CIF of severe toxicity over up to 6 cycles, as in Section 2.3.2,
we summed up the risk of toxicity at each cycle
P (Si ≤ 6) =
6∑
s=1
P (Si = s).
For both cycle and dose we considered a linear relationship on the probit scale. To in-
vestigate if the linearity assumption was correct, we assessed the model residuals. Specif-
ically, for the treatment cycle we investigated two different models, for patients treated
at the MTD. In the first one, we assumed a different hazard for cycles 1-3 and 4-6 and
in the second one a different hazard for cycles 1-2 and 3-6. The underline model is
P (Si = s|Si > s− 1) = 1− Φ(a0 + a1c1i(s−1) + a2c2i(s−1)),
where c1 and c2 are the corresponding cycle variables. Similarly for the dose, we assumed
a different dose effect for patients treated below the MTD and those treated at or above
the MTD,
P (Si = s|Si > s− 1) = 1− Φ(a0 + a1ci(s−1) + a2di1(l<MTD) + a3di1(l≥MTD),
where l is the dose level and 1 is the indicator function.
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In a first analysis, three subgroups of patients treated at doses below, above and at
the MTD were created. The per-cycle risk of severe toxicity and the CIFs were estimated
separately in all three groups. Then a complete model 4.1 adjusted on the dose was
built to develop a nomogram predicting the CIF over six cycles, if the risk of severe
toxicity observed at cycle 1 ranged from 5% to 35%. The same model was also estimated
separately on the individual studies that were large enough to fit the model (17 / 26
studies).
In a second analysis, interest lay in evaluating the CIFs of hematologic and non-
hematologic severe AEs. Hematologic toxicities included also mixed cases, i.e. hema-
tologic and non-hematologic AEs observed on the same treatment cycle. Thus, there
were strictly non-hematologic AEs and hematologic (with or without concomitant non-
hematologic toxicity). First, we performed a more “naive” analysis, supposing that only
one of the two risks was of interest and the other one was not considered. Therefore,
we estimated the risk of having a hematologic toxicity, possibly in the presence of non-
hematologic toxicities and vice versa. For a more elaborate analysis, we turned to the
competing risks framework (Lee et al., 2018). In that case, we were interested in the
risk of having a first hematologic or a first non-hematologic toxicity. All analyses were
performed for the three dose subgroups, i.e. above, below, and at the MTD. For the esti-
mation of the cause-specific hazards we applied model, similar to model 4.1. For instance
for competing event (1), i.e. the non-hematologic severe toxicity, we have
P(1)(Si = s|Si > s− 1) = 1− Φ(a0 + a1ci(s−1)), ci(s−1) ∈ C.
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Then, for the non-hematologic severe toxicity at cycle 6, the CIF is
P(1)(Si ≤ 6) = P(1)(Si = s|Si > s− 1)
s−1∑
t=1
P (Si > t− 1)
= P(1)(S = 1) + P(1)(S = 2|S > 1)P (S > 1) + P(1)(S = 3|S > 2)P (S > 2)
+ P(1)(S = 4|S > 3)P (S > 3) + P(1)(S = 5|S > 4)P (S > 4)
+ P(1)(S = 6|S > 5)P (S > 5).
When considering more than one treatment cycles we expect to have missing data.
This data is the result of severe toxicities, disease progression or consent withdrawal. In
our data, we had the information for severe toxicities, but we had no knowledge regarding
the cause of censored observations. A property of the underline model 4.1 is that it takes
into account censoring when estimating the risk of severe toxicity. Nonetheless, it makes
the assumption that censored observations would have the same risk as the observations
still at risk, which may not necessarily be true. Administrative censoring was considered
at the end of cycle 6.
Prediction intervals were obtained from the bias corrected bootstrap technique (Efron,
1981).
4.3.4 Sensitivity analysis
As a first sensitivity analyses, we repeated the competing risks analysis classifying AEs
into strictly hematologic and non-hematologic (with or without hematologic). For the
second sensitivity analysis we excluded grade 3 hematologic toxicities from the definition
of severe toxicities. As mentioned before, hematologic toxicities are often easier to treat
by the clinicians, thus quite often grade 3 is not considered in the definition of the DLT.
Then, we repeated the analyses for the three dose subgroups as well as the competing risks
analysis. Competing risks analysis was conducted with the same definition of competing
events as for the main analysis.
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4.4 Results
4.4.1 Trial characteristics
From the 27 phase I studies provided by the NCI, one did not reach the MTD and was
excluded from analysis (Figure 4.1). The 26 eligible trials enrolled a total of 942 patients
with solid tumors or lymphomas. AEs data was available for all patients. There were
7.7% antiangiogenic agents, 3.8% antivascular agents, 7.7% CDK inhibitors, 11.5% HDAC
inhibitors, 23.1% HSP inhibitors, 11.5% immunotherapy, 11.5% monoclonal antibodies,
7.7% proteasome inhibitors and 15.4% other classes of agents. Administration route was
mainly intravenous (80.8%), followed by oral (15.4%) and intraperitoneal (3.9%). Cycle
duration ranged from 14 to 42 days (Table 4.1).
4.4.2 Treatment administration
Of the 942 patients, 58.2% received a second cycle, 25.1%, 16.5%, 9.9%, and 7.2%
received a 3rd to 6th cycle, respectively (Table 4.2). A total of 289 of the 942 patients
(30.7%) were assigned to the dose later defined as the trial MTD. Of those 289, 20 (6.9%)
received 6 cycles (Figure 4.2 a), Table C.1). A total of 490 patients (52%) and 163 (17.3%)
were treated below and above the MTD respectively.
4.4.3 Toxicity outcomes
Over the 6 treatment cycles, 333 of the 942 patients (35.3%) had at least one severe
toxicity of any type. Among these, 203 had only severe non-hematologic toxicity, 91 had
solely severe hematologic toxicity and 39 had both severe non-hematologic and hema-
tologic toxicity at the same cycle (Figure 4.2 b)). Non-hematologic toxicities included
39% gastrointestinal disorders, 10% general disorders, 7% central nervous system disor-
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Trial characteristics
• Targeted therapies
• Monotherapy only
• Solid tumors
• No tumor subtype 
selection
Grade 3, 4 and 5 toxicities
• Cycle 1 to 6
• Possibly related to the 
drug according to the 
sponsor
• Not present at baseline
Patients’ characteristics
• Receiving at least one 
full cycle of therapy
Included 27 centrally reviewed NCI phase I studies (963 patients)
Excluded 1 study (21 patients)
Trial did not reach the MTD
Harmonization of all AEs to NCI-CTCAE v3.0 and
MedDRA 15 or later classification
Population analyzed (942 patients)
Figure 4.1: Flowchart of the study. Overview of the study design and trial se-
lection. Abbreviations: AEs, Adverse Events; NCI, National Cancer Institute;
NCICTCAE, NCI Common Terminology Criteria for Adverse Events; MedDRA,
Medical Dictionary for Regulatory Activities.
ders, 4% dermatological, 3% liver, 3% glycemia, 3% vascular disorders and others. More
specifically, in cycle 1, 15.1% of patients had a first non-hematologic toxicity, 6.7% a first
hematologic toxicity, and 3.5% had both of them as compared to cycle 6 during which
1.5% first toxicities of each type were recorded, among patients still at risk (Table C.2).
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Table 4.1: Trial characteristics
Characteristics N (%)
Agent class
Antiangiogenic agent 2 (7.7)
Antivascular agent 1 (3.8)
CDK inhibitor 2 (7.7)
HDAC inhibitor 3 (11.5)
HSP inhibitor 6 (23.1)
Immunotherapy 3 (11.5)
Monoclonal antibody 3 (11.5)
Proteasome inhibitor 2 (7.7)
Other 4 (15.4)
Administration route
Intravenous 21 (80.8)
Oral 4 (15.4)
Intraperitoneal 1 (3.9)
Cycle duration
14 days 2 (7.7)
21 days 6 (23.1)
28 days 15 (57.7)
42 days 3 (11.5)
Of the 942 patients treated in the 1st cycle, 97 had a DLT. Of them, 22 had been allocated
to the MTD, 17 to a dose below and 58 to a dose above the MTD.
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Table 4.2: Number (#) and percentage (%) of patients at each
treatment cycle.
cycle 1 cycle 2 cycle 3 cycle 4 cycle5 cycle 6
# patients 942 548 236 155 93 68
% patients 100 58.2 25.1 16.5 9.9 7.2
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Figure 4.2: a) Patients per treatment cycle for the dose subgroups; below, above and
at the MTD. b) Patients that had a toxic event per treatment cycle.
4.4.4 Time-to-first severe toxicity
The per-cycle risk of first severe toxicity decreased with treatment cycle (Table C.3).
For patients allocated to the MTD the probability of a severe toxicity at the first treatment
cycle was 27.3% [95% prediction interval: 22.6%; 32.1%] and this number monotonically
decreased from 18.1% [14.7%; 21.6%] at cycle 2 down to 1.6% [0.2%; 5.5%] at cycle 6
(Figure 4.3 a), Table C.4). Of note, the risk of DLT in the first cycle, was 7.6% for
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patients treated at the MTD, 3.5% and 35.6% for patients treated at doses below and
above the MTD, respectively. The CIF of severe toxicity for patients treated at the MTD
increased from 27.3% [22.6%; 32.1%] at cycle 1 to 52.9% [43.7%; 61.5%] at cycle 6. For
patients assigned to doses below the MTD, CIF increased from 12.1% [9.7%; 15.2%] to
33.3% [27%; 40.5%] and to doses above the MTD from 48.9% [40.4%; 56.7%] to 80.1%
[70.1%; 88.7%] (Figure 4.3 b)).
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Figure 4.3: a) Risk and b) cumulative incidence function of severe toxicity over 6
cycles, for groups of patients treated at doses below, above and at the MTD.
Results of the complete model 4.1 are presented in Table C.5. Adjusting the model for
both cycle and dose did yield similar results to those presented in the previous analysis.
Figure 4.4 presents the risk and the CIF of severe toxicity for patients treated at the
MTD for the 2 models. We can see that the predicted CIF of toxicity was close to the
observed one. Thus, we conclude to small bias concerning the results of the complete
model. Per-cycle results for patients at the MTD are given in Table C.6. The nomogram
obtained from the complete model relating the CIF at cycle 6 to the risk at cycle 1 is
given in Table 4.3. It shows that for a risk of severe toxicity of 5% in the first cycle of
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treatment, the predicted CIF over 6 cycles of treatment was 10.7% [7.1%; 15.8%]. Most
importantly, for the traditionally accepted thresholds of 20% and 30% of severe toxicity in
cycle 1, targeted to identify the RP2D, the predicted CIFs at cycle 6 were 44.1% [39.3%;
49.5%] and 63% [56.8%; 69.5%], respectively.
Results of the residual check for the cycle and dose linearity can be found in Ta-
bles C.7 - C.10 of Appendix C. The per-cycle risk of toxicity and the CIF, among the
different cycle effects, is presented in Table C.8. Assuming a different cycle effect for
cycles 1-3 and 4-6 does not yield different results from the model, where we consider time
to be linear on the probit scale. Assuming a different cycle effect for cycles 1-2 and 3-6
gives slightly higher rates of toxicity. Assuming a different dose effect below the MTD
and at and above the MTD give very similar results to the case where we consider dose
to be linear on the probit
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Figure 4.4: Risk and cumulative incidence function of severe toxicity at the MTD.
Model 1 refers to the dose subgroup model and Model 2 to the complete model.
Next, we fitted the complete model 4.1 for 17 trials separately, for which we had
enough data. We estimated the risk and the CIF of severe toxicity for patients allocated
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Table 4.3: Cumulative incidence function of severe toxicity, as-
suming that risk of severe toxicity in the first cycle ranges between
5% and 35%.
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
0.050 0.078 0.093 0.101 0.105 0.107
0.100 0.157 0.189 0.207 0.217 0.221
0.150 0.235 0.284 0.311 0.326 0.334
0.200 0.311 0.374 0.410 0.430 0.441
0.250 0.384 0.460 0.503 0.527 0.541
0.300 0.455 0.539 0.587 0.615 0.630
0.350 0.522 0.613 0.664 0.693 0.710
to the MTD (Figure 4.5 - 4.6). After 6 cycles of treatment, among the 17 trials, the CIF
exceeded 50% in 12 of them and remained below 30% in only 1.
4.4.5 CIF of hematologic and non-hematologic severe toxicity
Results of the “naive” approach comparing non-hematologic and hematologic severe
toxicity, assuming each time that one of the two was not of interest can be found in
Table C.11. For patients at the MTD, the CIF of non-hematologic severe toxicity by the
end of cycle 6 was 48.3% [38.9%; 59.0%], twice as high as that of hematologic toxicity
24.3% [17.8%; 33.1%] (Figure 4.7 b), Table C.12). Similar results were observed for the
other two dose subgroups. For patients below the MTD, the CIF of non-hematologic
toxicity after 6 cycles reached 23.8% [18.2%; 30.7%], whereas the CIF of hematologic
toxicity was 14.8% [9.9%; 20.7%] (Figure 4.7 a)). Finally, for patients above the MTD,
the CIF of non-hematologic toxicity after 6 cycles was 72% [61.2%; 82.2%] versus 39.6%
[27.7%; 53.6%] for hematologic toxicity (Figure 4.7 c)).
Next we proceeded with the competing risks analysis, estimating the cause-specific
hazards of strictly non-hematologic and hematologic severe toxicity (Table C.13). For
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Figure 4.5: Risk of severe toxicity at the MTD per study.
patients assigned to the MTD level, the CIF of non-hematologic severe toxicity by the
end of cycle 6 was 34.8% [26.6%; 44.1%] and was almost twice as much as that of having
hematologic severe toxicity (18.2% [12.8%; 23.9%]) (Figure 4.8 b), Table C.14). Similar
results were observed in patients treated below and above the MTD. In particular, for
patients below the MTD, the CIF of exclusively non-hematologic severe toxicity reached
20.2% [15.2%; 26.1%] versus 13.1% [8.8%; 18.7%] for hematologic toxicity. For patients
above the MTD it reached 45.6% [36.4%; 55.1%] for exclusively non-hematologic severe
toxicity and 34.2% [24.8%; 44.5%] for hematologic toxicity (Figure 4.8 a) , c)).
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Figure 4.6: Cumulative incidence function of severe toxicity at the MTD per study.
4.4.6 Sensitivity analysis
Reclassification of mixed cases into non-hematologic toxicities led, as expected, to
inflation of the CIF, of competing risks, of non-hematologic toxicity (Table C.15 for
cause-specific hazards). At the MTD, it reached 39.2% [31.2%; 48.9%] and 13.8% [9.2%;
19.6%], for non-hematologic and hematologic respectively (Figure 4.9 b), Table C.16).
For patients allocated to doses below the MTD, the CIF of non-hematologic toxicity
by cycle 6 was 21.8% [18.1%; 29%] versus 11.6% [7.5%; 16.5%] for hematologic toxicity
(Figure 4.9 a)). Above the MTD, the CIF of non-hematologic toxicity reached 63.2%
[52.4%; 73.2%], whereas that of hematologic was 17.1% [10.3%; 25.5%] (Figure 4.9 c)).
For the second sensitivity analysis, exclusion of hematologic grade 3 AEs from the
definition of severe toxicity led to a decrease in the number of hematologic severe toxic-
ities and a small increase in that of non-hematologic. More precisely, in cycle 1, 17.5%
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c) Patients treated above the MTD
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Figure 4.7: Cumulative incidence function for patients treated at doses below, above and
at the MTD. CIFs were calculated for non-hematologic toxicity alone and hematologic
toxicity alone.
of patients had a first non-hematologic toxicity (3.8% in cycle 6), 1% a first hematologic
toxicity (0% in cycle 6), and 1.3% had both of them (1.3% in cycle 6) (Figure 4.10, Ta-
ble C.17). After repeating the analysis for the 3 dose subgroups, separately (Table C.18),
we found similar CIFs of any type of severe toxicity (Figure 4.11, Table C.19), as in our
first analysis. However, the CIFs of strictly non-hematologic and hematologic toxicity
were higher and lower respectively (Tables C.20 - C.21). At cycle 6, the ratio of the two
CIFs was equal to 6. For instance, at the MTD, the CIF of strictly non-hematologic
toxicity by cycle 6 reached 45% [35.6%; 55.0%] versus 7.5% [3.2%; 14.0%] for hemato-
logic toxicity (Figure 4.12 b)). Likewise, below and above the MTD, the CIFs of strictly
non-hematologic and hematologic toxicity, by cycle 6, were 22.8% [17.3%; 29.5%] versus
3.3% [1.2%; 7.5%] and 61.4% [52.1%; 71.5%] versus 13.6% [6.4%; 22.8%], respectively
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Patients treated above the MTD
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Figure 4.8: Cumulative incidence function for patients treated at doses below,
above and at the MTD. CIFs were calculated for overall toxicity, non-hematologic
toxicity and both hematologic and non-hematologic toxicity.
(Figure 4.12 a) , c)).
4.5 Discussion
In this chapter we have investigated the association of time-on-treatment, i.e. the
number of treatment cycle, with the risk of severe toxicity. We showed that for patients
assigned at the MTD, the risk of severe toxicity was 27% in cycle 1 and then per-cycle
risk decreased for each successive cycle. This is in line with results from other studies
(Postel-Vinay et al., 2011). At the MTD the CIF of severe toxicity by the end of cycle
6 was 53%. This risk is much higher than the 20%-33% risk of severe toxicity usually
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Patients treated above the MTD
Cycle
Cu
m
u
la
tiv
e 
in
ci
de
nc
e 
fu
nc
tio
n
1 2 3 4 5 6
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
both
hematologic
any toxicity
Figure 4.9: Cumulative incidence function for patients treated at doses below, above
and at the MTD. CIFs were calculated for overall toxicity, both hematologic and
non-hematologic toxicity and hematologic toxicity alone.
targeted in cycle 1 for the determination of the MTD and the RP2D. This CIF reached
as much as 80% for doses above the MTD. We have shown the importance of considering
separately the CIF of non-hematologic and hematologic severe toxicity, as the first one
was always higher. What is more, at the MTD, the CIF of severe toxicity was 48%
for non-hematologic toxicity, in the presence or not of hematologic toxicity and 24% for
hematologic toxicity, in the presence or not of non-hematologic toxicity. At the MTD,
the CIF of severe toxicity was made of 35% exclusively non-hematologic toxicity and of
18% hematologic or mixed toxicity.
The appropriate design and approaches to conduct phase I trials of MTAs and more
recently, of immunotherapies is much debated. Many authors have underlined that de-
layed and cumulative toxicities of MTAs, resulting from the prolonged administration of
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Figure 4.10: Patients that had a toxic event per treatment cycle.
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Figure 4.11: Risk and cumulative incidence function of severe toxicity over 6 cycles,
for groups of patients treated at doses below, above and at the MTD.
these treatments, have a non-negligible impact on the MTD definition and on the selec-
tion of the RP2D. This raises the question of what is an adequate DLT period (Booth
et al., 2008; Le Tourneau et al., 2010a; Soria, 2011). Illustrative of this is the poor pre-
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Patients treated at the MTD
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Patients treated above the MTD
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Figure 4.12: Cumulative incidence function of severe toxicity for patients treated
at doses below, above and at the MTD. CIFs were calculated for overall toxicity,
non-hematologic toxicity and both hematologic and non-hematologic toxicity.
diction of future approved dose levels from phase I and the resulting re-evaluation of the
MTD in subsequent phases of treatment development (Le Tourneau et al., 2010b; Iasonos
et al., 2012; Jardim et al., 2014).
The strengths of our study, besides the large number of trials and patients included,
is the detailed information collected about e.g. planned doses, treatment cycles, grades
and types of toxicity, etc.
Nevertheless, the fact that the treatments evaluated in the included phase I studies are
not from the most recent classes of agents with late onset toxicity, such as immunotherapy,
is a limitation of our study. Furthermore, we used a definition of severe toxicity that is
probably much larger than the usual definition of the dose limiting toxicity that may
exclude some grade 3 events such febrile neutropenia that would last less than 7 days.
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Hence, it is likely that we have overestimated the CIF of severe toxicity. Due to the
fact that DLTs are generally not recorded after cycle 1 and we did not have access to all
protocols, we cannot predict what is the extent of this overestimation.
For phase I designs we believe that 3-6 cycles should be considered in order to more
reliably determine the RP2D. Conversely, the interest of a treatment that would not
result in disease stabilization after two cycles would be questionable. In our analysis
the risk of grade 3 to 5 toxicity of 20% to 30% on the 1st treatment cycle translated
into cumulative incidence function of such events of 44% to 63% at the end of the 6th
treatment cycle. Therefore, a reasonable target of cumulative risk of severe toxicity may
be of the order of 40% to 45% over 6 cycles. We then suggest that re-evaluation of the
CIF of severe toxicity should be part of the stated objectives of the now rather popular
expansion cohorts (Dahlberg et al., 2014). Several dose-escalation methods have been
proposed that take into account time-on-treatment in the dose-escalation process, such
as time-to-event CRM, the CRM for longitudinal data (Paoletti et al., 2015) and of
course the designs presented in Chapters 2 and 3. Nevertheless, as thoroughly discussed
before, toxicity is only one component of the overall evaluation leading to the definition of
the optimal dose of a treatment. Pharmacokinetic data or biomarker measurements are
also important factors that help refine the dose selected for the next phase of treatment
development. Designs that make use of all collected data should improve the efficiency of
phase I trials of MTAs at defining the RP2D and therefore avoid the need to re-evaluate
accepted doses in subsequent phases.
Chapter 5
Conclusion
The objective of this thesis was to develop adaptive designs that can be applied in
phase I/II trials of molecularly targeted agents in oncology. Phase I trials are the cor-
nerstone of drug development and their correct design and conduct can help improve
the overall procedure. A major step in order to improve phase I trials is to integrate
all information collected during the trial. First of all, we were interested in developing
a design, for the identification of the OD that can consider several treatment cycles and
not just the first one, as it is currently done. The principal goal was to account for
late-onset and cumulative toxicities. Furthermore, the extensive use of biomarkers that
measure the drug activity, requires alternative approaches, which consider the biomarker
as a continuous variable, measured at multiple time points during the course of the trial,
so as to capture the information provided. It is well known that dichotomization of such
endpoints can only lead to substantial loss of information. What is more, considering
only a single biomarker measurement is not sufficient to define the drug activity, since
the course of the biomarker changes in time, indicating first response to treatment and
eventually disease progression. Another important issue that was of interest to that thesis
was censored data. When the OD selection is defined based on a long period, i.e. 3-6
cycles, encountering missing data is inevitable.
For the OD selection we proposed an adaptive design that combines both toxicity and
activity data, measured over a period of six treatment cycles. We implemented a recent
joint modeling technique of time-to-DLT outcome and continuous repeated biomarker
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measurements, under a shared random effect. This joint model estimation was using like-
lihood inference and model parameters were obtained from the numerical maximization
of the likelihood. The MTD was defined cumulatively, over six cycles, and the OD was
the lowest within a range of active and safe doses.
To investigate the robustness of the design and its ability to correctly identify the
OD we assessed its operating characteristics in a wide range of scenarios. We considered
smaller sample sizes, larger variances, altered random effects distribution,we assumed
an increasing hazard per treatment cycle and most importantly we generated several
scenarios under model misspecification. The method was highly efficacious regarding the
correct OD selection. Even under excessive censoring, with only 7% of patients arriving
at the end of the trial, the method was robust and estimations had small bias. What is
more, our design was safe, since study participants were generally not exposed to highly
toxic or subtherapeutic doses. This was the first design for phase I trials that included
several treatment cycles, continuous and repeated biomarker measurements, a cumulative
definition for the MTD and tackled the issue of missing responses.
A limitation of this design is associated to the dose-activity model. We implemented
a linear mixed effects model with a log term for the dose so as to allow for a dose-activity
relationship that was not strictly linear. Nevertheless, it was not enough to capture a
plateau. Additionally, due to the large number of model parameters and the small sample
size we encountered certain difficulties regarding the joint model convergence. This issue
was apparent when the MTD was the first dose in the dose range.
To address the aforementioned limitations, we extended our adaptive design by al-
lowing for model flexibility in the dose-activity relationship and a broader OD definition.
The core of the design remained the same. To make the model suitable for an activity
that plateaus after a certain dose level, we substituted the log model by a model that can
capture both a plateau and a strictly linear dose-activity relationship.
Investigation of the robustness of the new design was focused on the same motivating
example of the ovarian cancer trial so as to allow for comparison of the two approaches.
Extensive simulations showed that the new model performed very well under various
degrees of model misspecification. An important feature of the plateau model was that
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when data was generated from the log model, the percentage of correct OD recommenda-
tion was almost identical to that observed when analyzing data with the log model. That
was an indication of the model’s adaptability to different activity biomarker trajectories.
Last but not least, we addressed the case of convergence failure. Under the log model,
certain simulations could not proceed with the joint modeling, whereas with the plateau
model and for the same simulations no such issue was observed.
The proposed adaptive designs could be applied to different settings from the ones
we investigated, such that of combinational therapies. Under this particular framework,
we combine a new treatment with one or more of the standard ones. Our models could
be adjusted to allow for more than one dose variable, as well as dose interactions in
case of synergistic effects. However, increasing the number of variables makes parameter
estimation more challenging, especially in the beginning of the trial. In that case, it
could be useful to use joint modeling but with simpler models or to turn to the Bayesian
inference, so as to incorporate prior information regarding the standard treatments. In
addition to this, the adaptive designs could also be employed when we work with more
that one measures of activity, i.e. multiple biomarkers. In that case there are two possible
solutions. The first one is to create a score of all activity outcomes and to use that score
as the outcome of the activity model. This is a quite common practice. The second
option, if for example we have two different biomarkers, would be to consider separately
both activity endpoints. In that case the joint models would consist of 3 models, two for
the activity and one for the toxicity.
A limitation of both adaptive designs is related to their lack of comparability with
existing methods. Several dose finding methods have been proposed in the literature.
There exist methods that account for a longer DLT period, without however considering
several treatment cycles or a cumulative definition for the MTD. There are also meth-
ods that consider activity as a continuous endpoint, but with a single measurement per
patient. Therefore, comparing our design with alternative approaches was not feasible,
since it would not be possible to create matching scenarios. Another limitation is with
regard to the joint modeling method. We mentioned earlier that Barrett et al. (2015)
used the probit model for toxicity and the linear mixed effects model for activity with the
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purpose to exploit specific properties of the skew normal distribution. Their aim was to
express the joint likelihood in a closed form, by integrating out the random effects. Al-
though this property allowed for exact likelihood inference, joint modeling was restricted
to shared random effects. Under shared random effects, we make the assumption that the
same random effect accounts for both the association between the longitudinal and event
outcomes, and the correlation between the repeated measurements. On the contrary,
there exist joint modeling techniques that are more flexible (Rizopoulos, 2012), and can
account for various kinds of shared quantities, such as shared random effects and shared
model parameters. Nonetheless, these methods come with certain hindrances, which are
either associated to computational difficulties or lack of interpretability of the results.
The majority of the existing dose finding methods, presented in Chapter 1, relies
on the Bayesian framework. Bayesian inference is appropriate for parameter estimation,
when prior information exists regarding the toxicity and activity endpoints. An example
is phase I trials in pediatrics, where the drug under investigation has already been tested
in adults. However, in most first in human clinical trials, there is little or no knowledge
with respect to toxicity and activity. An impediment, when considering both outcomes, is
that we need to elicit more priors than we normally would, if we considered only toxicity.
Under no prior knowledge, prior distributions are most often non-informative. This is
an issue under small sample sizes, because parameter estimation, in the absence of data,
depends only on priors. This is why, certain dose-finding methods, such as Riviere et al.
(2016) or Yuan and Yin (2009), start the trial with a rule-based design that imitates the
‘3+3’ or similar designs, with the purpose to obtain some data, before proceeding with the
Bayesian inference. This is not very different from our design that starts with the ‘2+2’
design and when there is enough data it switches to the joint modeling. Nevertheless, an
advantage of our design is that it does not rely on approximations to estimate the model
parameters, as it is the case for Bayesian methods, but on numerical maximization.
For our design, we relied on jointly modeling toxicity and activity for the OD selec-
tion. It has been shown that when two outcomes are correlated parameter estimation can
significantly benefit from the use of joint modeling. There have been several articles in
the literature (Schluchter, 1992; Faucett and Thomas, 1996; Wulfsohn and Tsiatis, 1997;
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Henderson et al., 2000; Tsiatis and Davidian, 2004; Rizopoulos, 2012) showing that joint
models provide more robust estimates, compared to models that consider the outcomes
independently. Joint modeling is a suitable way to correct the toxicity model for the
missing data, observed due to disease progression. However, a question raised here is
whether joint models are absolutely necessary for dose selection. For instance, when we
target 40% of cumulative toxicity, we aim to find a dose with a probability of DLT as
close as possible to the target. It is possible that even if estimates are obtained from in-
dependent models, the recommended dose will still be the same. Nonetheless, we showed
in a simulation study that most often under correlated outcomes joint modeling outper-
forms independent modeling, despite the estimation of the extra parameter. Depending
on the data variability, it is possible to observe differences between the two approaches
even in the presence of a weak correlation. It would be interesting though to further
investigate the value of joint modeling in phase I/II clinical trials, within a broader range
of scenarios. In the case where the two outcomes are not correlated considering them
separately could be a more appropriate approach.
Another point that drew our attention was model predictions. When we estimated
the MTD and OD, we used a conditional or else subject-specific model for both activity
and toxicity models. When applying a conditional model we make the assumption that
the patient entering the study is most likely to have a random effect that approximates a
mean value of zero. An alternative approach would be to estimate the marginal or else the
population-averaged expectation, by integrating over the random effect distribution. Due
to the symmetry of the normal distribution, both approaches, conditional and marginal,
give the same predictions for the linear outcome. However, this is not the case for
the survival outcome. Thus, the first question raised is which of the two approaches
would be more suitable for the survival outcome. We chose the conditional expectation,
since we wanted to select a dose for the next patient and not generalize the results
on the population. Another matter worth mentioning is whether we should focus on an
immortal cohort or on partly conditional predictions. We remind that an immortal cohort
implies that subjects under study would not drop out due to toxicity or lack of activity.
This scenario would be more realistic in a phase II or a phase III clinical trial, where
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patients would probably receive co-medication in the presence of serious adverse events.
On the contrary, partly conditional effects, population-averaged or subject-specific, are
estimated conditionally on the fact that subjects are still in the study. For example, a
partly conditional population-averaged expectation would be appropriate if we wanted to
predict the risk of toxicity in a specific treatment cycle. We mentioned above that for a
particular patient entering the study we used the subject-specific expectation. However,
if we wished to make individual predictions for patients already enrolled in the study
we would choose the partly conditional subject-specific expectation. This is because
we have already followed the patient and there exists information regarding his random
effect. Using joint modeling, we can predict at the same time the toxicity and activity
outcome of a patient, so as to allow for dose modification during the course of the trial, or
otherwise intrapatient dose modification. That would be very important, given the fact
that patients can be treated for several treatment cycles. We could potentially identify
patients for whom the drug can be proved to be highly toxic and therefore, decrease the
dose so as to avoid future dose limiting toxicities. In a similar way, if a patient does not
respond to the treatment and a higher dose is deemed to be safe, then it would be possible
to allow for dose escalation for that particular patient. As a result, patients could remain
for a longer period in the trial and potentially benefit from the treatment.
The last part of this thesis focused on the analysis of 27 completed phase I trials of
targeted therapies as monotherapy. These trials were conducted by the NCI and were
provided to the EORTC and the DLT-TARGETT. In the previous chapters, we discussed
the importance of considering time when conducting a phase I trial. However, till now
there was nothing in the literature, documenting the risk of severe toxicity, for more than
one treatment cycles. Therefore, our primary interest was to estimate the per-cycle risk,
as well as the cumulative incidence function of severe toxicity over up to six treatment
cycles. A secondary objective was to estimate the same quantities, but separately for
hematologic and non-hematologic severe toxicities. These types of toxicities do not occur
in the same way and do not have the same impact on the human body, thus there is merit
in estimating the risk separately.
To that end, we implemented a probit time-to-toxicity model that can estimate both
Conclusion 125
the per-cycle risk and the cumulative incidence function. We performed the analysis,
first separately for groups of patients treated at doses below, above, and at the MTD and
then overall patients and we provided a nomogram. We investigated the risk of toxicity
for hematologic and non-hematologic toxicities, and finally, we conducted a sensitivity
analysis. We showed that the cumulative incidence function of severe toxicity for patients
treated at the MTD was 27% at the end of the first cycle and reached 53% by the end
of cycle six. For patients administered to the MTD, the cumulative incidence function of
non-hematologic and hematologic toxicity was 35% and 18%, accordingly.
This project was the first one to provide results on the per-cycle risk and the cumula-
tive incidence function of severe toxicity over several treatment cycles. We additionally,
provided guidelines for the good conduct of phase I trials, and reasonable target toxicity
levels, based on the results from the DLT-TARGETT. A limitation of this analysis is
related to the severe toxicity definition. Traditionally, the MTD is defined based on the
DLTs occurring during the first treatment cycle. DLTs are defined upon on certain grade
3 and grade 4 toxicities and they are study specific. We were interested in the risk of
toxicity over several cycles, and for that we would need to reconstruct the DLT variable
for all six cycles. However, we did not have access to all 27 study protocols. As a conse-
quence, for the analysis we focused on the first severe toxicity, which does not necessarily
coincide with a DLT. Therefore, considering the first severe toxicity could have resulted
in an overestimation of the risk of toxicity. What is more, information recorded provided
the dose limiting toxicities that occurred during the first cycle and for the following cy-
cles patients were censored. Hence, we could not know if patients were removed from the
study due to excessive toxicity, disease progression or consent withdrawal.
It has been shown that the MTD of targeted therapies, contrary to cytotoxic therapies,
is quite often re-evaluated in subsequent phases (Le Tourneau et al., 2010b; Iasonos et al.,
2012; Jardim et al., 2014). This is a major problem of phase I trials of these agents,
indicating that new methods and new designs should be applied when recommending the
MTD and the OD. With this thesis, we wished to provide evidence that there is space
for improvement and to that end we developed an adaptive design and an extension of
that design that could be applied to these trials. Finally, after the analysis of the DLT-
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TARGETT, it became apparent that for the definition of the recommended phase II
dose, it is vital to consider 3-6 treatment cycles, consider a cumulative definition of the
target toxicity level and if possible, incorporate activity measurements. In conclusion,
integration of more information could lead to more efficient phase I trials of targeted
therapies.
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Table A.1: Simulation results of 2000 replicates. Shown are the percentage of bias and the
coverage of the joint model parameters over six different sample sizes: N = 15, N = 20,
N = 25, N = 30, N = 40, and N = 60 and for unbalanced data for the linear mixed effects
model.
Parameter Bias Coverage
N=15 N=20 N=25 N=30 N=40 N=60 N=15 N=20 N=25 N=30 N=40 N=60
Longitudinal
β0 −1.18 −0.36 −0.16 −0.10 −0.13 −0.02 0.92 0.93 0.95 0.95 0.95 0.94
β1 −0.18 0.02 0.00 0.00 −0.01 −0.01 0.91 0.93 0.94 0.93 0.94 0.95
β2 0.58 −0.13 0.20 0.02 0.02 −0.08 0.89 0.91 0.91 0.92 0.93 0.94
β3 −14.92 4.00 5.40 −0.25 −0.13 2.30 0.92 0.90 0.91 0.93 0.93 0.93
σ1 −5.32 −8.20 −8.30 −7.30 −5.90 −6.20 0.90 0.99 0.99 0.99 0.99 0.98
σ2 12.00 −3.40 −2.50 −2.10 −1.40 −0.88 0.98 0.97 0.97 0.97 0.96 0.96
Survival
a0 1.28 0.23 −0.19 0.15 −0.12 0.09 0.98 0.97 0.95 0.95 0.95 0.95
a1 −27.42 13.50 8.80 7.50 6.01 3.10 0.98 0.97 0.97 0.96 0.96 0.95
γ 368.71 40.62 −25.37 12.29 10.96 −2.70 0.99 0.99 0.99 0.99 0.99 0.97
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Figure A.1: Biomarker trajectory over time and for 6 dose levels.
Appendix A 139
Table A.2: Pocock-type sequential boundaries to monitor dose-limiting toxicity rate. Tox-
icity rate was set at 35% and the one-sided level test at 10%.
Number of patients, (N) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Boundary, (bN) - - 3 4 4 5 5 5 6 6 7 7 8 8 8
Table A.3: Joint model parameters for data generation of the eight
principal scenarios. Standard deviations were fixed at σ1 = 1 and
σ2 = 3, and the parameter of the shared random effect at γ = 0.1.
Parameter Scenario
1 2 3 4 5 6 7 8
Longitudinal
β0 270 90 115 115 80 270 115 90
β1 35 8.5 15 15 7 35 10 8.5
β2 -80 -19 -31.5 -31.5 -11 -80 -27 -19
β3 -4 -4 -4 -4 -4 -4 -4 -4
Survival
a0 7.50 7.43 5.20 7.43 5.82 7.20 7.20 2.7
a1 0.33 0.33 0.30 0.33 1.94 0.30 0.30 1.5
ag -3.30 -3.30 -3.50 -3.30 -3.12 -2.90 -2.90 -2.6
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Table A.4: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat), under the scenarios of Table 2.3. Residual standard deviation was σ2 = 4
and random effect standard deviation σ1 = 2. The optimal dose is in bold and the MTD
in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
1 (Y(l),min, pl) (200, 0.00) (176, 0.00) (147, 0.02) (115, 0.12) (79, 0.38) (40, 0.75)
P% 0.0 0.0 0.0 1.0 97.8 1.2 0.0
N¯pat 2.0 2.0 2.2 5.4 40.7 7.7
2 (Y(l),min, pl) (71, 0.00) (64, 0.00) (57, 0.03) (49, 0.12) (39, 0.38) (29, 0.75)
P% 0.3 10.7 80.0 8.5 0.5 0.0 0.0
N¯pat 2.3 7.2 31.4 8.2 5.8 5.1
3 (Y(l),min, pl) (87, 0.32) (78, 0.71) (67, 0.96) (55, 0.99) (41, 0.99) (26, 0.99)
P% 99.4 0.2 0.0 0.0 0.0 0.0 0.4
N¯pat 51.6 6.3 2.0 0.1 0.0 0.0
4 (Y(l),min, pl) (87, 0.00) (78, 0.00) (67, 0.03) (55, 0.12) (41, 0.38) (26, 0.75)
P% 0.1 0.0 3.9 91.5 4.5 0.0 0.0
N¯pat 2.0 2.1 5.5 36.3 9.0 5.0
5 (Y(l),min, pl) (71, 0.02) (68, 0.07) (65, 0.20) (61, 0.43) (57, 0.68) (52, 0.88)
P% 99.6 0.2 0.0 0.2 0.0 0.0 0.0
N¯pat 29.4 3.6 6.3 11.5 7.8 1.4
6 (Y(l),min, pl) (200, 0.00) (176, 0.00) (147, 0.01) (115, 0.04) (79, 0.16) (40, 0.41)
P% 0.2 0.0 0.0 0.0 5.3 94.5 0.0
N¯pat 2.0 2.0 2.0 2.4 8.1 43.4
7 (Y(l),min, pl) (84, 0.00) (73, 0.00) (61, 0.01) (48, 0.04) (32, 0.16) (16, 0.41)
P% 0.0 0.0 0.0 14.9 84.9 0.2 0.0
N¯pat 2.0 2.0 2.2 9.3 34.2 10.3
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Table A.5: Sensitivity analyses of 2000 replicates. Percentage of dose selection at the end
of the trial (P%) and mean number of patients assigned to each dose level (N¯pat), under the
scenarios of Table 2.3, with different standard deviations, sample size, and random effects’
distributions.
Conditions Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
N=40
σ1 = 2 and σ2 = 4 1 P% 0.0 0.0 0.0 3.6 90.8 5.6 0.0
N¯pat 2.0 2.0 2.2 5.1 21.7 7.0
2 P% 0.4 11.9 74.4 11.9 1.4 0.0 0.0
N¯pat 2.2 4.8 16.0 6.6 5.5 4.9
3 P% 99.5 0.2 0.0 0.0 0.0 0.0 0.3
N¯pat 31.9 6.0 1.9 0.2 0.0 0.0
4 P% 0.0 0.0 6.9 83.1 10.0 0.0 0.0
N¯pat 2.0 2.1 4.6 18.6 7.8 4.9
5 P% 98.8 0.2 0.0 1.0 0.0 0.0 0.0
N¯pat 16.7 3.5 5.3 8.2 5.3 1.0
6 P% 0.2 0.0 0.1 0.0 11.5 88.2 0.0
N¯pat 2.0 2.0 2.0 2.4 6.9 24.7
7 P% 0.2 0.0 0.1 17.6 81.0 1.1 0.0
N¯pat 2.0 2.0 2.2 6.4 18.1 9.2
U ∼ Γ(2, 2) for linear model
U ∼ N(0, 1) for probit model 1 P% 0.1 0.0 0.0 1.4 97.0 1.5 0.0
N¯pat 2.0 2.0 2.2 5.8 40.4 7.6
2 P% 0.4 11.7 73.7 14.0 0.2 0.0 0.0
N¯pat 2.3 7.2 30.0 9.6 5.8 5.1
3 P% 99.1 0.3 0.1 0.0 0.0 0.0 0.5
N¯pat 51.7 6.3 1.9 0.1 0.0 0.0
4 P% 0.0 0.0 4.2 87.4 8.4 0.0 0.0
N¯pat 2.1 2.1 5.6 34.7 10.3 5.2
5 P% 99.0 0.0 0.0 1.0 0.0 0.0 0.0
N¯pat 29.5 3.5 6.4 11.6 7.7 1.3
6 P% 0.2 0.0 0.0 0.0 4.5 95.3 0.0
N¯pat 2.0 2.0 2.0 2.4 8.1 43.5
7 P% 0.2 0.0 0.0 12.2 86.6 1.0 0.0
N¯pat 2.1 2.0 2.2 8.3 34.2 11.2
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Table A.6: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of dose
selection at the end of the trial (P%) and mean number of patients assigned to each dose
level (N¯pat). For scenarios A.6.1−A.6.3 data was generated from a saturated linear mixed
effects model for activity and the probit model for toxicity. For scenarios A.6.4 − A.6.6
data was generated from the linear mixed effects model for activity and a logistic model
for toxicity. The optimal dose is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
A.6.1 (Y(l),min, pl) (86, 0.00) (73, 0.00) (69, 0.01) (66, 0.04) (64, 0.13) (58, 0.35)
P% 4.1 91.1 4.3 0.5 0.0 0.0 0.0
N¯pat 3.9 30.0 7.6 3.3 3.9 11.3
A.6.2 (Y(l),min, pl) (89, 0.02) (88, 0.07) (66, 0.20) (59, 0.43) (48, 0.68) (33, 0.88)
P% 17.6 2.9 76.9 2.5 0.1 0.0 0.0
N¯pat 7.4 3.7 27.2 12.5 7.8 1.4
A.6.3 (Y(l),min, pl) (97, 0.00) (94, 0.00) (81, 0.01) (76, 0.04) (74, 0.13) (69, 0.35)
P% 0.2 8.5 59.0 32.0 0.2 0.1 0.0
N¯pat 2.1 5.8 19.5 17.1 3.9 11.6
A.6.4 (Y(l),min, pl) (200, 0.04) (176, 0.08) (147, 0.13) (115, 0.23) (79, 0.36) (40, 0.54)
P% 0.4 0.0 0.2 10.8 66.4 22.2 0.0
N¯pat 2.3 2.4 3.6 9.8 27.4 14.5
A.6.5 (Y(l),min, pl) (78, 0.10) (71, 0.19) (62, 0.33) (53, 0.51) (42, 0.72) (30, 0.88)
P% 81.6 17.6 0.4 0.2 0.2 0.0 0.0
N¯pat 30.8 14.8 6.0 5.2 2.6 0.6
A.6.6 (Y(l),min, pl) (193, 0.25) (167, 0.40) (135, 0.59) (99, 0.77) (60, 0.91) (16, 0.97)
P% 13.5 71.5 14.9 0.1 0.0 0.0 0.0
N¯pat 12.4 32.9 12.2 2.1 0.4 0.0
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Table A.7: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of dose
selection at the end of the trial (P%) and mean number of patients assigned to each dose
level (N¯pat). For the activity data was generated from a linear mixed effects model, with
response being associated with increase and progression with decrease of the biomarker, as
shown in Figure A.1. The optimal dose is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
A.7.1 (Y(l),min, pl) (39, 0.02) (43, 0.07) (46, 0.20) (49, 0.43) (52, 0.68) (75, 0.88)
P% 99.8 0.0 0.0 0.2 0.0 0.0 0.0
N¯pat 32.9 3.6 6.2 10.5 6.0 0.8
A.7.2 (Y(l),min, pl) (44, 0.00) (53, 0.00) (62, 0.03) (72, 0.12) (81, 0.38) (90, 0.75)
P% 0.2 6.7 73.7 19.0 0.4 0.0 0.0
N¯pat 2.1 5.1 28.9 12.8 6.6 4.5
Table A.8: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). For the activity data was generated from the linear mixed effects model
assuming both a random intercept and a random slope for time. Toxicity model was not
modified. The optimal dose is in bold and the MTD in italic.
Scenario Conditions Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
(Y(l),min, pl) (71, 0.00) (64, 0.00) (57, 0.03) (49, 0.12) (39, 0.38) (29, 0.75)
A.8.1 σ1 = 1, σ2 = 3 P% 0.2 10.8 80.3 8.0 0.7 0.0 0.0
σ3 = 1, ρσ1,σ3 = 0.7 N¯pat 2.2 7.4 31.1 8.4 5.8 5.0
A.8.2 σ1 = 1, σ2 = 3 P% 1.0 11.8 67.9 18.2 1.2 0.0 0.0
σ3 = 3, ρσ1,σ3 = 0.7 N¯pat 2.6 7.9 26.5 11.6 6.2 5.2
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Table A.9: Sensitivity analysis of 2000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). For the activity data was generated from a linear mixed effects model
that included both a linear and a quadratic term for time. Toxicity model was not modified.
The optimal dose is in bold and the MTD in italic.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
A.9.1 (Y(l),min, pl) (261, 0.00) (223, 0.00) (183, 0.03) (138, 0.12) (89, 0.38) (37, 0.75)
P% 0.2 0.0 0.0 1.1 97.5 1.2 0.0
N¯pat 2.1 2.0 2.2 5.2 40.6 7.9
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Table B.1: Joint model parameters for data
generation of the five principal scenarios.
Standard deviations were fixed at σ1 = 1 and
σ2 = 3, and the parameter of the shared ran-
dom effect at γ = 0.1.
Parameter Scenario
1 2 3 4 5
Longitudinal
β0 160 200 90 115 90
β1 8.5 9.5 12 16.5 12
β2 -40 -40 -20 -30 -20
Survival
a0 5.82 7.44 5.11 5.82 2.70
a1 1.94 0.33 1.94 1.94 1.50
ag -3.12 -3.30 -3.00 -3.12 -2.60
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Table B.2: Sensitivity analyses of 1000 replicates. Percentage of dose selection at the end
of the trial (P%) and mean number of patients assigned to each dose level (N¯pat), under
the scenarios of Table 3.1, with different standard deviations, sample size, and random
effects’ distributions.
Conditions Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
σ1 = 2 and σ2 = 5
N=40 1 P% 0.1 2.3 97.5 0.1 0.0 0.0 0.0
N¯pat 2.1 3.3 20.6 7.9 5.3 1.0
2 P% 0.0 0.0 0.0 4.2 95.8 0.0 0.0
N¯pat 2.0 2.0 2.2 5.3 23.6 4.9
3 P% 98.6 0.8 0.1 0.1 0.0 0.0 0.4
N¯pat 18.6 5.2 8.3 6.2 1.6 0.1
4 P% 17.3 79.0 3.6 0.1 0.0 0.0 0.0
N¯pat 5.1 15.0 5.8 8.0 5.2 0.9
U ∼ Γ(2, 2) for linear model
U ∼ N(0, 1) for probit model
N=40 and σ2 = 3 1 P% 0.0 0.1 99.9 0.0 0.0 0.0 0.0
N¯pat 2.1 2.5 21.1 8.2 5.1 1.0
2 P% 0.0 0.0 0.0 5.8 94.2 0.0 0.0
N¯pat 2.0 2.0 2.2 5.3 23.5 5.0
3 P% 97.0 1.8 1.1 0.0 0.0 0.0 0.1
N¯pat 18.7 5.3 8.2 6.2 1.5 0.1
4 P% 16.8 82.5 0.6 0.1 0.0 0.0 0.0
N¯pat 5.1 15.5 5.4 8.0 5.1 1.0
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Table B.3: Sensitivity analyses of 1000 replicates and a sample size of 60. Percentage
of dose selection at the end of the trial (P%) and mean number of patients assigned
to each dose level (N¯pat). Toxicity data was generated assuming increasing hazard at
each successive treatment cycle. The optimal dose is in bold, the MTD in italic and the
beginning of the plateau is underlined.
Scenario Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
B.3.1 (Y(l),min, pl) (88, 0.01) (59, 0.03) (59, 0.11) (59, 0.31) (59, 0.61) (59, 0.87)
P% 0.0 100.0 0.0 0.0 0.0 0.0 0.0
N¯pat 2.2 34.8 3.0 3.0 3.0 14.0
B.3.2 (Y(l),min, pl) (201, 0.00) (176, 0.00) (147, 0.00) (114, 0.03) (77, 0.14) (38, 0.42)
P% 0.0 0.0 0.0 0.0 6.5 93.5 0.0
N¯pat 2.0 2.0 2.1 2.4 7.9 43.6
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Table B.4: Sensitivity analyses of 1000 replicates and a sample size of 60. Percentage of
dose selection at the end of the trial (P%) and mean number of patients assigned to each
dose level (N¯pat). For the activity data was generated from the log model 2.2, assuming
both a random intercept and a random slope for time. Toxicity model was not modified.
The optimal dose is in bold and the MTD in italic.
Model Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 None
Selected
(Y(l),min, pl) (71, 0.00) (64, 0.00) (57, 0.03) (49, 0.12) (39, 0.38) (29, 0.75)
σ1 = 1, σ2 = 3
σ3 = 1, ρσ1,σ3 = 0.7
log
P% 0.2 10.8 80.3 8.0 0.7 0.0 0.0
N¯pat 2.2 7.4 31.1 8.4 5.8 5.0
plateau
P% 0.6 14.2 78.9 5.3 0.1 0.0 0.0
N¯pat 2.4 8.4 31.2 6.3 6.5 5.2
σ1 = 1, σ2 = 3
σ3 = 3, ρσ1,σ3 = 0.7
log
P% 1.0 11.8 67.9 18.2 1.2 0.0 0.0
N¯pat 2.6 7.9 26.5 11.6 6.2 5.2
plateau
P% 0.7 15.9 73.9 7.3 2.2 0.0 0.0
N¯pat 2.4 9.1 29.3 7.7 6.6 4.8
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C.1 Descriptives
Table C.1: Number (#) and percentage (%) of patients per treatment
cycle and dose subgroup.
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
# patients d<MTD 490 338 157 104 60 43
% patients d<MTD 100 69.0 32.0 21.2 12.2 8.8
# patients d=MTD 289 152 54 37 25 20
% patients d=MTD 100 52.6 18.7 12.8 8.7 6.9
# patients d>MTD 163 58 25 14 8 5
% patients d>MTD 100 35.6 15.3 8.6 4.9 3.1
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Table C.2: Number (#) and percentage (%) of patients per type of
toxicity and treatment cycle.
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
# non-hematologic 142 33 19 4 4 1
% non-hematogic 15.1 6.0 8.1 2.6 4.3 1.5
# hematologic 63 18 2 6 1 1
% hematologic 6.7 3.3 0.9 3.9 1.1 1.5
# both∗ 33 2 2 0 1 1
% both 3.5 0.4 0.9 0.000 1.1 1.5
∗ Both non-hematologic and hematologic toxicity at the same cycle
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C.2 Main analysis
Table C.3: Association of severe toxicity with cycle, for groups of patients treated at
doses below, above and at the MTD.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
below the MTD intercept 1.171 0.065 1.045 1.298
(490) cycle 0.160 0.044 0.074 0.246
at the MTD intercept 0.603 0.072 0.461 0.745
(289) cycle 0.307 0.062 0.187 0.428
above the MTD intercept 0.027 0.092 -0.152 0.207
(163) cycle 0.359 0.079 0.204 0.513
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.4: Risk and cumulative incidence function (CIF) of severe toxicity over 6 cycles, for groups
of patients treated at doses below, above and at the MTD.
Group of dose (n)∗ Treatment Risk Lower PI∗∗ Upper PI CIF Lower PI Upper PI
cycle
below the MTD
(490)
1 0.121 0.097 0.152 0.121 0.097 0.152
2 0.091 0.076 0.109 0.201 0.166 0.241
3 0.068 0.049 0.087 0.255 0.216 0.300
4 0.049 0.028 0.072 0.292 0.246 0.344
5 0.035 0.016 0.062 0.317 0.263 0.377
6 0.024 0.008 0.053 0.333 0.270 0.405
at the MTD
(289)
1 0.273 0.226 0.321 0.273 0.226 0.321
2 0.181 0.147 0.216 0.405 0.350 0.461
3 0.112 0.068 0.155 0.472 0.411 0.537
4 0.064 0.026 0.112 0.505 0.427 0.572
5 0.033 0.008 0.080 0.522 0.434 0.597
6 0.016 0.002 0.055 0.529 0.437 0.615
above the MTD
(163)
1 0.489 0.404 0.567 0.489 0.404 0.567
2 0.350 0.285 0.417 0.668 0.594 0.740
3 0.228 0.127 0.316 0.744 0.667 0.813
4 0.135 0.041 0.241 0.778 0.691 0.852
5 0.072 0.010 0.175 0.794 0.700 0.874
6 0.034 0.001 0.118 0.801 0.701 0.887
∗ Sample size
∗∗ Prediction interval
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C.3 Complete model
Table C.5: Association of severe toxicity with cycle and dose.
Parameter Estimate S.E.∗ Lower CI∗∗ Upper CI
intercept 1.381 0.075 1.233 1.529
cycle 0.245 0.033 0.181 0.309
dose -0.727 0.070 -0.864 -0.589
∗ Standard error
∗∗ Confidence interval
Table C.6: Risk and cumulative incidence function (CIF) of severe toxicity over 6
cycles, for patients treated at the MTD.
Treatment Risk Lower PI∗ Upper PI CIF Lower PI Upper PI
cycle
1 0.256 0.227 0.286 0.256 0.226 0.285
2 0.184 0.164 0.206 0.394 0.359 0.431
3 0.126 0.103 0.152 0.470 0.433 0.512
4 0.083 0.058 0.111 0.514 0.470 0.561
5 0.051 0.029 0.081 0.539 0.489 0.593
6 0.030 0.013 0.056 0.553 0.499 0.614
∗ Prediction interval
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C.4 Residual Check
C.4.1 For cycle effect
Table C.7: Association of severe toxicity with cycle. For the cycle variable, we
assume in model 1 a different effect among cycles 1-3 and 4-6 and in model 2
a different effect among cycles 1-2 and 3-6.
Parameter Estimate S.E.∗ Lower CI∗∗ Upper CI
Model 1
intercept 0.570 0.076 0.422 0.719
cycle 1-3 0.409 0.101 0.210 0.608
cycle 4-6 0.270 0.065 0.143 0.396
Model 2
intercept 0.525 0.077 0.375 0.676
cycle 1-2 0.691 0.155 0.388 0.995
cycle 3-6 0.276 0.058 0.162 0.390
∗ Standard error
∗∗ Confidence interval
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Table C.8: Risk and cumulative incidence function of severe toxicity assuming a) 1 linear cycle
effect b) 2 cycle effects 1-3 and 4-6 and c) 2 cycle effects 1-2 and 3-6.
Treatment Cycles 1-6 Cycles 1-3 Lower PI∗ Upper PI Cycles 1-2 Lower PI Upper PI
cycle linear Cycles 4-6 Cycles 3-6
Risk of severe toxicity
1 0.273 0.284 0.228 0.334 0.300 0.247 0.353
2 0.181 0.164 0.119 0.214 0.112 0.064 0.164
3 0.112 0.133 0.120 0.216 0.141 0.091 0.192
4 0.064 0.084 0.024 0.151 0.088 0.042 0.150
5 0.033 0.049 0.008 0.120 0.051 0.016 0.112
6 0.016 0.027 0.002 0.093 0.028 0.005 0.085
Cumulative incidence function
1 0.273 0.284 0.228 0.334 0.300 0.247 0.353
2 0.405 0.401 0.343 0.455 0.378 0.320 0.433
3 0.472 0.451 0.377 0.525 0.465 0.406 0.534
4 0.505 0.497 0.417 0.574 0.512 0.441 0.593
5 0.522 0.522 0.433 0.608 0.537 0.454 0.632
6 0.529 0.535 0.436 0.636 0.551 0.460 0.656
∗ Prediction interval
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C.4.2 For dose effect
Table C.9: Association of severe toxicity with cycle and dose. For the
dose we assume 2 dose effects; 1 for patients treated below the MTD
and 1 for patients treated above or at the MTD.
Parameter Estimate S.E.∗ Lower CI∗∗ Upper CI
intercept 1.103 0.058 0.990 1.217
cycle 0.241 0.033 0.177 0.306
dose1 -0.457 0.080 -0.614 -0.300
dose2 -1.004 0.094 -1.188 -0.820
∗ Standard error
∗∗ Confidence interval
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Table C.10: Risk and cumulative incidence function of severe toxicity assuming 2
variables for the dose effect.
Treatment cycle Dose linear Dose 1 - Dose 2 Lower PI∗ Upper PI
Risk of severe toxicity
1 0.256 0.259 0.216 0.301
2 0.184 0.187 0.155 0.220
3 0.126 0.129 0.097 0.161
4 0.083 0.085 0.055 0.118
5 0.051 0.053 0.027 0.084
6 0.030 0.032 0.013 0.060
Cumulative incidence function
1 0.256 0.259 0.216 0.301
2 0.394 0.398 0.340 0.453
3 0.470 0.476 0.410 0.536
4 0.514 0.521 0.450 0.586
5 0.539 0.546 0.471 0.617
6 0.553 0.561 0.480 0.638
∗ Prediction interval
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C.5 Competing events
C.5.1 Naive analysis
Table C.11: Association of severe toxicity with cycle for patients treated
at doses below, above and at the MTD. Estimation of hazards per type
of toxicity.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
non-hematologic toxicity
below the MTD intercept 1.383 0.072 1.243 1.523
(490) cycle 0.151 0.048 0.056 0.246
at the MTD intercept 0.909 0.076 0.759 1.058
(289) cycle 0.162 0.051 0.061 0.263
above the MTD intercept 0.282 0.092 0.103 0.462
(163) cycle 0.297 0.071 0.159 0.436
hematologic toxicity
below the MTD intercept 1.678 0.085 1.511 1.846
(490) cycle 0.121 0.057 0.010 0.232
at the MTD intercept 1.214 0.089 1.040 1.388
(289) cycle 0.256 0.076 0.106 0.405
above the MTD intercept 0.895 0.104 0.690 1.099
(163) cycle 0.264 0.082 0.103 0.425
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.12: Cumulative incidence function (CIF) of severe toxicity for patients treated at
doses below, above and at the MTD. CIFs were calculated for non-hematologic toxicity
alone and and hematologic toxicity alone.
Group of dose (n)∗ Treatment CIF Lower PI∗∗ Upper PI CIF Lower PI Upper PI
cycle non-hematologic hematologic
below the MTD
(490)
1 0.083 0.062 0.107 0.047 0.032 0.066
2 0.141 0.112 0.173 0.081 0.059 0.109
3 0.180 0.146 0.219 0.106 0.078 0.140
4 0.207 0.165 0.252 0.125 0.090 0.166
5 0.226 0.176 0.281 0.138 0.094 0.186
6 0.238 0.182 0.307 0.148 0.099 0.207
at the MTD
(289)
1 0.182 0.141 0.225 0.112 0.082 0.150
2 0.298 0.246 0.356 0.175 0.133 0.223
3 0.374 0.314 0.438 0.210 0.164 0.267
4 0.425 0.354 0.499 0.229 0.173 0.299
5 0.460 0.376 0.548 0.239 0.177 0.318
6 0.483 0.389 0.590 0.243 0.178 0.331
above the MTD
(163)
1 0.389 0.320 0.472 0.185 0.128 0.248
2 0.561 0.488 0.641 0.286 0.216 0.357
3 0.644 0.568 0.723 0.341 0.263 0.440
4 0.687 0.598 0.770 0.371 0.276 0.475
5 0.709 0.609 0.801 0.388 0.275 0.510
6 0.720 0.612 0.822 0.396 0.277 0.536
∗ Sample size
∗∗ Prediction interval
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C.5.2 Competing risks analysis
Table C.13: Association of severe toxicity with cycle for patients treated at
doses below, above and at the MTD. Estimation of cause-specific hazards
per type of toxicity.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
non-hematologic toxicity
below the MTD intercept 1.437 0.074 1.291 1.583
(490) cycle 0.153 0.052 0.051 0.255
at the MTD intercept 0.985 0.081 0.827 1.143
(289) cycle 0.211 0.065 0.084 0.338
above the MTD intercept 0.515 0.098 0.323 0.707
(163) cycle 0.367 0.103 0.165 0.570
both hematologic and non-hematologic toxicity
below the MTD intercept 1.688 0.086 1.518 1.857
(490) cycle 0.121 0.059 0.006 0.236
at the MTD intercept 1.206 0.092 1.026 1.385
(289) cycle 0.356 0.103 0.155 0.557
above the MTD intercept 0.876 0.105 0.670 1.082
(163) cycle 0.177 0.088 0.004 0.351
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.14: Cumulative incidence function (CIF) of severe toxicity for patients treated
at doses below, above and at the MTD. CIFs were calculated for overall toxicity, non-
hematologic toxicity and both hematologic and non-hematologic toxicity.
Group of dose(n)∗ Treatment CIF CIF Lower PI∗∗ Upper PI CIF both Lower PI Upper PI
cycle overall non-hematologic
below the MTD
(490)
1 0.121 0.075 0.056 0.099 0.046 0.030 0.064
2 0.201 0.124 0.096 0.156 0.077 0.053 0.100
3 0.255 0.157 0.126 0.193 0.098 0.070 0.126
4 0.292 0.178 0.143 0.221 0.113 0.080 0.147
5 0.317 0.193 0.151 0.243 0.124 0.086 0.167
6 0.333 0.202 0.152 0.261 0.131 0.088 0.187
at the MTD
(289)
1 0.273 0.162 0.121 0.201 0.114 0.080 0.150
2 0.405 0.246 0.196 0.299 0.157 0.119 0.204
3 0.472 0.294 0.235 0.354 0.173 0.128 0.224
4 0.505 0.322 0.253 0.394 0.179 0.132 0.234
5 0.522 0.338 0.261 0.419 0.182 0.133 0.241
6 0.529 0.348 0.266 0.441 0.182 0.128 0.239
above the MTD
(163)
1 0.489 0.303 0.238 0.375 0.190 0.129 0.251
2 0.668 0.400 0.329 0.477 0.265 0.200 0.337
3 0.744 0.435 0.356 0.515 0.301 0.229 0.378
4 0.778 0.449 0.366 0.532 0.322 0.241 0.405
5 0.794 0.454 0.362 0.543 0.334 0.246 0.426
6 0.801 0.456 0.364 0.551 0.342 0.248 0.445
∗ Sample size
∗∗ Prediction interval
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C.6 Sensitivity analysis
C.6.1 Reclassification of mixed cases with non-hematologic tox-
icities
Table C.15: Association of severe toxicity with cycle for patients treated at
doses below, above and at the MTD. Estimation of cause-specific hazards
per type of toxicity.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
both hematologic and non-hematologic toxicity
below the MTD intercept 1.385 0.072 1.243 1.527
(490) cycle 0.164 0.051 0.063 0.264
at the MTD intercept 0.876 0.078 0.724 1.029
(289) cycle 0.241 0.064 0.115 0.367
above the MTD intercept 0.268 0.093 0.086 0.450
(163) cycle 0.340 0.083 0.177 0.503
hematologic toxicity
below the MTD intercept 1.773 0.091 1.594 1.952
(490) cycle 0.103 0.060 -0.015 0.221
at the MTD intercept 1.373 0.100 1.178 1.568
(289) cycle 0.325 0.110 0.109 0.542
above the MTD intercept 1.306 0.128 1.055 1.557
(163) cycle 0.153 0.118 -0.079 0.384
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.16: Cumulative incidence function (CIF) of severe toxicity for patients treated
at doses below, above and at the MTD. CIFs were calculated for overall toxicity, both
hematologic and non-hematologic toxicity and hematologic toxicity alone.
Group of dose (n)∗ Treatment CIF CIF both Lower PI∗∗ Upper PI CIF Lower PI Upper PI
cycle overall hematologic
below the MTD
(490)
1 0.121 0.083 0.069 0.119 0.038 0.024 0.057
2 0.201 0.136 0.119 0.187 0.065 0.044 0.089
3 0.255 0.171 0.151 0.231 0.084 0.059 0.111
4 0.292 0.194 0.169 0.259 0.098 0.067 0.130
5 0.317 0.208 0.178 0.277 0.108 0.074 0.148
6 0.333 0.218 0.181 0.290 0.116 0.075 0.165
at the MTD
(289)
1 0.273 0.190 0.147 0.234 0.085 0.053 0.119
2 0.405 0.286 0.235 0.341 0.117 0.083 0.158
3 0.472 0.338 0.278 0.400 0.130 0.091 0.181
4 0.505 0.367 0.300 0.439 0.135 0.094 0.192
5 0.522 0.383 0.308 0.466 0.137 0.094 0.192
6 0.529 0.392 0.312 0.489 0.138 0.092 0.196
above the MTD
(163)
1 0.489 0.394 0.316 0.480 0.096 0.057 0.144
2 0.668 0.533 0.455 0.614 0.133 0.083 0.191
3 0.744 0.590 0.508 0.681 0.150 0.098 0.215
4 0.778 0.615 0.524 0.715 0.160 0.100 0.231
5 0.794 0.627 0.530 0.721 0.167 0.102 0.243
6 0.801 0.632 0.524 0.732 0.171 0.103 0.255
∗ Sample size
∗∗ Prediction interval
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C.6.2 Exclusion of grade 3 hematologic toxicity
Table C.17: Number (#) and percentage (%) of patients per type of toxicity
and treatment cycle.
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
# non-hematologic 163 41 22 8 5 3
% non-hematologic 17.3 7.0 8.4 4.6 4.7 3.8
# hematologic 9 4 3 1 1 0
% hematologic 1.0 0.7 1.2 0.6 0.9 0.0
# both∗ 12 0 2 1 1 1
% both 1.3 0.0 0.8 0.6 0.9 1.3
∗ Both non-hematologic and hematologic toxicity at the same cycle
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Table C.18: Association of severe toxicity with cycle, for groups of patients
treated at doses below, above and at the MTD.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
below the MTD intercept 1.348 0.070 1.210 1.485
(490) cycle 0.144 0.047 0.052 0.235
at the MTD intercept 0.850 0.075 0.703 0.996
(289) cycle 0.157 0.050 0.058 0.256
above the MTD intercept 0.257 0.091 0.078 0.436
(163) cycle 0.273 0.071 0.135 0.411
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.19: Risk and cumulative incidence function (CIF) of severe toxicity over 6 cycles,
for groups of patients treated at doses below, above and at the MTD.
Group of dose (n)∗ Treatment Risk Lower CI∗∗ Upper CI CIF Lower CI Upper CI
cycle
below the MTD
(490)
1 0.089 0.068 0.113 0.089 0.068 0.113
2 0.068 0.055 0.083 0.151 0.121 0.183
3 0.051 0.035 0.067 0.194 0.159 0.233
4 0.038 0.021 0.057 0.225 0.182 0.270
5 0.027 0.011 0.050 0.246 0.194 0.302
6 0.019 0.005 0.044 0.260 0.201 0.329
at the MTD
(289)
1 0.198 0.157 0.241 0.198 0.157 0.241
2 0.157 0.129 0.188 0.324 0.269 0.376
3 0.122 0.084 0.157 0.406 0.343 0.464
4 0.093 0.048 0.137 0.462 0.385 0.530
5 0.070 0.025 0.121 0.499 0.409 0.581
6 0.051 0.012 0.108 0.525 0.420 0.622
above the MTD
(163)
1 0.399 0.323 0.475 0.399 0.323 0.475
2 0.298 0.245 0.362 0.578 0.504 0.662
3 0.211 0.136 0.278 0.667 0.591 0.739
4 0.141 0.055 0.222 0.714 0.625 0.792
5 0.089 0.020 0.179 0.739 0.640 0.825
6 0.052 0.005 0.143 0.753 0.646 0.845
∗ Sample size
∗∗ Prediction interval
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Table C.20: Association of severe toxicity with cycle for patients treated at
doses below, above and at the MTD. Estimation of cause-specific hazards
per type of toxicity.
Group of dose (n)∗ Parameter Estimate S.E.∗∗ Lower CI∗∗∗ Upper CI
non-hematologic toxicity
below the MTD intercept 1.386 0.072 1.245 1.527
(490) cycle 0.160 0.050 0.063 0.258
at the MTD intercept 0.939 0.077 0.788 1.090
(289) cycle 0.161 0.053 0.057 0.265
above the MTD intercept 0.371 0.094 0.187 0.554
(163) cycle 0.327 0.082 0.168 0.487
both hematologic and non-hematologic toxicity
below the MTD intercept 2.489 0.169 2.158 2.819
(490) cycle -0.003 0.090 -0.180 0.174
at the MTD intercept 1.979 0.142 1.701 2.256
(289) cycle 0.058 0.092 -0.123 0.239
above the MTD intercept 1.667 0.150 1.374 1.961
(163) cycle 0.005 0.096 -0.182 0.192
∗ Sample size
∗∗ Standard error
∗∗∗ Confidence interval
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Table C.21: Cumulative incidence function (CIF) for patients treated at doses below,
above and at the MTD. CIFs were calculated for overall toxicity, non-hematologic toxicity
and both hematologic and non-hematologic toxicity.
Group of dose (n)∗ Treatment CIF CIF Lower PI∗∗ Upper PI CIF both Lower PI Upper PI
cycle overall non-hematologic
below the MTD
(490)
1 0.089 0.083 0.060 0.105 0.006 0.001 0.014
2 0.151 0.138 0.109 0.173 0.012 0.003 0.023
3 0.194 0.176 0.141 0.215 0.018 0.005 0.033
4 0.225 0.201 0.158 0.247 0.023 0.009 0.045
5 0.246 0.217 0.168 0.273 0.028 0.011 0.057
6 0.260 0.228 0.173 0.295 0.033 0.012 0.075
at the MTD
(289)
1 0.198 0.174 0.133 0.214 0.024 0.009 0.042
2 0.324 0.283 0.232 0.341 0.041 0.019 0.067
3 0.406 0.353 0.293 0.419 0.053 0.027 0.084
4 0.462 0.399 0.328 0.472 0.062 0.031 0.100
5 0.499 0.429 0.346 0.517 0.070 0.034 0.118
6 0.525 0.450 0.356 0.550 0.075 0.032 0.140
above the MTD
(163)
1 0.399 0.355 0.287 0.434 0.048 0.018 0.084
2 0.578 0.501 0.428 0.578 0.076 0.037 0.123
3 0.667 0.566 0.487 0.655 0.096 0.052 0.148
4 0.714 0.595 0.509 0.692 0.111 0.059 0.180
5 0.739 0.608 0.518 0.702 0.124 0.064 0.196
6 0.753 0.614 0.521 0.715 0.136 0.064 0.228
∗ Sample size
∗∗ Prediction interval
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Titre : Me´thodes statistiques pour les essais de phase I/II de the´rapies mole´culaires cible´es en cance´rologie.
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Re´sume´ : Les essais cliniques de phase I en
cance´rologie permettent d’identifier la dose optimale
(DO), de´finie comme la dose maximale tole´re´e (DMT).
Les approches conventionnelles de recherche de
dose reposent uniquement sur les e´ve´nements de
toxicite´ observe´s au cours du premier cycle de traite-
ment. Le de´veloppement des the´rapies mole´culaires
cible´es (TMC), habituellement administre´es sur de
longues pe´riodes, a remis en question cet objectif.
Conside´rer uniquement le premier cycle de traitement
n’est pas suffisant. De plus, comme l’activite´ n’aug-
mente pas ne´cessairement de fac¸on monotone avec
la dose, la toxicite´ et l’activite´ doivent eˆtre prises en
compte pour identifier la DO. Re´cemment, les biomar-
queurs continus sont de plus en plus utilise´s pour me-
surer l’activite´. L’objectif de cette the`se e´tait de pro-
poser et d’e´valuer des designs adaptatifs pour iden-
tifier la DO. Nous avons de´veloppe´ deux designs
de recherche de dose, base´s sur une mode´lisation
conjointe des mesures longitudinales de l’activite´ des
biomarqueurs et de la premie`re toxicite´ dose-limitante
(DLT), avec un effet ale´atoire partage´. En utilisant
des proprie´te´s de distribution normales asyme´triques,
l’estimation reposait sur la vraisemblance sans ap-
proximation ce qui est une proprie´te´ importante dans
le cas de petits e´chantillons qui sont souvent dispo-
nibles dans ces essais. La DMT est associe´e a` un
certain risque cumule´ de DLT sur un nombre pre´de´fini
de cycles de traitement. La DO a e´te´ de´finie comme la
dose la moins toxique parmi les doses actives, sous
la contrainte de ne pas de´passer la DMT. Le second
design e´tendait cette approche pour les cas d’une re-
lation dose-activite´ qui pouvait atteindre un plateau.
Un mode`le a` changement de pente a e´te´ imple´mente´.
Nous avons e´value´ les performances des designs
avec des e´tudes de simulations en e´tudiant plusieurs
sce´narios et divers degre´s d’erreur de spe´cification
des mode`les. Finalement, nous avons effectue´ une
analyse de 27 e´tudes des TMCs de phase I, en tant
que monothe´rapie. Les e´tudes ont e´te´ re´alise´es par
l’Institut National du Cancer. L’objectif principal e´tait
d’estimer le risque par cycle et l’incidence cumula-
tive de la toxicite´ se´ve`re, jusqu’a` six cycles. Les ana-
lyses ont e´te´ effectue´es se´pare´ment pour diffe´rents
sous-groupes de doses, ainsi que pour les toxicite´s
he´matologiques et non-he´matologiques.
Title : Statistical methods for phase I/II trials of molecularly targeted agents in oncology.
Keywords : Biomarker measurements ; Cumulative toxicity ; Dose-finding ; Joint modeling ; Molecularly targe-
ted agents ; Optimal dose.
Abstract : Conventional dose-finding approaches in
oncology of phase I clinical trials aim to identify the
optimal dose (OD) defined as the maximum tolerated
dose (MTD), based on the toxicity events observed
during the first treatment cycle. The constant develop-
ment of molecularly targeted agents (MTAs), usually
administered in chronic schedules, has challenged
this objective. Not only, the outcomes after the first
cycle are of importance, but also activity does not
necessarily increase monotonically with dose. The-
refore, both toxicity and activity should be conside-
red for the identification of the OD. Lately, continuous
biomarkers are used more and more to monitor acti-
vity. The aim of this thesis was to propose and eva-
luate adaptive designs for the identification of the OD.
We developed two dose-finding designs, based on
a joint modeling of longitudinal continuous biomar-
ker activity measurements and time to first dose li-
miting toxicity (DLT), with a shared random effect,
using skewed normal distribution properties. Estima-
tion relied on likelihood that did not require approxi-
mation, an important property in the context of small
sample sizes, typical of phase I/II trials. We addres-
sed the important case of missing at random data
that stem from unacceptable toxicity, lack of activity
and rapid deterioration of phase I patients. The MTD
was associated to some cumulative risk of DLT over
a predefined number of treatment cycles. The OD
was defined as the lowest dose within a range of ac-
tive doses, under the constraint of not exceeding the
MTD. The second design extended this approach for
cases of a dose-activity relationship that could reach
a plateau. A change point model was implemented.
The performance of the approaches was evaluated
through simulation studies, investigating a wide range
of scenarios and various degrees of data misspeci-
fication. As a last part, we performed an analysis of
27 phase I studies of MTAs, as monotherapy, conduc-
ted by the National Cancer Institut. The primary focus
was to estimate the per-cycle risk and the cumula-
tive incidence function of severe toxicity, over up to
six cycles. Analyses were performed separately for
different dose subgroups, as well as for hematologic
and non-hematologic toxicities.
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